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Abstract  
Accessing a large number of high quality pluripotent stem cells from differentiated cells by 
means of small molecule treatment, i.e. chemical reprogramming, is a prerequisite to bring 
stem cell technologies a step closer to clinical applications. Triamterene (TR), a pteridine-
based analog, has been previously shown to convert late-stage mouse epiblast stem cells 
(mEpiSCs) into embryonic stem (ES)-like cells. As a continuation of the efforts to further 
improve the reprogramming activity, a TR-based compound collection was synthesized that 
culminated in the identification of Epiblastin A, which is approximately 2.3 fold more active 
compared to the initial hit. Since genetic and chemical inhibition of the casein kinase 1 
(CSNK1) family has been previously identified as the driving force of the reprogramming 
process, the inhibitory activity of the compound collection against CSNK1 isoenzymes was 
investigated using a screening platform based on KinaseGlo
®
 reagent. This study revealed 
structural features required for potent and / or selective interaction of the TR-analogs and 
these isoforms. Furthermore, target engagement of Epiblastin A with CSNK1A1/D/E 
isoenzymes was demonstrated in cell lysates obtained from HCT116 colorectal carcinoma 
cell line using the ActivX
TM
 ATP probe. Moreover, additional targets addressed by Epiblastin 
A in HCT116 cell lysate were disclosed by means of chemical proteomics strategy using the 
same reagent. Among those, STK10, PIP4K2A and PIP4K2C kinases were identified and in 
addition STK10 was also shown to interact with Epiblastin A in cell lysates. Finally, an in 
vitro profiling study against 123 kinases furnished further kinase targets such as BRSK1, 
EEF2K, EGFR, MKNK2 and RIPK2, thus revealing potential modulators that might be 
involved in the chemical reprogramming mechanism.  
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Zusammenfassung 
Die chemisch induzierte Reprogrammierung von pluripotenten Stammzellen ist ein wichtiger 
Schritt in der Entwicklung von klinisch relevanten Methoden und Anwendungen von 
Stammzellen. Die Verfügbarkeit von qualitativ hochwertigen pluripotenten Stammzellen 
bildet dafür derzeitig eine wichtige Schlüsselstelle. In der Vergangenheit es wurde gezeigt 
dass das Pteridin-basierte Triamteren (TR) in der Lage ist Stammzellen aus Maus Epiblasten 
(mEpiSCs) auch aus späten Entwicklungsstadien in embryonale Stammzellen (ES) zu 
konvertieren. Im Zuge der TR-Optimierung in Hinblick auf eine gesteigerte 
Reprogrammierungsaktivität wurde Epiblastin A aus einer TR-inspirierten Substanz-
bibliothek identifiziert. Epiblastin A zeigt eine 2.3-fach erhöhte Aktivität im Vergleich zum 
Primärhit und stellt die Grundlage für die hier weiter aufgeführten Studien. Die Ergebnisse 
führten zur Hypothese, dass die Casein-Kinase (CSNK1) ein wichtiges potenzielles 
Schlüsselenzym für den von Epiblastin A induzierten Reprogrammierungsprozess ist. Hierzu 
wurden TR-Analoga in einem KinaseGlo
®
 basiertem Testsystem auf CSNK1-modulierende 
Aktivität getestet. Daraus wurde eine Strukturaktivitätsanalyse (SAR) aufgestellt. Im 
Folgenden konnte in zellbasierten Experimenten bestätigt werden, dass Epiblastin A die 
Aktivität der CSNK1A1/D/E Isoenzyme inhibiert. Hierzu wurde im komplexen Zelllysat der 
Darmkrebszelllinie (HCT116) die Wechselwirkung von Epiblastin A mit CSNK1A1/D/E 
Isoformen untersucht. In zusätzlichen Studien, die auf einem klassisch chemisch-
proteomischen Versuchsaufbau basierten, wurden aus HCT116-Lysat zusätzliche neue 
Zielproteine von Epiblastin A identifiziert. Darauf basierend wurde eine Interaktion mit den 
Kinasen STK10, PIP4K2A und PIP4K2C postuliert und in weiterführenden zelllysatbasierten 
Studien konnte STK10 als neuer Interaktionspartner von Epiblastin A bestätigt werden. In 
einer zusätzlichen, weitangelegten in vitro Studie wurden insgesamt 123 Kinasen als 
mögliche Zielproteine von Epiblastin A getestet. Hierbei wurden zusätzlich BRSK1, EEF2K, 
EGFR, MKNK2 und RIPK2 als weitere potenzielle Interaktionspartner im Epiblastin A 
induzierten Reprogrammierungsprozess von mEpiSC identifiziert. 
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Basic definitions  
 
Cell differentiation = defines the process whereby a cell changes towards a more specialized 
cell type, for example a pluripotent cell changes into somatic cell.  
(Stem) cell potency = defines the ability of a stem cell to differentiate into other cell types; 
the more cell types a stem cell can differentiate into, the greater its cellular potency.  
Totipotent stem cells = these cells can give rise to an entire viable organism; they can 
differentiate into embryonic as well as extraembryonic tissues that are required for the 
embryo development.      
Pluripotent stem cells = these cells can differentiate into cells derived from the three germ 
layers (ectoderm, mesoderm and endoderm).  
Multipotent stem cells = these cells can solely give rise to limited cell types mostly from 
related lineages.  
Oligopotent stem cells = stem cells that can differentiate into just few cell types.   
Unipotent stem cells = stem cells that can differentiate into a single cell type, namely their 
own.   
Cellular reprogramming / dedifferentiation = process upon which a specialized cell type 
transitions to a less specialized cellular state, i.e. a cell with limited differentiation potential is 
converted into a cellular state with increased differentiation potential.  
Self-renewal = cellular process whereby the identity of a stem cell is indefinitely maintained 
upon multiple cell divisions. 
Teratoma formation = experimental procedure assessing the ability of stem cells to form 
tumors containing differentiated cells derived from the three germ layers (ectoderm, 
mesoderm and endoderm).  
Transdifferentiation / lineage reprogramming = transition process of a cell type into 
another cell type without undergoing a pluripotent stem-like state.  
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1. Introduction 
1.1. Stem cell research  
1.1.1. Embryonic development 
Embryo development occurs in a stepwise and highly coordinated fashion. The process begins 
with the oocyte fertilization by the sperm that yields the zygote at 0.5 dpc (dpc = days post 
conception and suggests the age of an embryo; hereafter referred to as E0.5), a cell that is 
characterized by totipotency (see Figure 1). Subsequent cell divisions generate the early 
blastocyst at the pre-implantation stage (E3.5). At this point, embryonic stem cells (ESCs) can 
be isolated from the inner cell mass (ICM).  
 
Figure 1. Development of the mouse embryo from embryonic day 0 (E0) to organ formation. (A) Stages of the 
embryo development in mouse from embryonic day 0 (E0) to day 5 (E5) (© 2001 Terese Winslow).  (B) 
Hierarchical stem cell specification process (adapted after Figure 1 in Wobus et al. Physiol. Rev. 2005, 85, 635-678).  
These cells are descendants of the zygote and are pluripotent. Thus, they are characterized by 
self-renewal, the capacity of indefinite proliferation while maintaining their cellular identity. 
Moreover, these cells are able to differentiate into a broad range of cell types derived from the 
three germ layers, i.e. ectoderm, mesoderm and endoderm. This can experimentally be assessed 
by teratoma formation. The ultimate test of pluripotency, which is only applicable to animal 
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models, is the contribution to chimera formation whereby the stem cells are introduced and 
subsequently colonize the pre-implantation embryo followed by full development of a viable 
organism. Thus, this test not only assesses the stem cell developmental potential but also 
indicates the ability to contribute to germline transmission. The implantation of the embryo 
occurs at E4.5 followed by the post-implantation stage at day E5.5. Afterwards, the embryo 
initiates a complex transformation process whereby the cells from the inner cell mass gradually 
lower their stem cell potency and initiate a highly coordinated cell specialization process. As a 
result, the initial pluripotent stem cell population differentiates into adult stem cells, i.e. become 
multipotent. Adult stem cells are typical examples of multipotent stem cells. After this stage, 
oligopotent and unipotent stem cells are generated as a continuation of the differentiation 
process that culminates with terminally differentiated cells. The result of this highly specialized 
and hierarchical process is a viable organism. A complete overview of the embryonal 
development is properly presented in a literature contribution by Wobus et al.
1
    
Studying embryo development in vivo revealed that this process occurs stepwise, whereby the 
cell(s) gradually lose their developmental potential passing through defined cellular states 
coupled with precise changes in the expression levels of key regulatory genes. Thus, being able 
to trap and manipulate these stages under defined conditions in vitro would allow fundamental 
understanding of mammalian development and enable potential clinical applications.  
 
1.1.2. (Pluripotent) stem cell states                  
The regulatory network responsible for pluripotency is highly interconnected and 
encompasses the interplay of various signaling and metabolic pathways, chromatin-
modifying enzymes, regulatory RNA molecules, transcription factors and other proteins.
2
 
Studies related to the involvement of transcription factors in the establishment and 
maintenance of the pluripotent state identified an autoregulatory network composed mainly 
of Pou5f1 (hereafter referred to as Oct4), Nanog and Sox2 that serve as the core set of 
components responsible for this process. These three transcription factors share binding sites 
within promoters of various genes including their own. The combinatorial scrambling at the 
transcription sites directly modulates the expression levels of entire gene clusters, finally 
regulating stem cell fate. For example, lineage-differentiation programs are successfully 
suppressed in embryonic stem cells, while keeping key pluripotency associated genes at such 
levels that allow their continuous propagation.
3,4
 Besides their involvement in pluripotency 
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maintenance, Oct4, Nanog and Sox2 play crucial roles in the early lineage specification 
processes of stem cells as well.
5
 Interestingly, the three factors are expressed to certain 
extents in all pluripotent stem cells derived to date from human and mouse, suggesting a 
common mechanism of sustaining pluripotency across (mammalian) species.
6
 In addition to 
Oct4, Nanog and Sox2, other components were also characterized and shown to contribute to 
the regulation of pluripotency in embryonic stem cells derived from mouse such as Nr0b1 
(also known as Dax1),
7
 Smad1, Smad5 and Smad8,
8
 Tbx3 and Klf4,
9
 Nr5a2
10
 and Sall4.
11
 
Therefore, the machinery responsible for the establishment and maintenance of the 
pluripotent state is far more complex than initially assumed and insinuates the following 
features: (1) pluripotency can be sustained using different combinations of transcription 
factors; (2) compensatory effects are possible, i.e. transcription factors from related or distant 
families can compensate the absence of others; (3) defined expression levels of Oct4, Sox2 
and / or Nanog or a combination thereof allow stabilization of different pluripotent states in 
vitro that might closely mimic in vivo embryonic developmental stages.  
Therefore, one of the long standing goals in stem cell research has been the isolation of 
(pluripotent) stem cells, their maintenance and propagation in cell culture. Thus, defined 
protocols that permit trapping different developmental stages of the embryo in vitro would 
inevitably grant a comprehensive understanding of mammalian development and will further 
advance our knowledge in the area of stem cell biology.  
The organism of choice for studying embryonic development in vertebrates is the mouse, 
primarily due to the lack of stringent ethical issues concerning embryo manipulation. So far, 
various pluripotent stem cell lines have been characterized in culture either by direct isolation 
of cells from various developmental stages of the mouse embryo or by interconverting 
already established cell populations under defined conditions. For example, mouse embryonic 
stem cells (mESCs) were first derived in 1981 from the inner cell mass of the pre-
implantation blastocyst.
12,13
 This initial success and the following investigations facilitated 
the isolation and characterization of the corresponding human counterparts by Thomson et al. 
in 1995.
14
 25 years after the isolation of mouse embryonic stem cells, Brons
15
 and Tesar
16
 
independently reported the generation of mouse epiblast stem cells (mEpiSCs) from the post-
implantation blastocyst. Their results suggested that additional stem cell lines can be 
stabilized in vitro under carefully optimized conditions. Besides embryonic stem cells derived 
from human and mouse, equivalent cellular states from various other species such as rats,
17,18 
hamsters,
19
 rabbit,
20 
chicken,
21,22
 monkeys
23  
and marmosets
24 
were generated.  
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These findings prompted further searches for culture conditions that would allow the in vitro 
stabilization of cellular states that feature restricted differentiation potential. For example, 
embryonic germ cells (EG) have been isolated by extracting primordial germ cells (PGC)
25
 
from post-implantation embryo at developmental day E8.5-E12.5. The propagation under 
defined conditions of the PGC population generated EG cells that exhibited all pluripotency 
hallmarks, i.e. self-renewal, teratoma formation and germline contribution.
26,27,28
 Additional 
pluripotent stem cell lines were successfully isolated in the following years and 
comprehensively characterized. For example, early primitive ectoderm-like (EPL) stem cells 
were generated
29
 in vitro from embryonic stem cells under defined culture conditions. 
Compared to the parent embryonic stem cell population, these cells do not contribute to 
chimera. In-depth characterization revealed that this cell population might represent an 
intermediate state between embryonic and epiblast stem cells. Blastocyst-derived stem cells 
(bFGF, Activin and BIO-derived stem cells, termed FAB-SC) were reported in 2008 by Chou 
et al.
30
 Deep molecular and functional studies of this cell population revealed marked 
differences compared to embryonic and epiblast stem cells. Additionally, although the FAB-
SC cells express the common pluripotency markers such as Oct4, Nanog and Sox2, this cell 
population fails the pluripotency tests such as teratoma formation and chimera contribution. 
When the FAB-SC cells are stimulated with a specific growth factor cocktail, this population 
regained all the pluripotent features. In addition, two types of lineage-restricted stem cells 
have been successfully derived. Trophoblast stem cells (TS)
31
 and extra-embryonic endoderm 
stem cells (XEN)
32
 were exhaustively characterized from multiple perspectives, and have 
been demonstrated to only give rise to cells derived from trophectoderm and primitive 
endoderm, respectively.  
Literature reports so far suggest that a plethora of developmental stages, derived especially 
from mouse, can be isolated and propagated in vitro under carefully optimized conditions. 
These valuable discoveries offer the possibility to gain detailed insights into the 
developmental processes in vitro, to reveal signaling pathways governing lineage 
specification and finally offer the opportunity to manipulate cell fate for potential therapeutic 
benefit. 
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1.1.3. Integrative genetic methods to access pluripotent cellular states  
As mentioned in the previous section, (pluripotent) stem cell lines have been generated by 
using mainly two approaches. First, cells were isolated from various developmental stages of 
the mouse embryo and cultured in vitro under defined conditions. Most of these protocols 
were discovered by combinatorial mixing of growth factors, vitamins, amino acids, small 
molecules etc. in an attempt to maintain and propagate cell populations in vitro. The main 
drawback of this approach is the continuous need to sacrifice mouse embryos for 
experimental purposes. The second approach employs already characterized cell lines which 
are used as starting point to generate new cell populations by carefully manipulating culture 
conditions. Both strategies have proven to be successful along the years and have yielded 
cellular states with various differentiation potential that may indeed correspond to in vivo 
developmental stages. In contrast to the advances made in the area of mouse stem cell 
biology, the research of human embryonic stem cells (hESCs) has developed at a rather slow 
pace due to the ethical concerns related to sacrificing human embryos for experimental 
purposes. Thus, for a comprehensive exploration of the potential offered by stem cell biology, 
the development of novel protocols granting unlimited access to mouse and human 
embryonic stem cells without the requirement of sacrificing living embryos are urgently 
sought after.
33
 
The groundbreaking discovery of induced pluripotent stem cells (iPSCs) has reshaped the 
research landscape in the area of stem cell biology. The rapid development of this concept 
culminated in the Nobel Prize in Medicine Award in 2012 to Sir John B. Gurdon and Shinya 
Yamanaka for demonstrating that “…mature cells can be reprogrammed to become 
pluripotent”.34 Their paramount discovery in the area of cellular reprogramming has set the 
stage for a new era of exploring developmental biology and cellular lineage specification in 
vitro. On one hand, Sir John B. Gurdon made significant contributions to nuclear 
reprogramming
35,36
 using frogs as model organisms. His findings were further applied to 
higher organisms as well, such as sheep
37
 and mouse.
38
 Importantly, his discoveries pointed 
out the capacity of a fully differentiated cell to completely reset its cellular program and 
revert to a state similar to embryonic stem cells, i.e. a somatic cell is able to transform to 
cellular states with higher differentiation potential. Because of the technical hurdles 
associated with the nuclear transfer procedures, researchers sought alternative routes to 
access such cellular states. Along those lines, Kazutoshi Takahashi and Shinya Yamanaka 
reported in 2006 that mouse embryonic fibroblasts (MEFs) can be reprogrammed to an 
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embryonic stem-like state by overexpressing four transcription factors (currently known as 
Yamanaka factors), Oct4, Klf4, Sox2 and Myc.
39
 The subsequently generated cell population 
was termed induced pluripotent stem cells (iPSCs). These cells exhibited most of the 
embryonic stem cell characteristics such as cell morphology and shape, hypomethylation of 
pluripotency-associated markers such as Nanog and Fbxo15 (also known as Fbx15) and 
expressed specific embryonic stem cell markers like Fut4 (more popular known as stage-
specific embryonic antigen 1, SSEA-1 or CD15) and alkaline phosphatase (AP). Moreover, 
the gene expression profile of the newly generated population clustered rather well with that 
of the embryonic stem cells than with the initial fibroblast population. In addition, the cells 
exhibited a normal karyotype, formed teratoma and chimerized embryos. In-depth 
phosphoproteomic and transcriptomic analyses have revealed only subtle differences between 
embryonic and induced pluripotent stem cell lines,
40
 whereas epigenetic analysis by means of 
global methylome profiling reported hotspots of aberrant reprogramming at the DNA 
methylation level.
41
 Further investigations have shown that continuous culture of induced 
pluripotent stem cells in vitro promotes the accumulation of genetic aberrations,
42,43
 as well 
as the induction of an immune response in recipients that received differentiated cells 
produced from iPSCs.
44
 As a result, better reprogramming methods that can avoid genetic 
aberrations and remove the epigenetic memory barriers are likely to produce induced 
pluripotent stem cells of high quality that closely resemble the in vivo counterparts, i.e. 
embryonic stem cells.  
The first induced pluripotent stem cells reported by Yamanaka et al.
39
 were not able to give 
rise to live-born chimeric mice and the reprogramming yields were very low. These aspects 
were shortly delved by the same group
45
 and in the same time by other laboratories.
46,47
 One 
year later, human somatic cells were successfully converted to human induced pluripotent 
stem cells (hiPSCs) by various groups using the same four transcription factors as mentioned 
above.
48,49
 However, Yu et al.
50
 showed that another combination of transcription factors 
comprising Oct4, Sox2, Nanog and Lin28a could also promote the derivation of pluripotent 
stem cells when overexpressed in human somatic cells. The continuous optimization of the 
transcription factor combinations currently allows improved reprogramming yields compared 
to the initial results reported by Yamanaka et al.
39
 Moreover, recent studies have revealed that 
not only the transcription factor identities are crucial for a high yielding reprogramming 
process to occur but also the stoichiometry of the factors transduced. For example, the 
overexpression of Sall4, Nanog, Esrrb, Lin28a was recently reported to efficiently generate 
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high-quality induced pluripotent stem cells than with Oct4, Klf4, Sox2 and Myc.
51
 These 
parameters seem to affect not only the quality of the generated induced pluripotent stem cells 
but also influence their final epigenetic state.
52
 Factors such as the origin of the somatic cell 
apparently affect not only the reprogramming yields but also the differentiation potential of 
the induced pluripotent stem cell population.
53
  
The current view of the cellular reprogramming process consists of a stepwise mechanism 
encompassing global metabolic,
54,55
 proteomic
56
 and epigenetic
57,58
 rewiring of the cellular 
components and comprises multiple intermediate states characterized by specific barriers that 
need to be overcome.
59,60
 Research in the area of cellular reprogramming will most likely 
allow the identification of novel components of the pluripotency network, whose modulation 
would grant improved reprogramming efficiencies and higher quality of the derived induced 
pluripotent stem cells. Although this would allow the generation of novel cell lines, the 
genetic intervention associated with transcription factor overexpression would hamper the 
application of iPSC-based technology in regenerative medical areas such tissue engineering, 
cell replacement therapies, organ production and others. Thus, equivalently effective non-
integrative methods that avoid the genetic manipulation of the starting population are 
currently in high demand for exploiting the full clinical potential of stem cell research.  
 
1.1.4. Non-integrative genetic methods to access pluripotent cellular states 
Due to the necessity of long-lasting expression of the transcription factors in reprogramming 
protocols, the first induced pluripotent stem cell lines derived from mouse and human 
somatic cells were generated using virus-based genome integrating systems. However, the 
viral integration of exogenous genetic material raised numerous concerns
61
 in the scientific 
community. Issues related to the residual expression and / or reactivation of the inserted 
genes, cell death and senescence, immunogenicity
44
 and others still represent major hurdles 
that need to be addressed before considering clinical applications. In addition, some of the 
reprogramming factors are reported to be tumorigenic, especially Myc.
62
 Indeed, the 
introduction of the transcription factor Myc in the reprogramming cocktails was reported to 
induce formation of tumor in chimeric mice.
63
 Thus, in order to fully exploit stem cell 
technologies for clinical applications, the integration of foreign DNA needs to be avoided. 
For this reason, scientists oriented themselves towards other methods that can reduce or even 
completely eliminate transgene integrations. Recently employed protocols involve direct 
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delivery of various types of RNAs such as miRNA (microRNA), mRNA encoding for the 
reprogramming factors, successive transfections with non-replicating plasmids, direct 
delivery of proteins, use of excisable transgene systems such as Cre / loxP recombination 
technology and addition of small molecules that can substitute for the transcription factors 
during the reprogramming process. A detailed description of the current technologies 
available for the generation of induced pluripotent stem cells including non-integrative 
methods can be found in an excellent contribution of Hu.
61
 Moreover, a recent report shows a 
direct comparison among the non-integrating reprogramming methods that lead to the 
generation of human induced pluripotent stem cells.
64
 According to this study, the most 
efficient non-integrative method is based on the direct delivery of mRNA encoding for the 
Yamanaka transcription factors. This procedure reproducibly generated reprogramming 
yields of approximately 2 %. Thus, advances in the field of non-integrating methods clearly 
made the production of transgene-free induced pluripotent stem cells possible, albeit with low 
yields. Future investigations hold the promise of generating large quantities of high-quality 
stem cells amenable for clinical applications. 
 
1.1.5. Small molecules in stem cell research   
One of the most appealing non-integrating methods to promote and maintain the pluripotent 
state is the use of small molecules. Indeed, these agents have emerged as elegant and safe 
alternatives to transgene-based methods, furnishing encouraging results in research areas 
such as self-renewal, differentiation and reprogramming both in vitro and in vivo. As small 
molecules can modulate various targets involved in signaling, epigenetic, metabolic and 
transcriptional processes, they represent valuable tools to probe stem cell biology and to 
manipulate cellular fate at will, using straightforward and defined conditions.  
The numerous reports involving small molecule approaches to stem cell biology are not 
surprising considering their advantages compared to genetic integration-based methods, i.e. 
transgene-based methods. First, the use of small molecules does not necessitate any kind of 
intervention within the host genome. Second, the mode of action of small molecules is, in 
most of the cases, rapid and reversible leading to transient perturbation of the cellular system 
exemplifying a higher degree of temporal modulation. Third, small molecules can be 
administered in combination either sequentially or at the same time using a wide range of 
concentrations. A more comprehensive discussion related to the advantages of small 
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molecules over classical genetics approaches can be found in section 1.2.2. Chemical versus 
genetic intervention to probe biology. As a result of these notable features, small molecules 
have proven to be crucial in almost all areas related to stem cell research, such as 
maintenance (self-renewal), differentiation, transdifferentiation and reprogramming. 
 
Figure 2. Chemical structures of small molecules modulating various processes in stem cell research areas. 
RasGAP = Ras-GTPase activating protein; ERK1 = Extracellular signal-regulated kinase-1;                                
MEK1 = Mitogen-activated protein kinase kinase 1; GSK3 = Glycogen synthase kinase 3 beta;                         
ROCK = Rho-associated protein kinase. 
For example, a high-throughput phenotypic screen in mESCs yielded pluripotin (see chemical 
structure in Figure 2),
65
 a small molecule capable of promoting self-renewal over multiple 
passages in the absence of feeder cells, cytokines such as Leukemia Inhibitory Factor (LIF), 
Bone Morphogenetic Protein 4 (BMP4) or serum components. Deeper investigations 
divulged that pluripotin targets Ras-GTPase activating protein (RasGAP) and extracellular 
signal-regulated kinase-1 (ERK1) and maintains self-renewal via a mechanism independent 
of Wnt / -catenin, LIF / STAT3 (Signal transducer and activator of transcription 3) or BMP4 
/ Smad. Other studies have revealed that self-renewal of pluripotent stem cells can also be 
achieved if the signaling pathways responsible for differentiation are inhibited upon small 
molecule treatment. For example, the dual inhibition of MEK1 and GSK3with PD0325901 
and CHIR99021 respectively (see chemical structures in Figure 2) in combination with LIF 
(termed 2i / LIF conditions)
66
 is able to support the long-term self-renewal of embryonic stem 
cells derived from mouse,
67,68
 rat
17,18,69,70
 and even naïve human induced pluripotent stem 
cells
70,71
 (see section 1.1.8. Differences between mESCs and mEpiSCs). These experimental 
observations ultimately illustrated the high degree of conservation among signaling pathways 
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responsible for stem cell self-renewal across species. Similar protocols using small molecules 
that inhibit differentiation mechanisms of adult stem cells were also developed.
72
 Other 
examples in the area of stem cell self-renewal include Y27632 (see chemical structure in 
Figure 2),
73
 a Rho-associated kinase (ROCK) inhibitor that promotes the maintenance of 
hESCs after cell dissociation. In a parallel study, Xu et al.
74
 found in a phenotypic screen 
another structurally unrelated ROCK inhibitor, termed Thiazovivin (see chemical structure in 
Figure 2), that significantly increased the stem cell survival after single-cell dissociation as 
well as the self-renewal capacity.  
A largely unexplored research area is the identification of defined culture conditions that 
allow the expansion of adult stem cell / tissue-specific stem cells and their progenitors in 
vitro. One of the main challenges in the area of transplantation of hematopoietic stem cells 
(HSCs) is the production of sufficient cell numbers for treatment of blood disorders such as 
leukemia. Recently, a high-content chemical screening campaign yielded StemRegenin1 (see 
chemical structure in Figure 3),
75
 a purine derivative that promotes HSC self-renewal in vitro 
via the modulation of the aryl hydrocarbon receptor (AhR).  
 
Figure 3. Chemical structures of small molecules modulating processes in various stem cell research areas. AhR 
= Aryl hydrocarbon receptor; BMP = Bone morphogenic protein; TGF = Transforming growth factor beta 
receptor 1; FGFR = Fibroblast growth factor receptor; VEGFR = Vascular endothelial growth factor receptor.  
Another extensively explored research area encompasses the use of small organic molecules 
to promote in vitro differentiation of pluripotent stem cells into various cell lineages. In an 
early study, Chambers et al.
76
 showed that a combination of LDN193189 (Bone morphogenic 
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protein signaling pathway inhibitor) and SB431542 (TGF inhibitor) (see chemical structures 
in Figure 3) promotes rapid and efficient (more than 80 %) induction towards neural lineage 
in monolayer culture. An improved protocol was later reported, whereby the addition of three 
small molecules to the above mentioned cocktail, i.e. CHIR99021, SU5402 (FGFR and 
VEGFR inhibitor), DAPT (-secretase inhibitor) (see chemical structures in Figure 3) 
induced differentiation of human pluripotent stem cells toward nociceptor neurons with high 
efficiency (more than 75 %).
77
 Further research identified small molecule combinations that 
promote the stem cell derivation towards endoderm,
78
 cardiac
79,80
 and ectoderm lineages.
81
  
One of the main research areas that hugely benefited from the advent of small molecules is the 
cellular reprogramming of somatic or partially differentiated cells to embryonic stem-like cells.  
  
1.1.6. Chemical reprogramming 
Chemical reprogramming is a robust and viable alternative for transgene-free mediated 
conversion of somatic cells to pluripotent stem cells. Numerous studies showed the 
fascinating capacity of small molecules not only to replace crucial components of the 
pluripotency network, but also to increase the reprogramming yields with or without genetic 
intervention. These include small molecules targeting epigenetic modifiers such as DNA 
methyl transferases (DNMTs), histone deacetylases (HDACs) and components of signaling 
pathways such as kinases, enzymes involved in cell metabolism and other biomacromolecules. 
For example, early reports showed that the 5-azacytidine (see chemical structure in Figure 
4), a DNA methyl transferase inhibitor, is able to increase the reprogramming yield when 
somatic cells were transduced using Yamanaka factors.
82
 Moreover, this compound is able to 
convert even an intermediate reprogrammed cellular state to embryonic stem-like cells, 
suggesting the major involvement of epigenetic modifiers in resetting global epigenetic 
marks.
82
 Increased reprogramming efficiency
83,84
 was also reported with popular HDAC 
inhibitors such as Trichostatin A (TSA), vorinostat (SAHA) and sodium butyrate (NaB) (see 
chemical structures in Figure 4). Even a structurally simple small molecule such as Vitamin 
C (see chemical structure in Figure 4) was shown to boost the reprogramming efficiencies in 
various contexts,
85,86,87
 revealing the importance of Vitamin C-dependent histone 
demethylases during cellular transition processes. 
13 
 
 Figure 4. Chemical structures of small molecules modulating processes in various stem cell research 
areas. DNMT = DNA methyl transferase; HDAC = Histone deacetylase; TGF = Transforming growth factor 
beta receptor 1; G9aHMTase = G9a histone methyltransferase; PRMT = Protein arginine methyltransferases. 
These initial successful studies prompted researchers to reduce the number of overexpressed 
transcription factors required during the cellular reprogramming and replace by small 
molecules. Thus, a small molecule inhibitor of TGF termed RepSox (see chemical structure 
in Figure 4) was reported to act as a surrogate for Sox2 when somatic cells were transduced 
with Oct4, Klf4 and Myc.
88
 Even in the absence of Myc, the compound was still active and 
therefore reduced the number of transcription factors to just Oct4 and Klf4.
89
 Similarly, a 
cocktail of Bay K8644 (L-type calcium channel inhibitor) and Bix-01294 (G9a histone 
methyltransferase inhibitor) (see chemical structures in Figure 4) facilitated the 
reprogramming to pluripotent stem cells by ectopically expressing Oct4 and Klf4 in somatic 
cells.
90
 In 2011, Ding et al.
91
 proved that reprogramming is possible with the overexpression 
of Oct4 alone. Thus, the Yamanaka factors were reduced to just Oct4 supplemented with a 
cocktail of small molecules comprising AMI-5, a protein arginine methyltransferase (PRMT) 
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inhibitor and A-83-01 (TGF inhibitor) (see chemical structures in Figure 4). A 
comprehensive description of small molecule modulators of the reprogramming process can 
be found in excellent review contributions listed here.
92,93
   
Due to these findings, now a toolbox of compounds is available that is expediting the 
dissection of the biological complexity behind cellular reprogramming. This recently 
culminated with the generation of chemically induced pluripotent stem cells (ciPSCs),
94
 a 
transgene-free reprogramming method of mouse somatic cells that employs a cocktail of 
seven small molecules. This study emphasized that chemical reprogramming is feasible even 
from a fully differentiated state, when the right dosage and combination of perturbing agents 
are applied. However, the low conversion efficiencies (approximately 0.2 %) are still not 
optimal for clinical applications. Nevertheless, continuous exploration of the chemical 
space
95,96,97
 for finding active ingredients acting on cellular reprogramming may likely 
address the low yields and stem cell heterogeneity in future. 
 
1.1.7. Potential applications of stem cell technologies       
Stem cell research has substantial influence on the future medicine despite many challenges 
that lie ahead
98
 and the slow progress.
99
 Regenerative medicine,
100,101
 which includes cell-
based therapies for various diseases,
102,103
 tissue engineering
104,105
 and disease modeling
106,107
 
can directly benefit from advances in stem cell biology, pushing even further the impact of 
potential applications that society can benefit from.  
The possibility to access any cell type of the human body via defined differentiation protocols 
from human pluripotent stem cells has a major impact in regenerative medicine research 
areas such as tissue engineering, cell replacement therapies and regeneration of failed organs. 
The aim of the regenerative medicine is to restore the normal function of the human cells via 
replacement. As a consequence, the main starting point for regenerative medical therapies is 
the large-scale production of various types of human cells. At present, the most appealing cell 
types to start with are human pluripotent stem cells but adult stem cells and somatic cells are 
an important part of regenerative medicine as well. One of the main reason for using human 
pluripotent stem cells lies on their ability to differentiate into all cells of a human body such 
as hepatocytes,
108
 β cells,109 cardiomyocytes110 and cells derived from neural lineages such as 
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motoneurons.
111
 As previously mentioned, the safety issues related to the use of transgenes 
are still a major concern.  
More promising results in the area of regenerative medicine are supplied by the multipotent 
adult stem cells. Various pools of adult stem cells have been characterized in vivo, for 
example in the hematopoietic system (hematopoietic stem cells), liver (liver stem cells), gut 
(intestinal crypt stem cells) and others. Although the adult stem cells have slower 
proliferation rate and lower differentiation potential in vitro than pluripotent stem cells, they 
offer a diminished risk of tumor initiation after transplantation, as recently reported.
112
 As a 
result, there are more than 1000 open clinical trials using hematopoietic stem cells registered 
at the National Institute of Health (NIH).
92
 Despite human induced pluripotent stem cells 
were first generated in 1998, the US Food and Drug Administration (FDA) agency approved 
only five stem cell-based medical products up to date.
99
 These are exclusively derived from 
hematopoietic stem cells and used to cure blood and immunological disorders. Several 
reasons are held accountable for such scarcity of stem cell-based therapies. One of the most 
important factors is the necessity of large-scale production of human pluripotent stem cells 
and their expansion or differentiation under well-defined (xeno-free, if possible) conditions. 
For example, if applied in the clinical context, cardiac cell-based therapies would require 
approximately 10
8
-10
10
 cells per patient
113
 since a myocardial infarct damages approximately 
10
9
 myocytes as previously reported.
114
 Other obstacles related to high costs, patient 
recruitment, limited funding, regulatory stringency and public opinion contribute to the 
relatively slow development of clinically relevant stem cell products.  
Another appealing area of applying stem cell research is the generation of functional 
organs.
115,116,117
 For instance, combining the capacity of pluripotent stem cells to differentiate 
in any cell type with the scaffolding ability of different polymers or biomaterials, led to the 
assembly of various functional tissue constructs which are readily available for 
transplantation. Along the same lines, a recent study illustrated the production of a functional 
human liver by transplanting liver buds obtained by in vitro differentiation protocols of 
human pluripotent stem cells.
118
  
Disease modelling is another research area that would profit from advances in the generation 
of human pluripotent stem cells. Thus, it is nowadays possible to collect somatic cells from a 
patient, such as fibroblasts. Following defined reprogramming protocols, these differentiated 
cells can then be converted to pluripotent stem cells. Upon optimized conditions these cells 
16 
 
can be induced to differentiate into disease-relevant cell types which usually recapitulate the 
disease phenotype. Then, drug screens with clinical candidates can be performed at this stage 
to assess the clinical efficacy in a patient-oriented manner. The ability of the pluripotent stem 
cells to differentiate into all types of cells of a human body enable unprecedented possibilities 
to evaluate clinical candidates, perform phenotypic screens and asses cytotoxicity in an 
patient-oriented fashion. These features represent decisive steps towards personalized 
medicine that overcome the limited accessibility to primary cells isolated from patients.     
Most of the advances in the stem cell research were possible due to continuous efforts to 
decipher the signaling pathways governing various processes related to stem cell biology 
such as differentiation, self-renewal and reprogramming. Further investigations will most 
likely illuminate important discoveries in the field that might bring stem cell therapies one 
step closer towards the clinical applications.   
 
1.1.8. Differences between mESCs and mEpiSCs 
The seminal paper published by Nichols and Smith
119
 introduced two phases of pluripotency, 
namely naïve and primed pluripotency, to better distinguish the various pluripotent cellular 
states isolated and characterized so far. This concept can best be exemplified using mESCs 
and mEpiSCs, which define naïve and primed pluripotent cellular states respectively. A 
comprehensive comparison between these two pluripotent states can be found in recent 
literature contributions as well as in Table 1.
6,120
  
For example, whereas mESCs grow as small and oval domed-shape three-dimensional 
colonies, mEpiSCs form large and round flattened structures in vitro and barely survive 
clonal propagation from single cells in culture. Moreover, whereas mESCs are maintained in 
vitro in the presence LIF / STAT3 and BMP / Smad, mEpiSCs are propagated in growth 
media supplemented with FGF / Activin A. Both mESCs and mEpiSCs are pluripotent, i.e. 
they exhibit indefinite self-renewal and can differentiate into cells derived from the three 
germ layers. However, in contrast to mESCs, mEpiSCs contribute poorly to chimera 
formation. Thus, mEpiSCs lose their capacity to colonize the inner cell mass of an embryo at 
the blastocyst stage, i.e. their ability to participate in germline transmission is compromised. 
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Pluripotency  
Features Naïve  Primed 
Cell morphology small and oval domed-shape  large and round flattened  
Self-renewal YES YES 
Teratoma formation  YES YES 
Chimera contribution YES NO 
Pluripotency factors Oct4, Nanog, Sox2, Klf2, Klf4 Oct4, Nanog, Sox2 
Naïve markers Zpf42, Fgf4, Gbx2, Dppa3, Nr0b1  absent 
Differentiation Markers absent Fgf5, T 
X chromosome status XaXa XaXi 
Doubling time 14 h  18 h 
Alkaline phosphatase YES NO 
Response to 2i  self-renewal differentiation / death 
Response to LIF / STAT3 self-renewal none 
Response to FGF / ERK differentiation self-renewal 
Table 1. Cellular and functional properties of mESCs and mEpiSCs. Xa = X-chromosome activation; Xi = X-
chromosome inactivation, 2i = chemical cocktail comprising PD032590 (MEK1 inhibitor) and CHIR99021 
(GSK3 inhibitor); LIF = Leukemia inhibitory factor; STAT3 = Signal transducer and activator of transcription 
3; FGF = Fibroblast growth factor; ERK = Extracellular-signal regulated kinase (adapted after Table 1 in 
Nichols et al. Cell Stem Cell 2009, 4, 487-492). 
Furthermore, the doubling time of 18 h in the case of mEpiSCs compared to only 14 h for 
mESCs is consistent with the unusually shorter G1 phase of the cell cycle. In addition, in the 
case of female cells, X-chromosome inactivation (XaXi) occurs at the epiblast stage in 
comparison to mESCs which exhibit two active X-chromosomes (XaXa). Although mESCs 
and mEpiSCs express similar set of pluripotency-associated genes such as Oct4, Nanog and 
Sox2, mEpiSCs lack the expression of embryonic stem cell-specific genes such as Klf4, 
Dppa3, Zpf42 (commonly known as Rex1) and Gbx2. Moreover, mEpiSCs show increased 
levels of the early differentiation markers such as Fgf5, T (known as Bra) and do not express 
alkaline phosphatase compared to mESCs. These discrepancies suggest that mESC and 
mEpiSC populations represent two distinct pluripotent stages of the embryo development: 
mESC step resembles the pre-implantation embryo, i.e. inner cell mass stage, whereas 
mEpiSC step corresponds to the post-implantation embryo (epiblast) stage. As a result, the 
cellular programs and signaling pathways characterizing these two cellular states are very 
different. On one hand, FGF / Erk pathway inhibition promotes differentiation of the naïve 
mESCs, whilst under these condition mEpiSCs undergo self-renewal. On the other hand, the 
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later property is maintained in mESCs under 2i conditions while mEpiSCs differentiate. 
Thus, the concept of naïve and primed pluripotency greatly facilitates the characterization of 
the cellular states and introduces specific features to better describe pluripotent cellular states.   
Surprisingly, human embryonic stem cells (hESCs) behave similarly to mEpiSCs in many 
aspects such as culture conditions, cell morphology and others, suggesting that the human 
pluripotent stem cells might resemble a similar developmental stage, i.e. hESCs feature 
primed pluripotency. Recently mESC-like states for human pluripotent stem cells were 
reported by various labs,
121,122,123
 proving that naïve pluripotency can be achieved in human 
induced pluripotent stem cells under defined conditions. Moreover, it confirmed the previous 
assumptions that human embryonic stem cells represent a distinct developmental stage 
compared to mouse embryonic stem cells. Due to the similarities between hESCs and 
mEpiSCs mentioned above, the latter might be used in principle as substitute model for 
hESCs studies, therefore avoiding ethical issues.  
Researchers possess nowadays a broad range of (pluripotent) stem cells derived from various 
developmental stages of rodents and human, allowing a deeper exploration of the embryo 
development process in vitro. This has a tremendous impact on the ability to model early 
mammalian events in a dish for the use in clinical applications for example. 
 
1.1.9. The mEpiSC population is heterogeneous  
It is nowadays well accepted that stem cell populations are heterogeneous.
124,125 
As a 
consequence, it is not surprising that transcription factors responsible for the maintenance of 
pluripotency are also heterogeneously expressed both in vitro and in vivo. For example, only 
approximately 80 % of the mESC population expresses Nanog.
126,127
 A similar observation 
was made in the case of Zpf42,
128
 a naïve ESC-specific marker,
128,129
 whose levels fluctuate 
in the mouse embryonic stem cell population.
130
 These studies indicated that the 
heterogeneity observed is not due to coexistence of isolated cell populations, but rather to 
different populations of cells which are able to interconvert into one another. In the case of 
the heterogeneous Nanog subpopulations, it was shown that Nanog-positive cells maintained 
undifferentiated colonies for prolonged time, whereas Nanog-negative cells underwent 
differentiation under continuous propagation in culture.
126
 This observation indicates that the 
two cell states represent slightly different developmental stages that are present within the 
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same population. Of note, transcription factor heterogeneities were previously evidenced in 
vivo in the case of Nanog and Gata6.
131
 
Following the same line of evidence, Han et al.
132
 showed that mEpiSCs are analogously 
dissimilar, comprising a Oct4-positive population (>99 % of the cell population) and a Oct4-
negative population (less than 1 % from the total amount of cells). These subpopulations are 
not embryonic stem cells as demonstrated by gene expression profiling, epigenetic marks and 
Oct4 promoter usage. Similar to embryonic stem cells, the authors could show that the two 
populations are interconvertible in vitro and represent distinct states derived from the epiblast 
trapped at different developmental stages. The study could also clarify the previous 
observation made by Garner et al.,
133
 whereby primitive ectoderm (PrE) cells isolated from 
E5 embryos were capable of contributing to chimera formation in comparison to cells 
isolated from E6-E7 embryo. By comparing the gene expression profiles of the in vivo and in 
vitro mEpiSCs samples, the study concluded that the Oct4-positive population might 
represent an early-stage epiblast (E5.5), whereas the Oct4-negative population a late-stage 
epiblast (E6.5). Thus, the Oct4-negative cell population corresponds to the most 
differentiated state that can be trapped in vitro within the epiblast stage. This study highlights 
the paramount importance of comprehensive characterization of the cellular heterogeneity 
across stem cell populations. 
Mouse epiblast stem cells represent an important cellular model to study germ layer 
specification, because the epiblast stage is the last pluripotent cellular state before 
gastrulation. Recently, mEpiSCs were used as starting point to generate neural stem cells,
134
 a 
multipotent stem cell population with the ability to differentiate into neurons and glial cells as 
previously reported.
135
 
 
1.1.10. Reprogramming mEpiSCs to mES-like cells – state of the art 
Various methods have been reported so far detailing the conversion of mEpiSCs to 
embryonic stem-like cells. For example, a simple change of the FGF / Activin A growth 
medium to LIF / STAT3 alone, was sufficient to promote conversion of epiblast stem cells 
isolated from E5.5-E7.5 mouse embryos to naïve pluripotency.
136,137
 Under these conditions, 
dramatic changes at the genetic and epigenetic level of the starting population such as global 
DNA demethylation, reactivation of the X-chromosome and expression of E-cadherin were 
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observed. Moreover, the obtained reprogrammed embryonic stem cells exhibited all 
pluripotency hallmarks such as self-renewal, teratoma formation and chimera contribution.
136
 
Other reports demonstrated that genetic manipulation of various transcription factors at the 
epiblast stage such as Prdm14-Klf2,
138
 Nr5a2,
139
 Klf4
140
 can generate cell populations that 
exhibit naïve pluripotency features. Moreover, the overexpression of E-cadherin in the 
presence of LIF increased the transition efficiency from mEpiSCs to chimera-competent 
mESCs.
141
 The authors revealed by genetic and chemical means that the sequestration of -
catenin inside the nucleus is responsible for the enhanced reprogramming efficiency. 
Recently, Zhou et al.
142
 reported the conversion towards an ESC-like state by chemical means 
only, using a cocktail of five small molecules that include CHIR99021 (GSK3 inhibitor), 
PD0325901 (MEK1 inhibitor), A-83-01 (TGF inhibitor), PD173074 (FGF inhibitor) and 
Parnate, a Lysine-specific histone demethylase 1 (LSD1) inhibitor. Additionally, Rao et al.
143
 
could achieve the same transition using a similar protocol comprising a combination of 
fibroblast growth factor 2 (FGF2) and four small molecule inhibitors, namely Y27632 
(ROCK inhibitor), PD032590 (MEK1 inhibitor), SB431542 (TGF inhibitor) and 
CHIR99021 (GSK3 inhibitor). 
However, in all reports mentioned above, unsorted mEpiSCs were employed.  As previously 
mentioned by Han et al.,
132
 mEpiSC population is heterogeneous, consisting of two distinct 
subpopulations characterized by Oct4-GFP expression. The Oct4-GFP-positive cells 
represent less than 1 % of the entire cell population and—as reported—might correspond to 
the early-stage epiblast. On one hand, it has been shown that this tiny fraction has a greater 
developmental potential and can be converted to an ESC-like state solely by the use of 2i / 
LIF conditions. On the other hand, the Oct4-GFP-negative fraction represents more than 99 
% of the mEpiSC population and might represent the late-stage epiblast (thereafter late-stage 
mEpiSCs). Surprisingly, these cells are refractive towards conversion to mESCs under 2i / 
LIF conditions suggesting that the late-stage population represents a distinct and less potent 
cellular state than the Oct4-GFP-positive population. Based on these findings, it can be 
surmised that the previous studies might only succeeded to reprogram the Oct4-GFP-positive 
cells, since an unsorted mEpiSC starting population has been used. In addition, Berneman et 
al.
144
 and Hanna et al.
131
 independently showed that epiblast stem cell lines are disparate 
among each other, namely some are refractive towards 2i / LIF treatment, whereas others 
smoothly undergo reprogramming towards an ESC-like state. This behavior was explained by 
the expression levels of the mesendodermal marker T,
145
 a transcription factor part of the T-
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box family involved in the formation of the mesoderm.
146,147 
There is an inverse reciprocal 
relationship between the expression levels of this marker and the efficiency of generating 
ESC-like cells under stringent mESC conditions, i.e. 2i / LIF. Moreover, the overexpression 
of T in T-negative cells blocks the conversion capacity of these cells. This observation 
suggests that some mEpiSC lines are more prone to transition to higher cellular states, i.e. 
they possess lower reprogramming barriers than others.  
 
1.1.11. Reprogramming late-stage mEpiSCs to mES-like cells – preliminary 
results   
A cell-based assay in a 96-well format was performed by Dr. Damir J. Illich (Max Planck 
Institute of Biomolecular Medicine, Münster, Germany) under previously described 
conditions.
148,149
 This assay monitors the reactivation of Oct4-GFP expression upon treatment 
of late-stage mEpiSCs with small molecules and quantifies the GFP fluorescence intensity by 
means of fluorescence activated cell sorting (FACS). Screening the Library of 
Pharmacologically Active Compounds (LOPAC
®
) yielded the compound 6-phenylpteridine-
2,4,7-triamine (Triamterene, thereafter TR; see chemical structure in Figure 5), a known 
inhibitor of the epithelial sodium channel (ENaC).
150
  
 
Figure 5. Chemical structure of the pteridine scaffold and Triamterene (TR). 
In-depth investigations revealed the ability of TR to reprogram the initial cell population first 
to a pre-ESC state that features most of the embryonic stem cell hallmarks such as cell 
morphology, propagation conditions in vitro, and differentiation potential, however fails to 
contribute to chimera formation.
148,149
 Global gene expression and epigenetic profiling 
studies confirmed that the generated cells are trapped in an intermediate state between 
mEpiSCs and mESCs.
148,149 
The transition to a naïve state was only possible by combining 
TR with PD0325901 (thereafter PD, see chemical structure in Figure 2, section 1.1.5. Small 
molecules in stem cell research), a known MEK1 inhibitor. This compound promotes and 
sustains naïve pluripotency in various contexts.
151
 Under these conditions, the TR / PD 
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combination successfully yielded pluripotent stem cells that regained the germline 
contribution ability.   
 
1.2. Chemical Genetics  
1.2.1. Definition 
One of the major goals of natural sciences is to investigate and understand biological 
systems. For example, the relationship between genetic material represented by genes and 
their involvement in particular processes is fundamental to understand the regulation of 
biological systems. This correlation can be studied by means of classical genetics methods 
that investigate the relationship between genes and physiological effects (phenotypes) using 
two approaches (see Figure 6).  
 
Figure 6. Concept representation for the forward / reverse genetics and chemical genetics. Forward genetics / 
chemical genetics involve top-down approaches and try to identify the gene / gene product responsible for a 
certain cellular event, i.e. phenotype.  Reverse genetics / chemical genetics use a bottom-up approach where the 
impact of targeted gene / gene product inactivation on the phenotype is studied (adapted after Figure 1 in 
Kawasumi et al. J. Invest. Dermatol 2007,127(7),1577-1584).  
On one hand, forward genetics allows a top-down approach whereby genes involved in a 
biological process of interest are identified by means of analyzing their impact on the 
phenotype by generating random mutations within the genome. On the other hand, reverse 
genetics is a bottom-up approach whereby an already selected gene is randomly mutated or 
the expression levels are altered. Thereafter, the impact of these modifications is used to 
investigate the effect on the phenotype. Both approaches furnished valuable insights into 
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fundamental biological processes and allowed a deeper understanding of the basic principles 
governing living systems. These were only possible due to development of powerful 
molecular and cell biology techniques such as mutagenesis and manipulation of gene 
expression levels by various means, including gene knock-in / -out, RNA interference 
(RNAi) technology and other related methods.   
By analogy to classical genetics, chemical genetics
152,153
 explores gene products by chemical 
means (see Figure 6). In this area of research, biological systems, processes, phenomena are 
analyzed by means of small molecule intervention in a complementary fashion to the 
classical genetics methods.
154,155,156
 Accordingly, forward chemical genetics approaches 
biological processes from phenotype (effect) to genotype (cause) using small molecules. For 
example, by performing a phenotypic screen with compound libraries the capacity of a small 
molecule to induce a certain cellular effect is determined. Biologically active compounds are 
identified, confirmed by complementary assays and afterwards the addressed 
biomacromolecule (protein, RNA or DNA or others) is deconvoluted by means of target 
identification techniques. Instead, reverse chemical genetics starts with a defined target, and 
small molecules that specifically modulate its function are revealed by target-based screening 
approaches. Once identified, these derivatives are employed in relevant cellular models or 
even in whole organisms to probe the involvement of the biomacromolecular target in the 
biological process of interest. 
Both approaches have yielded numerous small molecules that can alter the function of 
various biomacromolecules such as enzymes, receptors, ion channels, RNA, DNA and others. 
Although the number of biological targets modulated by small molecule means is steadily 
increasing, this might still represent a tiny fraction of the total number of possible druggable 
biomacromolecules found in the human genome, i.e. human druggable genome.
157
 Thus, 
chemical genetics intends to expand this small molecule toolbox in the attempt to furnish 
modulators for novel biological targets and pathways to unveil biological principles that 
govern living systems.  
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1.2.2. Chemical versus genetic intervention to probe biology  
Both classical and chemical genetics approaches represent powerful tools for the study of 
biological processes. The advantages and disadvantages related to both methods are analyzed 
in the section below. 
One of the main benefits of using chemical compounds over genetic intervention is the ability 
of a small molecule to disrupt a single module within a multifunctional biomacromolecule. 
Moreover, in the case when the gene of interest encodes a protein with multiple domains, 
chemical genetics can render specific small molecule binders for each module and thereby 
prevent the abolishment of the function of the entire biomacromolecule. For example, kinase 
inhibitors block only the phosphotransferase activity concomitantly leaving intact the 
scaffolding function of the protein, where biological partners might dock. Thus, small 
molecule intervention can dissect the two protein functions as compared with the genetic 
ablation which would have removed the whole protein upon gene deletion. An interesting 
example is tubacin,
158
 a small molecule designed to only interfere with the tubulin 
deacetylase activity of the multifunctional histone deacetylase 6 (HDAC6) protein. Thus, 
tubacin just inhibits the catalytic domain that is responsible for tubulin deacetylation without 
perturbing the HDAC6 activity. The ability of tubacin to distinguish between histone and 
tubulin deacetylase activity within the same enzyme was subsequently employed in further 
biological studies related to the involvement of HDAC6 activity in cell motility and protein 
degradation.
159
    
Another unique feature of small molecules is the ability to disrupt protein-protein 
interactions.
160,161
 Therefore, this aspect further expands the applicability area of small 
molecules in perturbing biological systems.  
Small molecules are efficient tools, especially in cases where classical genetics approaches 
are not effective or applicable. Although the manipulation of genomes can easily be 
performed in prokaryotes, viruses and bacteria, mammalian cells are usually not 
straightforwardly accessible to genetic intervention due to the diploid nature of their genome. 
However, the newest developments in genetic engineering methods such as Clustered 
Regularly Interspaced Short Palindromic Repeats CRISPR / Cas9
162,163
 allow the generation 
of precise knock-in / -outs in mammalian cells relatively straightforward. Nevertheless, it is 
often difficult to distinguish if the observed phenotype is a result of losing the function or the 
scaffolding feature of the biological target when complete deletion of the gene construct 
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occurs. In contrast, small molecules can be readily applied regardless of the biological 
context, either to cells or whole organisms across species. However, compounds can exhibit 
cytotoxicity and therefore optimization of the chemical structure occurs before probing a 
certain phenotype or before administration to patients in clinical trials. Chemical genetics is 
also employed when removal of an essential gene by genetic means would translate to 
lethality. In this case, working with small molecules at concentrations below the lethal dose 
could render a partial knock-out phenotype that might allow studying the biological 
significance of that specific target.    
One of the most important features of using small molecules is their rapid and often 
reversible action in biological context. Compounds can be straightforwardly added and 
removed from the culture media providing the possibility to precisely manipulate the 
exposure time. In addition, by applying different concentrations of the small molecule one 
can generate dose-dependent studies of the phenotype of interest both in vitro and in vivo. 
However, small-molecules have often disadvantages such as specificity issues when targeting 
closely related protein isoforms or protein families with conserved function. Lack of 
specificity mostly originates from identical amino acids in the active sites among the 
members of a protein family. Whereas genetic methods might be able to specifically address 
a single protein isoform of a protein subfamily, chemical genetics often fails to supply small 
molecules for each particular isoform of interest. Additionally, even highly optimized small 
molecules exhibit unintended targets (“off-targets”) in cellular context, which might impair 
the phenotype of interest.  
A new method is currently emerging that tries to compensate for the lack of specificity of the 
small molecules and the lack of temporal control associated with genetic methods. The so-
called allele-specific chemical genetics
164
 combines the specificity achieved with genetic 
tools and the reversible and tunable character of chemical genetics (see Figure 7). This 
approach involves the simultaneous optimization of the small molecule target protein pair by 
means of recombinant DNA technology and organic synthesis, respectively.
165,166
 On one 
hand, relying on available structural information of a protein, mutants can be generated by 
means of site-directed mutagenesis in two different directions. First, the mutant is engineered 
such that it is able to engage the natural ligand that can be outcompeted with an allele-
specific derivative generated from the original compound (see Method A, Figure 7). In this 
way, the natural ligand binding capacity is left intact and this event can be specifically 
disrupted with the allele-specific derivative. On the other hand, the structure of the protein of 
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interest can be engineered to block the binding event of the natural ligand. As a result, the 
protein structure and overall conformation remain intact but the binding of the natural ligand 
is blocked. In this case, small molecules that specifically interact with this mutant protein can 
be synthesized (see Method B, Figure 7). 
 
Figure 7. Concept of allele-specific chemical genetics. Two methods are used to study the specific modulation 
of the protein of interest (POI) by small molecules. Method A: POI is specifically mutated to allow binding of 
the natural ligand that can be outcompeted by a chemically synthesized analogue. Method B: A disrupting 
mutation is introduced in the POI that blocks the interaction with the natural ligand while keeping the binding of 
the chemically synthesized analogue (adapted after Figure 1B from Islam ACS Chem. Biol. 2015, 10, 343-363). 
The method has been reported to be robust and successfully implemented in the case of 
kinases, GTPases, methyltransferases, acetyltransferases, proteases and other classes of 
enzymes.
164
 For example, many important observations have been made related to the 
differences that can arise from chemical versus genetic inhibition of protein kinases.
167
 
However, the allele-specific chemical genetic approach requires detailed structural 
information about the small molecule protein target combination in order to rationally design 
a complementary pair that is orthogonal to the natural variant. Additionally, the engineered 
protein mutant needs to conserve the natural conformation, structure and function once 
translated within the host proteome.  Thus, the availability of such methods allows the 
characterization of the protein function at relevant biological time scale in a highly specific 
manner that would otherwise be difficult to investigate with any other technologies.   
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By analogy to allele-specific chemical genetics, “allele-specific RNAi” has also been 
developed.
168,169
 This method selectively targets mutant transcripts in the context of human 
diseases by means of RNA interference technology, unveiling the biological impact of 
disease-causing mutations. 
  
1.2.3. Forward chemical genetics applied to stem cell research  
In the context of stem cell research, the forward chemical genetics approach is predominantly 
employed. Many examples in this area report phenotypic screens of compound libraries for 
studying processes such as differentiation of human pluripotent stem cells into different 
lineages, reprogramming of fully or partially differentiated cells or self-renewal of pluripotent 
stem cells. Advances in miniaturization, fluorophore development, imaging and microscopy 
techniques, and genetic engineering protocols nowadays enable assaying large compound 
libraries both faster and with higher content than ever before. Most of the chemical screens 
related to stem cells presented in the previous sections make use of commercial compound 
collections that contain small molecules or drug candidates with known targets and mode of 
action. For example, many compounds that act on different stem cell related processes are 
kinase inhibitors that have been already optimized during oncology-oriented research 
campaigns. As a consequence, the identification of the underlying biological mechanism is in 
this case relatively straightforward. For example, Aurora A kinase represents a barrier in 
reprogramming
170
 and thus inhibition of this target by genetic or chemical means was 
described to facilitate reprogramming of somatic cells as revealed from a phenotypic screen 
monitoring the reactivation of the Oct4-GFP expression in somatic cells.
171
 Other studies 
highlighted the importance of kinase inhibition in increasing the reprogramming efficiencies 
in various experimental setups.
171,172
   
Although successful in identifying agents that manipulate stem cell fate, phenotypic screens 
have several drawbacks. First, depending on the phenotype under investigation, the screening 
throughput might be low and thus a limited number of compounds can be tested. Moreover, 
the price per well might hamper screening of large compound libraries also. Secondly, 
although a phenotypic screen can provide a plethora of information, it does not point out the 
cellular target(s) responsible for the biological event under investigation. At this point, 
various target identification and confirmation techniques are employed in order to elucidate 
the underlying biological target(s) addressed by the identified hit molecule(s). This process 
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occurs stepwise and encompasses the interplay of different biological and biophysical 
methods rendering this process time consuming. For a comprehensive description of target 
identification and confirmation techniques, important review contributions are 
available.
173,174,175,176
  
  
1.2.4. Chemical genetics and stem cells – future challenges           
Chemical genetics principles were successfully applied in many studies related to stem cell 
research. However, most of these reports employed forward (chemical) genetics approaches. 
For example, genome-wide loss-of-function screens using RNAi or shRNA (small hairpin 
RNA) identified barriers in the context of cellular reprogramming.
59,60
 Thus, genetic and / or 
chemical inhibition of the barriers allowed increased reprogramming yields for generating 
pluripotent stem cells. Conversely, reverse chemical genetics has not often been employed in 
stem cell research, although gene targets that block the reprogramming of mouse embryonic 
fibroblasts (MEFs) have been reported such as Nfe2, Cdkn2aip (CDKN2A-interacting 
protein), Msx3, Dbx1, Lzts1 (Leucine zipper putative tumor suppressor 1), Gtf2i (General 
transcription factor II-I) and Ankrd22 (Ankyrin repeat domain-containing protein 22).
59
 
Additionally, the application of a shRNA lentiviral library targeting 19.527 human genes 
revealed ubiquitination, endocytosis and cell adhesion / motility as roadblocks towards the 
generation of human iPSCs, when BJ human fibroblasts (human forseskin) were 
reprogrammed using OKSM transgenes in combination with TP53 RNAi.
60
 Thus, starting 
with a target-based screen for such barriers would be advantageous in revealing novel 
chemotypes that can then be evaluated in relevant stem cell-based screens. Improved organic 
synthesis protocols will most likely aid the synthesis of compound collections of closely 
related analogues that will better address the concerns of the stem cell community.   
While most of the studies so far use derivatives already optimized for other research purposes 
such as oncology, the reverse chemical genetic approach might be able to reveal new 
chemical entities with improved mode of action. The knowledge gathered about the barriers 
in cellular reprogramming could also be used to design polypharmacological agents that 
engage multiple targets simultaneously. Thus, instead of using cocktails of small molecules 
that target two or more biomacromolecules, one could envisage the design of single agents in 
an attempt to reduce the complexity of the targeted interactome. Computational approaches 
are currently available that facilitate the de novo design of ligands with different 
29 
 
pharmacological profiles.
177
 Therefore, polypharmacological agents could in principle be 
exploited in phenotypic screens when the intended targets are addressed at the right dosage. 
Next generation therapeutics are expected to harness the potential of endogenous stem cell 
pools to promote replacement of damaged cell populations in vivo, promote tissue repair and 
stimulate proliferation of dormant cells.
98,178,179
 The identification of new chemicals and their 
addressed targets will most likely reveal the signaling pathways that govern developmental 
biology at the level of the whole organism.  
 
 
 
 
 
 
 
 
 
 
` 
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2. Aim of the Thesis 
There is a continuous need for discovering new chemical entities with novel modes of action 
to achieve chemical reprogramming of fully or partially differentiated cells to embryonic 
stem-like cells. These compounds and their molecular targets would enable a better 
understanding of the signaling pathways governing cell dedifferentiation and would more 
efficiently advance stem cell-based technologies in academic and clinical settings.    
The combination of Triamterene (TR) and the MEK1 inhibitor PD0325901 (PD) (see 
chemical structures in the figure below) has been shown to promote the reprogramming of 
partially differentiated cells termed late-stage mouse epiblast stem cells (mEpiSCs) to an 
embryonic stem (ES)-like cell population. In-depth biological studies revealed that the 
mechanism driving the cellular transition is mediated by casein kinase 1 (CSNK1). 
 
Based on these preliminary results, one of the main goals of the current study is to improve 
the reprogramming activity of the initial hit TR. This can be achieved by means of 
synthesizing a compound collection of closely related analogs based on the TR scaffold 
bearing various substituents at positions C2, C6 and C7 (see above). Synthesis of the 
pteridine-based derivatives is straightforward from commercially available starting materials 
using methods mentioned in the literature. The access to such compounds will enable a 
comprehensive study of the substitution pattern(s) on the pteridine ring that allow increased 
cellular transformation rates of late-stage mEpiSCs to mES-like cells. The biological activity 
will be assessed by quantifying the re-expression of the Oct4-GFP construct, a crucial 
pluripotency-specific marker, in the reprogrammed cells by means of flow cytometry. In 
addition, the compound collection shall explore the correlation between the conversion 
efficiency and the extent of CSNK1 inhibition mediated by the pteridine-based derivatives. 
Profiling the newly synthesized derivatives for CSNK1 enzyme inhibition will be achieved 
by means of state-of-the-art setups that allow measuring kinase activity. This study shall 
reveal the structural features of the pteridine-scaffold necessary for potent and / or selective 
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inhibition of the CSNK1 kinase family as well as the mode of inhibition with respect to ATP. 
Additionally, the interaction of the most promising candidates with CSNK1 isoenzymes will 
be analyzed in cells or cell lysates using affinity-based methods. Target engagement of ATP 
binding proteins, in particular kinases, by ATP competitive agents shall be demonstrated by 
means of activity-based profiling using the ActivX
TM
 ATP probe and immunoblotting when 
the target of interest is known beforehand. Since kinase inhibitors are rarely specific, special 
focus will be placed on the identification of further protein targets addressed by this class of 
compounds. This will be investigated by in vitro kinase profiling study and employing a 
chemical proteomics strategy performed in cell lysates using the ActivX
TM
 ATP probe.  
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3. Experimental part 
3.1. Experimental part – chemistry  
3.1.1. Materials 
All the chemicals mentioned in the current study were purchased from Alfa Aesar and Sigma 
Aldrich and used as provided, without any further purification. Analytical thin-layer 
chromatography (TLC) was executed on silica gel aluminium plates with F-254 indicator 
(Merck, Germany). Compounds were visualized on the TLC plates by irradiation with UV 
light. Acros 60A (particle size 0.035 – 0.070) silica gel was employed for the column 
chromatography purification of the derivatives reported in this study. Compound 
characterization by means of 
1
H- and 
13
C-NMR analyses was performed on Bruker DRX400 
(400 MHz), Bruker DRX500 (500 MHz) and INOVA500 (500 MHz). Deuterated DMSO 
(DMSO-d6) was used as internal standard. Signal characterization is described using the next 
abbreviations: s (singlet), d (doublet), dd (double doublet), dt (double triplet), t (triplet), q 
(quartet) and m (multiplet). Coupling constant values are presented in Hertz (Hz). Fourier 
transform infrared spectroscopy (FT-IR) characterizations were recorded with a Bruker 
Tensor 27 spectrometer (ATR, neat) and are reported in terms of frequency of absorption 
(cm
-1
). Chemical yields refer to isolated and pure substances. High resolution mass (HRMS) 
spectra were recorded on a LTQ Orbitrap mass spectrometer coupled to an Accela HPLC-
System (HPLC column: Hypersyl GOLD, 50 mm × 1 mm, 1.9μm). Solvent mixtures for thin 
layer chromatography are depicted as volume : volume. PE is the abbreviation for petroleum 
ether.  
 
3.1.2. Methods 
Derivatives 32-34 (entries 32-34, Table 3) were synthesized according to literature 
procedures.
180
 Starting materials 35 and 36 (entries 35-36, Scheme 3) were synthesized 
following a procedure already reported in the literature.
181
 Derivatives 37 and 39 (entry 37 
and 39, Table 4) were generated using a known synthetic route.
182
 Starting materials 41-49 
(entries 41-49, Scheme S1) were generated starting from 4-chloro-2,6-diaminopyrimidine 
following a two-step procedure previously reported.
183
 The confirmation of the identity and 
purity of the compounds mentioned in the literature was assessed by 
1
H-NMR and HPLC-MS 
analyses only. Synthesis of the derivatives shown in Table 2, except for the compounds 
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already mentioned above, was performed using a slightly modified workup procedure than 
originally reported in the literature.
182,184,185,186
 The derivatives not mentioned in the literature 
are characterized below by means of 
1
H- and 
13
C-NMR, HRMS and FT-IR (see section 11. 
Compound characterization). 
General procedure for the synthesis of derivatives 2-30 (entries 2-30, Table 2 and entries 60-
72, Table A2)  
Epiblastin A (entry 12): NaH (60 % oil dispersion, 0.75 mmol, 1.1 eq) was dissolved in 8 mL 
anhydrous 2-ethoxyethanol and vigorously stirred at room temperature. After H2 evolution, a 
clear solution was obtained and then, (3-chlorophenyl)acetonitrile (0.75 mmol, 1.1 eq) was 
added followed by 5-nitroso-2,4,6-triaminopyrimidine (0.68 mmol, 1 eq). The reaction 
mixture was heated to 140ºC and refluxed for 2 hours. After cooling to room temperature, the 
mixture was concentrated in vacuo. The obtained solid is treated with 5 mL water, filtered 
and additionally washed twice with 3 mL methanol. The solid was dried to finally furnish 107 
mg of a yellow solid (yield = 55 %). 
General procedure for the synthesis of derivatives 50-59 (entries 50-59, Table 6) 
Compound 50: (3-chlorophenyl)acetonitrile (0.5 mmole, 1.2 eq) was dissolved in 3 mL dry 
THF and then Cs2CO3 (0.5 mmole, 1.2 eq) was added followed by 4-ethoxy-5-nitroso-2,6-
diaminopyrimidine (0.4 mmole, 1.0 eq). The mixture was stirred at 65ºC for 3 hours. After 
solvent evaporation, the mixture is purified using column chromatography on silica using 
acetone : petroleum ether 4:1 (Rf = 0.12) furnishing 55 mg of an yellowish brown solid (yield 
= 44 %).    
Chemical structures and IUPAC nomenclature of the derivatives synthesized in the current 
study are presented in Table A1 (see below). These compounds showed a good solubility in 
DMSO and stock solutions of 10 mM in 100 % DMSO could be obtained. Conversely, 
derivatives shown in Table A2 were either insoluble in 100 % DMSO or precipitated out 
easily from the solution. As a consequence, these compounds were analyzed neither in the 
stem cell assay or the inhibition of CSNK1A1/D/E isoenzymes.   
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No. Compound structure IUPAC name 
2 
 
6-phenylpteridine-2,4,7-triamine 
3 
 
6-(4-fluorophenyl)pteridine-2,4,7-triamine 
4 
 
6-(4-(allyloxy)phenyl)pteridine-2,4,7-triamine 
5 
 
6-(4-methoxyphenyl)pteridine-2,4,7-triamine 
6 
 
6-(p-tolyl)pteridine-2,4,7-triamine 
7 
 
6-(4-aminophenyl)pteridine-2,4,7-triamine 
8 
 
6-(4-nitrophenyl)pteridine-2,4,7-triamine 
9 
 
6-(4-isopropylphenyl)pteridine-2,4,7-triamine 
10 
 
6-([1,1'-biphenyl]-4-yl)pteridine-2,4,7-triamine 
11 
 
6-(4-(benzyloxy)phenyl)pteridine-2,4,7-triamine 
12 
 
6-(3-chlorophenyl)pteridine-2,4,7-triamine 
13 
 
6-(3-fluorophenyl)pteridine-2,4,7-triamine 
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No. Compound structure Compound name 
14 
 
6-(3-bromophenyl)pteridine-2,4,7-triamine 
15 
 
6-(3-(trifluoromethyl)phenyl)pteridine-2,4,7-triamine 
16 
 
6-(m-tolyl)pteridine-2,4,7-triamine 
17 
 
6-(3-methoxyphenyl)pteridine-2,4,7-triamine 
18 
 
6-(3-aminophenyl)pteridine-2,4,7-triamine 
19 
 
6-(2-methoxyphenyl)pteridine-2,4,7-triamine 
20 
 
6-(2-fluorophenyl)pteridine-2,4,7-triamine 
21  6-(2,6-dichlorophenyl)pteridine-2,4,7-triamine 
22  6-(2,4-dichlorophenyl)pteridine-2,4,7-triamine 
23  6-(3,4-dichlorophenyl)pteridine-2,4,7-triamine 
24  6-(2,6-difluorophenyl)pteridine-2,4,7-triamine 
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No. Compound structure Compound name 
25  6-(2,5-difluorophenyl)pteridine-2,4,7-triamine 
26 
 
6-(naphthalen-1-yl)pteridine-2,4,7-triamine 
27 
 
6-(pyridin-2-yl)pteridine-2,4,7-triamine 
28 
 
6-(benzo[b]thiophen-3-yl)pteridine-2,4,7-triamine 
29 
 
6-(thiophen-2-yl)pteridine-2,4,7-triamine 
30 
 
6-(pyridin-3-yl)pteridine-2,4,7-triamine 
32 
 
6,7-diphenylpteridine-2,4-diamine 
33 
 
6-phenylpteridine-2,4-diamine 
34 
 
3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol 
37  2-methyl-6-phenylpteridine-4,7-diamine 
38  6-(3-fluorophenyl)-2-methylpteridine-4,7-diamine 
37 
 
No. Compound structure Compound name 
39  2-(methylthio)-6-phenylpteridine-4,7-diamine 
40  6-(3-fluorophenyl)-2-(methylthio)pteridine-4,7-diamine 
50 
 
6-(3-chlorophenyl)-4-ethoxypteridine-2,7-diamine 
51 
 
6-(3-chlorophenyl)-4-propoxypteridine-2,7-diamine 
52 
 
6-(3-chlorophenyl)-4-isopropoxypteridine-2,7-diamine 
53 
 
4-(allyloxy)-6-(3-chlorophenyl)pteridine-2,7-diamine 
54 
 
4-butoxy-6-(3-chlorophenyl)pteridine-2,7-diamine 
55 
 
4-(sec-butoxy)-6-(3-chlorophenyl)pteridine-2,7-diamine 
56 
 
6-(3-chlorophenyl)-4-(cyclopentyloxy)pteridine-2,7-diamine 
57 
 
6-(3-chlorophenyl)-4-(cyclopentylmethoxy)pteridine-2,7-diamine 
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No. Compound structure Compound name 
58 
 
6-(3-chlorophenyl)-4-(cyclohexylmethoxy)pteridine-2,7-diamine 
59 
 
4-(benzyloxy)-6-(3-chlorophenyl)pteridine-2,7-diamine 
Table  A1. Chemical structures and IUPAC nomenclature of pteridine derivatives 2-59. 
 
 
No. Compound structure Compound name 
60 
 
6-(4-iodophenyl)pteridine-2,4,7-triamine 
61 
 
6-(2-bromophenyl)pteridine-2,4,7-triamine 
62 
 
6-(o-tolyl)pteridine-2,4,7-triamine 
63 
 
6-(3,4-difluorophenyl)pteridine-2,4,7-triamine 
64 
 
6-(3,4-dimethoxyphenyl)pteridine-2,4,7-triamine 
65 
 
6-(2,3-dichlorophenyl)pteridine-2,4,7-triamine 
66 
 
6-(naphthalen-2-yl)pteridine-2,4,7-triamine 
39 
 
No. Compound structure Compound name 
67 
 
6-(pyridin-4-yl)pteridine-2,4,7-triamine 
68 
 
6-(thiophen-3-yl)pteridine-2,4,7-triamine 
69 
 
6,7-dimethylpteridine-2,4-diamine 
70 
 
7-phenylpteridine-2,4-diamine 
71 
 
acenaphtho[1,2-g]pteridine-9,11-diamine 
72 
 
phenanthro[9,10-g]pteridine-11,13-diamine 
Table A2. Chemical structures and IUPAC nomenclature of pteridine derivatives 60-72. These compounds were 
not investigated in biological context due to solubility issues. 
 
 
3.2. Experimental part - Biology  
3.2.1. Materials 
Human basic fibroblast growth factor (bFGF) was purchased from Peprotech (Germany). 
Human leukemia inhibitory factor (LIF) was produced in-house.
148
 KO-DMEM was acquired 
from Invitrogen. CHIR99021 and PD0325901 were purchased from Tocris Bioscience. 
Hoechst 33258 was obtained from Sigma. 4',6-diamidino-2-phenylindole (DAPI) was 
purchased from Invitrogen. Dulbecco’s Modified Eagle’s medium (DMEM), sodium 
pyruvate, penicillin / streptomycin, non-essential amino acids and trypsin were purchased 
from PAN Biotech (Germany). Fetal bovine serum was purchased from Invitrogen 
(Germany). Cell culture flasks were purchased from Sarstedt (Germany). Anti-CSNK1D 
(Abcam, mouse, ab85320), anti-CSNK1E (BD Biosciences, mouse, 610445), anti-CSNK1A1 
(Santa Cruz, goat, C-19, sc-6477) and anti-REX1 (Abcam, ab28141) antibodies have been 
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used according to the vendor’s recommended protocols. STK10 antibody (Santa Cruz, 
mouse, D-6, sc-398083) was purchased from Santa Cruz Biotechnology and used according 
to the vendors indications. 96-well plates were purchased from BD Biosciences (Germany). 
384-well white plates with clear bottom were purchased from Corning (Germany). Protease 
and phosphatase inhibitor cocktails were obtained from Roche (Germany). LoBind Tubes 
(Eppendorf, Germany) were used for target engagement and proteomics experiments.  
 
3.2.1.1. Cell lines  
For testing reprogramming efficiencies of the pteridine-based derivatives the E3 EpiSC-
GOF18 cell line was used which is derived at E5.5 from (C57BL/6 X DBA/2) X 129/Sv. In 
this case the Oct4 transgene corresponds to a 10 kbp fragment (genomic Oct4 fragment 
18kbp: GOF18).
187
 EpiSC medium (MEF-conditioned) contained Knockout(KO)-DMEM, 20 
% Knockout - Serum Replacement (KOSR), 1 x L-glutamine, penicillin / streptomycin, non-
essential amino acids, 100 M 2-mercaptoethanol and 5 ng / mL bFGF (before and after 
conditioning over MEFs). Cells were cultured on fetal calf serum (FCS)-coated dishes and 
passaged with Accutase
®
 (Life Technologies). mESCs or reverted EpiSCs were grown on 
MEFs using mESC medium containing Knockout (KO)-DMEM, 20 % Knockout - Serum 
Replacement, 1 x L-glutamine with penicillin / streptomycin, non-essential amino acids, 100 
M 2-mercaptoethanol and 2000 U / mL LIF. HS-578T (DSMZ-No. ACC-781), HT1080 
(DSMZ-No. ACC-315), U2OS (DSMZ-No. ACC-785), SKBR3 (DSMZ-No. ACC-736), 
HCT116 (DSMZ-No. ACC-581), HEK293 (DSMZ-No. ACC-305), MCF7 (DSMZ-No. 
ACC-115) and HeLa (DSMZ-No. ACC-57) were purchased from Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cultures (Germany). ACHN (ATCC
®
 CRL-
1611™), MCF10A (ATCC® CRL-10317™), HEK293T (ATCC® CRL-3216™) and BT-549 
(ATCC
®
 HTB-122™) were obtained from ATCC (USA). HCT116 TP53+/- and HCT116 
TP53
-/- 
were a kind gift from Bert Vogelstein (Baltimore, USA). All cell lines were cultured 
following the growth media indicated by the vendors at 37°C in a 5 % CO2 humidified 
atmosphere.  
 
41 
 
3.2.2. Methods 
3.2.2.1. Reprogramming assay using mouse epiblast stem cells  
(This experiment was fully performed by Dr. Damir J. Illich, Max Planck Institute for 
Molecular Biomedicine, Münster, Germany) 
100,000 E3 EpiSC GOF18 cells were plated into 6 cm low attachment dishes on day 0. The 
reprogramming assay was performed in EpiSC medium CF1 MEF-conditioned KO-DMEM 
containing 20 % serum replacement and without additional bFGF. The compounds were 
added on day 0 at a concentration of 10 M and the cells were incubated for 8 days at 37°C. 
Medium containing the compounds was changed on day 4 and 6. The basic EpiSC conversion 
medium was used as negative control, whereas a mixture of 3 M CHIR99021 (GSK3 
inhibitor), 1 M PD0325901 (MEK1 inhibitor) and 2000 U / mL LIF (commonly referred to 
as 2i / LIF) was used as a positive control for reprogramming E3 EpiSC GOF18 cells. On day 
8, cells were dissociated using trypsin. Approximately one million cells were resuspended in 
500 L of cell culture medium and the suspension was passed through a 40 m cell strainer 
to remove debris and undissociated tissue. 4',6-diamidino-2-phenylindole (DAPI) was added 
at this stage to stain the nuclei of reprogrammed cells. Cells were subjected to fluorescence-
activated cell sorting using a FACSAria cell sorter (BD Biosciences) to detect the selective 
expression of the Oct4-GFP construct in embryonic stem-like cells, i.e. reprogrammed cells. 
On day 8 of reprogramming, reverted E3 EpiSCs displayed reactivation of the Oct4-GFP 
transgene. The conversion efficiency was related to the initial found hit Triamterene (TR), 
whose efficiency was set to 1.  
 
3.2.2.2. Immunocytochemistry 
(This experiment was fully performed by Dr. Miao Zhang, Max Planck Institute for 
Molecular Biomedicine, Münster, Germany) 
Cells seeded on coverslips were fixed with 4 % paraformaldehyde (PFA) for 10 min and then 
rinsed with 0.1 % Tween
® 
20 in phosphate-buffered saline (PBS) (PBS-T). Cells were 
permeabilized for 10 min with 0.5 % Triton X-100 in PBS at room temperature prior to 
incubation in a solution of 1 % bovine serum albumin (BSA), 5 %  fetal calf serum and 2 % 
glycine in PBS-T for 1 h to block non-specific binding. Cells were then incubated with REX1 
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antibody (Abcam, ab28141, 1 g / mL) overnight at 4°C. Afterwards, cells were washed in 
PBS-T and the secondary antibody (Alexa Fluor
® 
568, goat anti-rabbit IgG (H+L), 1:1000 
dilution) was added for 1 h at room temperature. Cells were again washed in PBS-T and 
nuclei were stained with Hoechst 33342 for 5 min. Cells were then mounted onto glass slides. 
Images were acquired using a Leica fluorescence microscope.   
 
3.2.2.3. Preparation of cell lysate for detecting CSNK1A1/D/E 
HeLa, HCT116, MCF7, ACHN and HEK293T cells were cultured up to 80-85 % confluency. 
Growth media was removed, and cells were washed and collected by scrapping in ice-cold 
PBS. Cells were centrifuged for 5 min at 400 x g and lysed for 10 min on ice in a lysis buffer 
containing 50 mM PIPES (pH 7.4), 50 mM NaCl, 5 mM MgCl2, 5 mM EGTA, 0.1 % NP40, 
0.1 % Triton X-100, 0.1 % Tween
 
20 and freshly added 0.1 % 2-mercaptethanol EDTA-free 
protease inhibitor cocktail (Complete EDTA free, Roche, Germany) and phosphatase 
inhibitors (PhosphoSTOP, Roche, Germany). Lysates were homogenized by passing them 
five times through 20G and 24G needles, respectively. Cellular debris was separated by 
centrifugation at 12000 x g for 20 min at 4°C. Clear cell lysates were frozen at -80°C. Protein 
concentration was determined using the Bradford reagent (Bio-Rad, Germany).  
 
3.2.2.4. Immunoblotting 
Cells were collected by scrapping and lysed following the procedure described above. Protein 
concentration determined using the Bradford reagent (Bio-Rad, Germany). Samples were 
adjusted to the same protein concentration prior to denaturation in Laemmli buffer at 95 °C 
for 8 min. Proteins were then separated by means of sodium dodecylsulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred by means of semi-dry electroblotting to a 
polyvinylidene difluoride (PVDF) membrane (Thermo Scientific, Germany). Membranes 
were blocked using 5 % non-fat dry milk in Tris-buffered solution (10 mM Tris-HCl (pH 
7.5), 100 mM NaCl, 0.1 % Tween
®
 20 for CSNK1E and 20 mM Tris-HCl (pH 7.6), 140 mM 
NaCl, 0.05 % Tween
®
 20 for CSNK1A1, CSNK1D and STK10) and were then incubated 
with the appropriate primary antibodies, diluted in blocking solution (CSNK1A1 1:300, 
CSNK1D 1:5000, CSNK1E 1:2000 and STK10 1:200) overnight at 4°C. Anti--tubulin (for 
CSNK1A1) or anti-GAPDH (for CSNK1D/E) antibodies were employed to detect -tubulin 
or GAPDH as loading controls. Detection of bound primary antibodies was performed by 
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incubating with appropriate secondary antibodies coupled to horseradish peroxidase (HRP, 
Pierce, USA) and SuperSignal West Pico or Femto Maximum Sensitivity Substrate (Pierce, 
USA). For reprobing, membranes were stripped in Restore Western Blot Stripping Buffer 
(ThermoScientific, USA) for 10 min at room temperature according to the vendor’s 
instructions.  
 
3.2.2.5. Plasmid construction, protein expression and purification 
(The plasmid construction, protein expression and purification was fully performed at the 
Dortmund Protein Facility, Max Planck Institute of Molecular Physiology, Dortmund, 
Germany) 
Fully sequenced human cDNA constructs for CSNK1D (former cat. no. MHS4771-
202829011; replaced by MHS6278-202829011, clone ID 3546633, accession no. BC003558) 
and CSNK1E (cat. no. MHS6278-202830217, clone ID 3937782, accession no. BC006490) 
were purchased from Open Biosystems - Dharmacon (GE Healthcare). The nucleotide 
sequence corresponding to amino acids 1-294 of the human CSNK1D and CSNK1E cDNA 
was amplified using the oligonucleotides:             
5’-GAAGTTCTGTTTCAGGGTCCCATGGAGCTGAGAGTCGGGAACA-3’ 
5’-CTTTGTTAGCAGCCGGATCATTATTTGAGCATGTTCCAGTCGAACACG-3’  
for CSNK1D and 
5’-GCGAACAGATCGGTGGTATGGAGCTACGTGTGGGGAAC-3’ 
5’-ATTTCAGCATGTTCCAGTCAAAGACGTA-3’ 
for CSNK1E and subsequently subcloned in pET19-nHis-3C for CSNK1D and pOPIN-His-
Sumo for CSNK1E. pET19-nHis-3C-CSNK1D_1-294 and pOPIN-His-Sumo-CSNK1E_1-
294 were transformed in the E. coli strain BL21 DE3 RIL(K+). Bacteria were grown in SB 
medium (3.2 % peptone, 2 % yeast extract and 0.5 % NaCl) at 37°C. Expression was induced 
with 400 M IPTG at OD600 of 0.6. Cells were grown at 25°C for 18 h. Harvested cells were 
suspended in lysis buffer (50 mM Tris, pH 8.0, 400 mM NaCl, 5 % glycerol, 0.1 % Triton X-
100, 1 mM DTT, 5 mM imidazol and protease inhibitors) and lysis was performed by 
sonication. After centrifugation the supernatant was loaded on a Ni-NTA column (Qiagen). 
After washing with 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 % glycerol and 5 mM 
imidazol, proteins were eluted with 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 % glycerol 
and 30 mM imidazol. In collected fractions proteins were digested using Prescission protease 
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/ Sumo protease and were further purified by size exclusion chromatography using a 
Sephadex G200 column with 25 mM Hepes pH 7.0, 150 mM NaCl, 2 mM TCEP, 10 mM 
MgCl2 and 5 % glycerol for CSNK1D and 25 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM 
TCEP, 10 mM MgCl2 and 5 % glycerol for CSNK1E. For both proteins, the buffer was 
exchanged to CK1 dilution buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 
0.25 mM DTT, 25 % glycerol). To this end, Zeba Spin Desalting Column (7K MWCO, 2 
mL; Thermo Scientific) was centrifuged at 1000 x g for 2 min at room temperature. The 
column was equilibrated three times with 1.2 mL ice-cold CK1 dilution buffer at 1000 x g for 
2 min at room temperature. After the final centrifugation step, the kinase containing fraction 
was added and centrifuged for 2 min at 1000 x g and room temperature. The newly obtained 
kinase containing solution was collected and protein concentration was determined using the 
Bradford reagent (Bio-Rad Protein Assay Kit I, Bio-Rad, cat no 5000001) and adjusted to 
approx. 1 g / L. Proteins were snap-frozen in liquid nitrogen and stored at -80°C.  
 
3.2.2.6. Crystal structure determinations  
(This experiment was performed by Arthur Porfetye, Max Planck Institute of Molecular 
Physiology, Dortmund, Germany)  
Crystals of CSNK1D were obtained at 4°C in hanging drops containing 0.1 M Li2SO4, 0.7 - 
0.8 M Na-K tartrate and 0.1 M CHES (pH 9.5). Protein concentration used was 7.45 mg / mL 
in CK1 dilution buffer. Crystals appeared after 21 days as small ellipsoids and were mounted 
in a thin film of mother liquor without additional cryo protectant. Structures of CSNK1D in 
complex with Epiblastin A and derivative 15 were obtained by soaking crystals overnight in 
mother liquor containing 4 mM of Epiblastin A and derivative 15 (40 % DMSO 
concentration in the final drop). The crystals belonged to the space group 152 (P3121) with a 
unit cell parameters of a = b = 64.5 Å, c = 151.8 Å,  =  = 90˚,  = 120˚ and one molecule in 
the asymmetric unit. Diffraction data was collected at PXII at Swiss Light Source (SLS) at 
Paul-Scherrer-Institute, Villigen, Switzerland using a Pilatus 6M detector. The data was 
processed and scaled using XDS / XSCALE
188
 and solved by molecular replacement with 
PHASER
189
 from the CCP4-suite
190
 using PDB entry code 3UYS as template. Model 
building and refinement was carried out using REFMAC5
191
 and coot.
192
 The data collection 
and refinement parameters of the apo-CSNK1D and CSNK1D in complex with Epiblastin A 
and derivative 15 crystal structures can be found in Table A3. 
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Apo-
CSNK1D 
CSNK1D -  
Epiblastin A 
complex 
CSNK1D -   
derivative 15 
complex 
CSNK1D - 
derivative 15  
complex 
data set 2 
PDB ID     
Data collection     
Wavelength (Å) 0.91639 0.92019 1.76995 0.91883 
Resolution (Å) 
55.89 - 1.91 
(1.95 -1.91) 
50 - 2.59 
(2.66 - 2.59) 
45.74 - 2.76 
(2.83 - 2.76) 
2.8Å (2.87-2.8) 
Space group P31 2 1 P31 2 1 P31 2 1 P31 2 1 
Unit cell     
a, b, c (Å) 
64.5, 64.5, 
151.8 
65.1, 65.1, 
151.6 
65.4, 65,4 
151.7 
65.4, 65.4, 
151.7 
α, β, γ (˚) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120 
Total reflections 
542,287 
(29,503) 
223,430 
(16,573) 
104,020 
(15,080) 
189,434 
(13,879) 
Unique reflections 
53,992 
(3,340) 
22,311 (1,668) 18,722 (2,960) 17,797 (1,303) 
Rmerge 
[a] 0.115 
(1.323) 
0.148 (1.546) 0.087 (0.897) 0.151 (1.2) 
Redundancy 10.0  10.0 5.6 10.6 (10.7) 
Completeness (%) 96.0 (83.9) 99.9 (99.7) 99.6 (95.7) 99.5 (99.3) 
I/σI 13.45 (1.64) 12.23 (1.59) 11.73 (1.74) 10.64 (1.84) 
CC1/2 99.8 (87.1) 99.9 (86.7) 99.8 (91.6) 99.9 (89.2) 
Refinement     
Resolution (Å) 
55.89-1.91 
(1.96 -1.91) 
56.38-2.59 
(2.66-2.59) 
45.47-2.76 
(2.83-2.76) 
56.72-2.8 
(2.87-2.8) 
No. reflections used 27,094 11,526 9,718 9,225 
Rwork (%) 20.2 (53.4) 23.2 (41.1) 20.9 (37.9) 20.6 (31.3) 
Rfree (%) 23.6 (53.2) 29.0 (43.3) 30.1 (45.5) 31.6 (45.7) 
No. atoms / 
Mean B-values (Å
2
) 
    
Protein 2373 / 41 2320 / 74 2307 / 92 2243 / 90 
Inhibitor / Solute 31 / 75 41 / 98 41 / 82 41 / 107 
Water 243 / 48 15 / 59 34 / 105 33 / 78 
Rms deviation     
Bond length (Å) 0.007 0.012 0.01 0.009 
Bond Angle (˚) 1.177 1.318 1.27 1.303 
Ramachandran (%)     
favoured 97.92 96.43 98.92 98.89 
accepted 2.08 3.57 1.08 1.11 
outlier 0.0 0.0 0.0 0.0 
Table A3. Crystallographic data collection and refinement statistics for the crystal structures of apo-CSNK1D, 
and CSNK1D in complex with Epiblastin A and derivative 15, respectively. Data set 2 refers to the detection of 
the anomalous scattering of the bromine atom from derivative 15. 
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3.2.2.7. Cell lysate preparation for target engagement and chemical proteomics 
HCT116 cells were grown up to
 
80-90 % confluency. Cells were washed and collected by 
scraping using ice-cold PBS. Cells from multiple T175 flasks were combined and centrifuged 
for 5 min at 500 x g and 4°C. Cell pellets were either directly frozen (and stored at -80°C) or 
subsequently lysed in ice-cold Pierce IP Lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1 % NP-40 and 5 % glycerol) supplemented with Halt Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific, prod. no. 78440) for 10 min on ice. To 
assure complete cell lysis samples were gently vortexed every three min until a homogeneous 
mixture was obtained. The resulting homogenate was centrifuged for 5 min at 16000 x g and 
4°C and supernatant were carefully transferred into a new vial. For the buffer exchange 
procedure, the protocol suggested by the vendor was applied. Zeba Spin Desalting Columns 
(7K MWCO, 5 mL; Thermo Scientific, prod. no. 89891) were centrifuged at 1000 x g for 2 
min at room temperature. The column was equilibrated with ice-cold Kinase buffer (20 mM 
Hepes pH 7.4, 150 mM NaCl, 0,1% Triton X-100) and centrifuged at 1000 x g for 2 min at 
room temperature prior to addition of the cell lysate and centrifugation for 2 min at 1000 x g 
and room temperature. The buffer-exchanged lysate was and the protein concentration was 
adjusted to approximately 2 mg / mL with ice-cold Kinase buffer. Lysates were subsequently 
stored at -80°C.  
 
3.2.2.8. Kinase profiling at Eurofins (former Milipore) 
Single-point measurement analyses of Epiblastin A against a panel of 123 kinases was 
performed at Eurofins (former Milipore) using a radiometric-based assay and Km-ATP (Km is 
defined as the concentration of ATP that allows half-maximal reaction velocity) 
concentration for each individual kinase. Dose-dependent investigations of Epiblastin A 
against BRSK1, EGFR, EEF2K, MKNK2, RIPK2 and STK10 have been performed under the 
same experimental setup, i.e. at Km-ATP value. Half-maximal inhibitory concentrations 
(IC50) were obtained by fitting the obtained data with three parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows (GraphPad Software, USA). For 
more details related to the experimental conditions employed at Eurofins please consult the 
following website:  
http://www.eurofins.com/pharma-services/pharma-discovery-services/services/in-vitro-
pharmacology/kinases/biochemical.aspx 
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3.2.2.9. Determination of CSNK1D/E activity using the KinaseGlo
®
 Plus 
luminescent assay  
(The assay conditions were preliminary optimized by Dr. Yasushi Takemoto, RIKEN-Max 
Planck Joint Research Center for Systems Chemical Biology, Wako, Japan)  
A stock solution of 5 % DMSO (BioReagent for molecular biology, Sigma Aldrich) in water 
was prepared. The CSNK1 substrate peptide RRKDLHDDEEDEAMSITA (Jena Bioscience, 
cat. no. PE-206, 2 mM stock solution in water) was diluted in water to a final concentration 
of 250 μM. CSNK1D or CSNK1E kinases were diluted with CK1 dilution buffer to 50 ng / 
μL. In addition, fresh Reaction buffer was prepared containing 250 mM Tris-HCl (pH 7.5), 
50 mM MgCl2, 5 mM DTT and 0.5 mg / mL bovine serum albumin (BSA). Compounds were 
serially diluted in 5 % DMSO solution to the desired concentrations (maximal concentration 
employed in the assay was 50 M). Additional samples included blank sample containing 
Reaction buffer, water and CSNK1D / CSNK1E kinase and control sample containing 
Reaction buffer, CSNK1 substrate peptide and CSNK1D / CSNK1E kinase. CSNK1 substrate 
peptide, Reaction buffer and CSNK1D / CSNK1E kinase stock solutions were mixed in 1:1:1 
ratio. 6 μL of this mixture was added to 384-well plates (384 well low volume white round 
bottom polystyrene NBS™, Corning®, prod. no. 3673). 2 L of the test compound stock 
solutions were subsequently added to the wells. The same volume of the 5 % DMSO solution 
was added to the blank and control samples, respectively (final DMSO concentration in the 
assay was 1 %). The content of the plate was centrifuged for 1 min at 750 x g and room 
temperature. The plate was incubated under rotation / shaking at room temperature for 5 min, 
followed by 25 min incubation at room temperature. The kinase reaction was initiated by 
adding 2 L ATP (Ultra Pure ATP, Promega, product no V703A-C, 100 mM stock solution 
in water) from a 50 M stock solution in water. The content of the plate was centrifuged for 1 
min at 750 rpm and room temperature, followed by shaking for 5 min at room temperature 
and incubation at room temperature for 55 min. Afterwards, 10 L of the Kinase-Glo® Plus 
reagent (Promega, cat. no. V3771) was added to each well and the plate was incubated at 
room temperature for 5 min. Luminescence was recorded on an Infinite
®
 M200 plate reader 
(Tecan, Austria) (integration time 1000 ms, settle time 5 ms). CSNK1D / CSNK1E kinase 
activity (% of control) was calculated as follows:  
Kinase activity (%) = ((<luminescence (blank sample)> - <luminescence (compound 
sample)>) / (<luminescence (blank sample)> - <luminescence (control sample)>)) x 100. 
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Half-maximal inhibitory concentrations (IC50) were generated by fitting the obtained data 
with three parameters nonlinear regression analysis using GraphPad Prism version 6.00 for 
Windows (GraphPad Software, USA).    
 
3.2.2.10. CSNK1A profiling at Reaction Biology 
Single-point measurements analyses and subsequent dose-dependent investigations of 
selected pteridine derivatives for inhibition of CSNK1A1 were performed at Reaction 
Biology (USA) using a radiometric-based assay and ATP concentration of 10 M. For more 
details related to the experimental conditions employed please consult the following 
websites: http://www.reactionbiology.com/webapps/site/KinaseDetail.aspx 
http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx   
Half-maximal inhibitory concentrations (IC50) were generated by fitting the obtained data 
with three parameter nonlinear regression analysis using GraphPad Prism version 6.00 for 
Windows (GraphPad Software, USA).     
 
3.2.2.11. Detection of target engagement using the ActivX
TM
 ATP probe 
HCT116 cell lysate (approx. 1 mg total protein) was thawed on ice prior to activation by 
adding 10 L of 1 M MgCl2 stock solution to each sample. Samples were vortexed gently and 
incubated for 1 min at room temperature. 1 % of the entire volume was removed and replaced 
by the same volume of DMSO (BioReagent for molecular biology, Sigma Aldrich) or 
Epiblastin A stock solution in 100 % DMSO, respectively (0.1, 1 and 10 mM Epiblastin A 
initial stock solutions were used to yield 1, 10 and 100 M Epiblastin A final concentration in 
the cell lysate; DMSO content in all samples was 1 %). Samples were gently vortexed and 
incubated at room temperature for 10 minutes. Two vials containing 12.6 g of the ActivXTM 
ATP probe each (Life Technologies, cat. no. 88311; stored at -80°C) were pre-equilibrated at 
room temperature. 22.5 L water was added to one vial and the content from the first vial 
was transferred to the second vial (final solution contains 2 x 12.6 g ActivXTM ATP probe 
dissolved in 22.5 L water). 5 L from the final solution was transferred to the DMSO and 
Epiblastin A-treated samples, respectively. The content was gently mixed and incubated at 
room temperature for 10 min. The solution was diluted 1:2 in 8 M urea stock solution in 
Pierce IP lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % NP-40 and 
5 % glycerol), followed by the addition of 45 µL of high capacity streptavidin agarose resin 
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(50 % slurry; Pierce™ Streptavidin Agarose, cat no 20347). The resulting mixture was 
incubated for 1 hour at room temperature with overhead rotation (speed 10; Rotator SB3, 
Stuart). Samples were centrifuged at 1000 x g and room temperature for 1 min. The 
supernatant was carefully replaced by the same volume of 4 M urea in Pierce IP lysis buffer 
(same volume that has been added in the case of 8 M urea dilution; see previous step). This 
mixture was transferred into a spin column and centrifuged at 1000 x g and room temperature 
for 1 min. The washing step with 4 M urea in Pierce IP lysis buffer was repeated twice. 
Finally, 45 L of a 2 x Laemmli buffer (100 mM Tris pH = 6.8, 7 % SDS, 200 mM DTT, 
0.014 % Bromphenol blue) was added to the separated beads on the spin column. The spin 
column was closed, placed in a new vial and proteins were denatured for 10 min at 95ºC 
under shaking. The vials were left to cool down at room temperature and the content of the 
spin column was collected in a new vial at 5000 x g for 3 min at room temperature. Target 
engagement experiments were carried out by varying compound incubation time and / or the 
incubation time for the ActivX
TM
 ATP probes, respectively with respect to each kinase. 
Samples were then analyzed by means of immunoblotting or mass spectrometry. 
 
3.2.2.12. Chemical proteomics experiment based on the ActivX
TM
 ATP probe 
Same protocol was applied as previously described for the detection of target engagement. In 
addition, a BSA control was prepared by adding 1 L of 5 pmol / L BSA stock solution in a 
separate vial together with 45 L of the 2 x Laemmli buffer. A total of 7 samples were boiled 
for 10 min at 95ºC with shaking (500 rpm) (Thermomixer
®
 comfort, Eppendorf). Samples 
were left to cool down at room temperature and centrifuged in new vials at 5000 x g for 3 
min at room temperature. Samples were loaded onto Mini-Protean TGX precast gels (4-20 
%). 2 x Laemmli buffer was loaded in a separate well as an additional control for the 
proteomics procedure. Proteins were separated for 20 min at 80 V. The gel washed overnight 
with a mixture containing water, EtOH (ethanol) and acetic acid in a 5:4:1 ratio. The gel was 
cut in pieces with a scalpel and transferred into new LoBind tubes. Gel pieces were washed 
with 200 µL washing solution 1 (WS1, 25 mM ammonium bicarbonate : acetonitrile, 3:1), 
tubes were briefly centrifuged and incubated for 30 min at 37°C with shaking at 600 rpm. 
Supernatants were removed and the procedure was repeated by adding 200 L washing 
solution 2 (WS2, 25 mM ammonium bicarbonate : acetonitrile; 1:1) under the same 
conditions and incubation for 15 min. The solution was removed and 200 L reducing 
solution was added (50 mM dithiothreitol in 25 mM ammonium bicarbonate, always freshly 
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prepared). Vials were briefly centrifuged and incubated for 45 min at 37°C. The reducing 
solution was then exchanged for 200 L alkylating solution (55 mM iodacetamide in 25 mM 
ammonium bicarbonate). Samples were briefly centrifuged and the content was incubated 
under shaking for 1 hour at room temperature in the dark. The alkylating solution was 
removed and gel pieces were washed twice for 15 minutes with WS2 at room temperature. 
Afterwards, the solutions were removed as completely as possible. The gel pieces were 
dehydrated by adding 100 L acetonitrile for 10 minutes at room temperature. At this stage 
the gel turned white. The acetonitrile was removed and the gel pieces were left to dry for 10 
min. Subsequently, 50 L digest solution was added (0.01 g / l Trypsin in 25 mM 
ammonium bicarbonate solution). Vials were briefly centrifuged and incubated for 15 
minutes at room temperature. 75 L 25 mM ammonium bicarbonate was subsequently added 
and vials were again briefly centrifuged and incubated overnight at 30°C with shaking (350 
rpm). 10 L 10 % trifluoroacetic acid was added to the gel pieces and vials were briefly 
centrifuged and incubated for 30 min in a sonicator bath on ice. 75 L acetonitrile was added 
to the gel pieces, vials were briefly centrifuged and were left to shake for 15 minutes at 350 
rpm at room temperature. The supernatant was transferred into new vials and 75 L 
acetonitrile was added to the gel pieces, the vials were briefly centrifuged and subsequently 
incubated for additional 15 minutes at room temperature with shaking (350 rpm). Both 
acetonitrile containing fractions were combined and vacuum concentrated. Samples were 
stored at -20°C.   
 
3.2.2.13. Mass spectrometric analysis 
For protein identification tryptic peptides were separated and analyzed by nano-
HPLC/MS/MS. The separations were carried out on UltiMateTM 3000 RSLCnano system 
(Dionex, Germany). The MS and MS / MS experiments were carried out on a Q Exactive™ 
Hybrid Quadrupole-Orbitrap Mass Spectrometer equipped with a nano-spray source 
(Nanospray Flex Ion Source, Thermo Scientific). All solvents were LC-MS grade. The 
lyophilized tryptic peptides were dissolved in 20 l 0.1 % TFA in water. 3 L of sample were 
injected onto a pre-column cartridge (5 m, 100 Å, 300 m ID * 5 mm, Dionex, Germany) 
using 0.1 % TFA in water as eluent with a flow rate of 30 L/min. Desalting was performed 
for 5 min with eluent flow to waste followed by back-flushing of the sample during the whole 
analysis from the pre-column to the PepMap100 RSLC C18 nano-HPLC column (2 m, 100 
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Å, 75 m ID × 25 cm, nanoViper, Dionex, Germany) using a linear gradient starting with 95 
% water containing 0.1 % formic acid  / 5 % acetonitrile containing 0.1 % formic acid and 
increasing to 70 % water containing 0.1 % formic acid / 30 % acetonitrile containing 0.1 % 
formic acid after 95 min using a flow rate of 300 nL / min.  
The nano-HPLC was online coupled to the Quadrupole-Orbitrap Mass Spectrometer using a 
standard coated SilicaTip (ID 20 μm, Tip-ID 10 μM, New Objective, Woburn, MA, USA). 
Mass range of m/z 300 to 1650 was acquired with a resolution of 70000 for full scan, 
followed by up to ten high energy collision dissociation (HCD) MS / MS scans of the most 
intense at least doubly charged ions. 
Data evaluation was performed using MaxQuant software
193
 (v.1.4.1.2) including the 
Andromeda search algorithm and searching the human reference proteome of the Uniprot 
database. The search was performed for full enzymatic trypsin cleavages allowing two 
miscleavages. For protein modifications carbamidomethylation was chosen as fixed and 
oxidation of methionine and acetylation of the N-terminus as variable modifications. The 
mass accuracy for full mass spectra was set to 5 ppm and for MS / MS spectra 20 ppm. The 
false discovery rates for peptide and protein identification were set to 1 %. Only proteins for 
which at least two peptides were quantified were chosen for further validation. Relative 
quantification of proteins was carried out using the label-free quantification algorithm 
implemented in MaxQuant. Briefly, samples resulting from affinity enrichments with the 
active molecule bound to the solid support were grouped together and those resulting from 
similar enrichment using control molecules as well. All experiments were performed in 
technical triplicates. Label-free quantification (LFQ) intensities were logarithmized (log2) 
and proteins which were not three times quantified in at least one of the groups were filtered 
off. Missing values were imputed using small normal distributed values and a median test 
was performed. Proteins which were statistically significant outliers were considered as hits. 
 
3.2.2.14. WST-1 cell proliferation assays 
The WST-1 cell proliferation assay (Roche, cat no 11644807001) was performed in 96-well 
plates (clear and sterile; BD Biosciences, Germany) as follows. HCT116 cells (80-85 % 
confluent) were seeded in quadruplicate (4000 cells / well, final volume 100 L) and 
incubated overnight at 37°C. Afterwards, the culture medium was replaced with fresh growth 
medium previously supplemented with DMSO and various concentrations of Epiblastin A, 
respectively. Cells were then incubated for 24 h at 37°C prior to addition of the WST-1 
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reagent following the indications from the vendor. Samples were incubated at 37°C between 
30 min and 60 min. To detect the conversion of WST-1 to formazan, absorbance at 450 nm 
(and reference wavelength of 620 nm) was recorded on an Infinite
®
 M200 plate reader 
(Tecan, Austria). 12 different Epiblastin A concentrations were employed for the final 
determination of the half-maximal growth inhibitory (GI50) concentration. The absorbance 
corresponding to the background control (containing culture media without cells and WST-1 
reagent) recorded at 620 nm was subtracted from the absorbance values determined at 450 
nm for each compound-treated sample including DMSO. The percentage of viable cells was 
calculated by relating absorbance of the compound-treated samples to the absorbance 
obtained for cells treated with DMSO, which was set to 100 % cell viability. Half-maximal 
growth inhibitory concentrations values were determined by fitting the generated data with 
the four parameters equation using GraphPad Prism version 6.00 for Windows (GraphPad 
Software, USA). Analogous procedure was followed for analyzing the cell viability of other 
cell lines upon treatment with Epiblastin A or D4476. The number of cells plated for 24 h 
incubation time was as follows: U2OS: 2000 cells / well, BT549: 300 cells / well, HS578T: 
1500 cells / well, HT1080: 500 cells / well, MCF10A: 1500 cells / well, SKBR3: 4000 cells / 
well. HCT116 cells that lack one or both TP53 alleles (HCT116 TP53
-/+
 and HCT116 TP53
-/-
) 
were plated as follows: 4000 cells / well for 24 h incubation and 3000 cells / well for 48 h 
incubation.  
 
3.2.2.15. CellTiter-Glo
®
 viability assay 
This assay follows an analogous experimental procedure as previously described for WST-1 
cell proliferation assay. After overnight incubation with the compound under investigation, 
100 L CellTiter-Glo® reagent (prod. no. G7570, Promega) was added. The luminescent 
signal generated was recorded on an Infinite
®
 M200 plate reader (Tecan, Austria). The 
percentage of viable cells was calculated by relating the luminescence of the compound-
treated samples to the luminescent signal generated by the DMSO treated sample, which was 
set to 100 % cell viability. Half-maximal growth inhibitory concentrations (GI50) values were 
determined by fitting the generated data with the four parameters equation using GraphPad 
Prism version 6.00 for Windows (GraphPad Software, USA).For more details regarding the 
CellTiter-Glo
®
 cell viability assay please consult the following website: 
https://www.promega.de/en/products/cell-health-and-metabolism/cell-viability-
assays/celltiter_glo-luminescent-cell-viability-assay/  
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3.2.2.16. CellTox
TM
 Green cytotoxicity assay 
This assay follows an analogous experimental procedure as previously described for WST-1 
and CellTiter-Glo
®
 assays. After overnight incubation with the compound under 
investigation, 100 L CellToxTM Green reagent (prod. no. G8741, Promega) was added 
following the Endpoint method (2 x) described by the vendor. The fluorescence emission was 
recorded at 515 nm upon excitation with 490 nm light using an Infinite
®
 M200 plate reader 
(Tecan, Austria). The percentage of viable cells was calculated by relating the signal 
generated by the compound-treated sample to the emission detected from the cells treated 
with DMSO, which was set to 100 % cell viability. Half-maximal growth inhibitory 
concentrations (GI50) values were determined by fitting the generated data with the four 
parameters equation using GraphPad Prism version 6.00 for Windows (GraphPad Software, 
USA).For more details regarding the CellTox
TM
 Green cell viability assay please consult the 
following website:  
https://www.promega.de/en/products/cell-health-and-metabolism/cytotoxicity-assays/real-
time-cytotoxicity-assay/celltox-green-cytotoxicity-assay/ 
 
3.2.2.17. Determination of the cell viability using Tryphan blue 
The assay was performed in 6-well plates (clear and sterile; prod. no. 83.3920, Sarstedt, 
Germany) as follows. HCT116 cells (80-85 % confluent) were seeded in duplicate (35,000 
cells / well for 24 h experiment and 25,000 cells / well for 48 h; final volume 2 mL) and 
seeded overnight at 37°C. Afterwards, the media was replaced with fresh growth medium 
supplemented with DMSO and various concentrations of Epiblastin A. Cells were then 
incubated for 24 h and 48 h, respectively at 37°C. Afterwards, the media was removed, cells 
were washed twice with 1 mL PBS, tripsinized and collected with 500 L of fresh growth 
medium. 10 L of this solution was combined with 10 L of 0.4 % Trypan blue stain (prod. 
no. T10282, Invitrogen) and incubated at room temperature for 2 min. 10 L of the final 
solution was added to counting chamber slide (prod. no. C10228, Thermo Scientific) and the 
number of viable cells was assessed using Countess™ Automated Cell Counter (Thermo 
Scientific, Germany). The percentage of viable cells upon compound treatment was 
calculated by relating to the number of cells determined for the DMSO treated sample, which 
was set to 100 % cell viability.   
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4. Results 
4.1. Structure activity relationship (SAR) studies 
To avoid any biases associated with either the origin of the mouse epiblast stem cell line or 
the population heterogeneity previously reported (see section 1.1.10. Reprogramming 
mEpiSCs to mES-like cells – state of the art), small molecules capable of reprogramming 
late-stage mEpiSCs are required. Moreover, these chemical agents would desirably act on 
refractive mEpiSC lines also, namely cell lines that do not undergo spontaneous conversion 
to ESC-like cells upon 2i / LIF media switching. The identification of such small molecules 
offers a much more generalized reprogramming method coupled with the potential to identify 
the signaling pathways responsible for the cellular transition mechanism.  
Following the preliminary results previously mentioned (see section 1.1.11. Reprogramming 
late-stage mEpiSCs to mES-like cells – preliminary results), pteridine derivatives with higher 
reprogramming efficiencies compared to the initial found hit TR were sought. In order to 
determine how the substitution pattern on the pteridine core impacts the conversion ability of 
the starting cell population, structural variations at different positions such as C2, C6 and C7, 
respectively were explored (see Figure 8). All derivatives were tested for reprogramming 
late-stage Oct4-GFP-negative mEpiSCs in combination with PD, both applied at 10 µM 
concentration for 7 days following the previously described conditions.
148,149
 The assay was 
fully performed by Dr. Damir J. Illich (Max Planck Institute for Molecular Biomedicine, 
Münster, Germany). 
 
Figure 8. Derivatization positions on the pteridine scaffold employed for the synthesis of pteridine-based 
compound library. 
First, the substitution pattern on the benzene ring attached to the pteridine scaffold at position 
C6 was explored because of the synthetic accessibility of analogues from readily available 
starting materials and the observation that seemingly small modifications produce marked 
perturbations of the activity of various enzymes.
185,194,195 
Therefore, parameters such as 
electron density on the phenyl ring as well as the steric demand of the substituents might be 
crucial for modulation of enzymatic activity. Moreover, the dihedral angle at position C6 
might also play an important role in fine-tuning potency and / or selectivity. For compound 
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collection synthesis, commercially available 5-nitroso-2,4,6-triaminopyrimidine 1 was 
subjected to reaction with a broad range of phenylacetonitriles to yield derivatives 2 – 30 in a 
single step, using a procedure reported in the literature.
182,184,185,186
 (see Scheme 1).  
 
a. Phenylacetonitrile (1.1 eq), NaH (1.1 eq), 2-ethoxyethanol, reflux (1 - 3 h) 
Scheme 1. Synthesis route to access pteridine-derived compounds bearing substitutions at position C6.  
Even small modifications of the phenyl ring affected the conversion efficiency significantly 
as shown by entries 2-30 in Table 2. For example, a fluorine atom in the para-position as in 
derivative 3 (entry 3) diminished the reprogramming activity to approximately half compared 
to TR (entry 2; the relative biological activity of TR was arbitrarily set to 1). Introduction of 
bulkier substituents like methyl-, amino- or methoxy- in derivatives 6, 7 and 5 respectively, 
led to a larger drop or complete loss of the reprogramming activity (compare entry 2 with 
entries 6, 7 and 5, respectively). Thus, it could be demonstrated that an unsubstituted para-
position on the phenyl ring at position C6 is essential for maintaining the biological activity. 
In addition, varying the substitution pattern at the meta-position was well accepted. For 
example, meta-fluoro (entry 13) and meta-methyl (entry 14) containing derivatives were 
more active than TR (compare entry 2 with entries 13 and 14 respectively). The introduction 
of a chlorine atom in the same position yielded derivative 12 (entry 12) that exhibited an 8-
fold increased reprogramming efficiency compared to the guiding compound (compare entry 
2 with entry 12). A slightly larger halogen substituent such as bromine generated derivative 
15 (entry 15) which is equipotent to TR. Introduction of an alkoxy, trifluoromethyl or amino 
group as in derivatives 17, 16 and 18 (entries 17, 16 and 18 respectively) led to a reduction of 
the biological activity compared to TR. Derivatization of the ortho-position was also well 
tolerated, as seen in ortho-fluorine and ortho-methoxy substitution of compounds 20 and 19 
(entries 20 and 19) which showed activities comparable to the parent molecule TR.  
Overall, the structure-activity relationship study revealed that meta- and ortho-substitutions 
were tolerated and in some cases even led to higher biological activity compared with the 
parent hit. However, even minor structural changes of the para-position, such as the 
introduction of a fluorine atom, nearly abolished the conversion efficiency.   
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Nr. R1 R2 R3 Efficiency 
2 -H -NH2 -NH2 1 
3 p-F-Ph -NH2 -NH2 0.6 
4 p-OAllyl-Ph -NH2 -NH2 0.1 
5 p-OCH3-Ph -NH2 -NH2 0.1 
6 p-CH3-Ph -NH2 -NH2 0.07 
7 p-NH2-Ph -NH2 -NH2 0 
8 p-NO2-Ph -NH2 -NH2 0 
9 p-iPr-Ph -NH2 -NH2 0 
10 p-Ph-Ph -NH2 -NH2 0 
11 p-OBz-Ph -NH2 -NH2 0 
12 m-Cl--Ph -NH2 -NH2 8.4 
13 m-F-Ph -NH2 -NH2 3.1 
14 m-Me-Ph -NH2 -NH2 1.6 
15 m-Br-Ph -NH2 -NH2 1.1 
16 m-CF3-Ph -NH2 -NH2 0.7 
17 m-OCH3-Ph -NH2 -NH2 0.3 
18 m-NH2-Ph -NH2 -NH2 0.2 
19 o-OCH3-Ph -NH2 -NH2 1.3 
20 o-F-Ph -NH2 -NH2 1.3 
21 o,o‘-diCl-Ph -NH2 -NH2 2.2 
22 o,p-diCl-Ph -NH2 -NH2 0.5 
23 m,p-diCl-Ph -NH2 -NH2 1.6 
24 o,o‘-diF-Ph -NH2 -NH2 2.3 
25 m,o‘-diF-Ph -NH2 -NH2 0.8 
26 Naphtalen-1-yl -NH2 -NH2 2.6 
27 Pyridin-2-yl -NH2 -NH2 0.5 
28 Benzo[b] thiophen-3-yl -NH2 -NH2 0.4 
29 Thiophen-2-yl -NH2 -NH2 0.1 
30 Pyridin-3-yl -NH2 -NH2 0.01 
Table 2. Reprogramming efficiency of late-stage mEpiSCs upon treatment with derivatives 2-30 and PD at 10 
M concentration for 7 days. The relative reprogramming activity of TR (entry 2) was arbitrary set to 1. PD = 
PD0325901 (MEK1 inhibitor). Data are representative of three independent experiments. 
Given the strong influence of phenyl mono-derivatization on the biological activity, various 
disubstituted derivatives were subsequently generated following the same synthetic 
procedure. Not surprisingly, the disubstitution pattern on the phenyl ring had a strong impact 
on the reprogramming yield. For example, two ortho-fluorine or ortho-chlorine atoms as 
shown for derivatives 24 and 21 (entries 24 and 21) are beneficial as compared to TR 
(compare entry 2 with entries 24 and 21, respectively). However, introduction of two 
chlorines in para- and meta-position as in compound 23 (entry 23) only slightly increased the 
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reprogramming efficiency. This is in agreement with the previous observation made for the 
monosubstituted analogs, i.e. the positive influence of the meta-chloro derivatization appears 
to be negatively balanced by the para-substituent. The remaining derivatives 22 and 25 
(entries 22 and 25) failed to generate more active compounds than the initial found hit 
(compare entry 2 with entries 22 and 25).  
The presence of a phenyl ring is important for the conversion to an ESC-like state, since the 
replacement with different heterocycles led to disparate reprogramming activity (entries 26-
30). On one hand, the introduction of a 1-naphthalenyl moiety as shown for derivative 26 
(entry 26) yielded a more active compound than TR (compare entry 2 with entry 26). On the 
other hand, derivatives 27-30 (entries 27-30) failed to deliver more potent agents compared to 
the parent hit, suggesting limited acceptance of heterocyclic moieties other than phenyl (entry 
2) and naphthyl (entry 26).  
In conclusion, the structure-activity relationship study within this series indicated that the 
range of allowed derivatizations at position C6 of the pteridine core is rather limited to just 
few key substitutions on the phenyl ring. 
The next position addressed for derivatization was the amino group adjacent to the phenyl 
ring located at C7. Several derivatives were generated from commercially available 
derivative 31 following synthetic procedures already reported in the literature (see Scheme 
2).
180
 The biological activity of the newly generated compounds is shown in Table 3.  
 
a. NaHCO3 (2 eq), H2O; then benzil (1 eq), reflux (3h) [derivatives 32 and 34]                    
b. Phenylglyoxal (1.1 eq), hydroxylamine hydrochloride (1.1 eq), MeOH, reflux [derivative 33] 
Scheme 2. Synthesis route to access pteridine-derived compounds bearing substitutions at position C6 and C7. 
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Nr. R1 R2 R3 Efficiency 
2 -Ph -NH2 -NH2 1 
32 -Ph -Ph -NH2 0.5 
33 -Ph -H -NH2 0.1 
34 m-OH-Ph m-OH-Ph -NH2 0.07 
Table 3. Reprogramming efficiency of late-stage mEpiSCs upon treatment with derivatives 32-34 and PD at 10 
M concentration for 7 days. The relative reprogramming activity of TR (entry 2) was arbitrary set to 1. PD = 
PD0325901 (MEK1 inhibitor). Data are representative of three independent experiments. 
As shown in Table 3, the various substitutions at position C7 did not generate more active 
derivatives than the initial hit TR (compare entry 2 with entries 32-34, Table 3). Whereas the 
introduction of a phenyl ring as shown for derivative 32 (entry 32) diminished the activity to 
half, replacement of the original amino group with hydrogen (entry 33) and 3’-
hydroxyphenyl (entry 34), respectively almost completely abolished the biological activity. 
These results suggest that the presence of the amino group at C7 is mandatory for an efficient 
reprogramming process. 
The last derivatization investigated was at position C2 of the pteridine scaffold. Derivatives 
37-40 were generated from the readily accessible starting materials 35 and 36, respectively 
(see Scheme 3). Biological activities exhibited by these derivatives are presented in Table 4.   
 
a. Phenylacetonitrile (1.1 eq), NaH (1.1 eq), 2-ethoxyethanol, reflux (1-3h) 
Scheme 3. Synthesis route to access pteridine-derived compounds bearing substitutions at position C2 and C6. 
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Nr. R1 R2 R3 Efficiency 
2 -Ph -NH2 -NH2 1 
37 -Ph -NH2 -CH3 0 
38 m-F-Ph -NH2 -CH3 0 
39 -Ph -NH2 -SCH3 0.08 
40 m-F-Ph -NH2 -SCH3 1.72 
Table 4. Reprogramming efficiency of late-stage mEpiSCs upon treatment with derivatives 37-40 and PD at 10 
M concentration for 7 days. The relative reprogramming activity of TR (entry 2) was arbitrary set to 1. PD = 
PD0325901 (MEK1 inhibitor). Data are representative of three independent experiments.  
As evidently shown in Table 4, the replacement of the initial amino group at C2 with either 
methyl or thiomethyl as shown for derivatives 37 and 39 (entries 37 and 39) completely 
reduced the biological activity (compare entry 2 with entries 37 and 39). This result indicates 
that the presence of the original amino group is imperative for the reprogramming process to 
occur. Taking in consideration the beneficial aspects upon introducing halogen atoms in the 
meta-position of the C6 phenyl ring, derivatives that maintain this substitution pattern and 
additionally possess methyl or thiomethyl groups in position C2 (entries 38 and 42) were 
consequently synthesized. Only the addition of a fluorine atom in the case of thiomehyl 
derivative as shown by compound 40 (entry 40) could reproduce the phenotype. Surprisingly, 
these compounds were even more active than TR, but less potent than the congeners 
containing the original amino group in position C2 (compare entry 13, Table 2 with entry 40, 
Table 4). The current finding suggests that the amino-group at C2 position can be replaced 
with thiomethyl, however only in combination with fluorine in the meta-position of the 
phenyl ring located at C6. 
In conclusion, the structure activity relationship indicated that the range of derivatizations 
permitted on the pteridine ring is rather limited (see Figure 9). Thus, only substitutions in the 
meta- and ortho-positions of the C6 phenyl ring could yield compounds with better 
reprogramming efficiencies than TR. Any tentative placement of groups other than hydrogen 
in the para position led to significant reduction or completely abolished the biological 
activity. Moreover, both amino groups in positions C2 and C7 were crucial, although the 
former could be replaced with thiomethyl moiety but only when the phenyl ring is equipped 
with a fluorine atom in the meta-position. 
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Figure 9. Conclusions of the structure-activity relationship study derived from the capacity to induce 
reprogramming of late-stage mEpiSCs by derivatives 2-40 in combination with PD, both compounds at 10 M 
for 7 days. PD = PD0325901 (MEK1 inhibitor).  
 
4.2. Characterization of the reprogramming activity 
As shown in Table 2-4, several compounds were identified to be more potent compared to 
the parent derivative TR, namely derivatives 12, 13, 26, 21 and 23 (entries 12, 13, 26, 21 and 
23, Table 2).  
 
Figure 10. Chemical structures of Epiblastin A-E. The number between the brackets indicates the entry number 
shown in Table 2. R.E. is the abbreviation for Reprogramming Efficiency which in case of TR (entry 2) was 
arbitrary set to 1. 
As these compounds share the common ability of converting late-stage mEpiSCs into mES-
like cells, these derivatives were designated Epiblastins, and were further labelled according 
to their decreasing biological activity as Epiblastin A-E, e.g. derivative 12 (entry 12, Table 2) 
is termed Epiblastin A (see chemical structure in Figure 10). Due to their increased 
biological activity compared to TR, Epiblastin A-E were selected for further in-depth 
biological characterization. Epiblastin B contains a meta-fluoro substitution and is the second 
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most active compound. The introduction of the 1-naphthalenyl moiety as in Epiblastin C 
slightly decreased the biological activity compared to Epiblastin B. Finally, the specific 
arrangement of two chlorine atoms on the phenyl ring in Epiblastin D and Epiblastin E, 
respectively, generated biologically more active compounds compared to TR.  
Employing the same screening assay conditions established for TR
148,149
 in 96-well format 
(experiments performed by Dr. Damir J. Illich, Max Plank Institute for Molecular 
Biomedicine, Münster, Germany), Epiblastin A-E derivatives were separately tested for 
reprogramming of late-stage mEpiSCs in lower throughput. TR was added in all the 
performed assays as the reference compound. Experiments carried out by Dr. Miao Zhang 
(Max Plank Institute for Molecular Biomedicine, Münster, Germany) confirmed that 
Epiblastin A-E reproducibly convert the late-stage mEpiSC to an Oct4-GFP-positive ESC-
like population in combination with PD. As shown in Figure 11, these derivatives 
reproducibly achieve reprogramming efficiencies between 38 % and approximately 70 % as 
quantified by means of fluorescence activated cell sorting (FACS).  
 
Figure 11. Reprogramming activity of TR and Epiblastin A-E on late-stage mEpiSCs evaluated by mean of the 
Oct4-GFP intensity of reprogrammed cells quantified using fluorescence-activated cell sorting (FACS). 
Reprogramming activity of TR / Epiblastin A-E has been measured in the presence PD0325901 (MEK1 
inhibitor). All compounds were used at 10 M concentration. LS EpiSCs = late-stage mouse epiblast stem cells; 
ESCs = mouse embryonic stem cells; TR = Triamterene. Representative histograms show the expression of 
Oct4-GFP (pluripotency-associated marker) in percentage on the x-axis. FSC = Forward scatter counts. Data are 
representative of three independent experiments. 
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Therefore, 38 % to 70 % of the initial cell population could reactivate the expression of Oct4 
upon treatment with Epiblastins A-E and PD. For comparison, the expression levels of the 
same gene construct in an authentic mESC line was evaluated to be approximately 93 %, 
whereas TR converted only 31 % of the starting population.  
 
Figure 12. Detection of REX1, an ESC-specific marker, in the reprogrammed cells generated upon treatment 
with TR / Epiblastin A-E in combination with PD at 10 M for 7 days. TR = Triamterene; PD = PD0325901 
(MEK1 inhibitor). Cells were stained for DNA (blue) and REX1 (red) using anti-Rex1 antibody and a secondary 
antibody coupled to Alexa Fluor
®
 568 and DAPI, respectively. Scale bar: 100 m. 
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Immunofluorescence experiments showed that the Oct4-GFP-positive cell population 
obtained upon treatment with Epiblastin A-E and PD homogeneously express Rex1 (also 
known as Zpf42),
128
 a known marker associated with embryonic stem cells only (see Figure 
12).
128,129
 This result substantiates that the transition of the initial population indeed 
progressed to a naïve pluripotent state.  
 
4.3. Pteridine-based analogs inhibit the CSNK1 kinase family 
Since TR has been associated with antagonistic effects on the epithelial sodium channel 
(ENaC),
150
 this target was first investigated to check if it is responsible for reprogramming 
late-stage mEpiSCs. The structurally unrelated ENaC inhibitor amiloride (see chemical 
structure in Figure 13) failed to reproduce the phenotype, indicating that ENaC is not 
responsible for the cellular transition. Additionally, a TR-related derivative termed TG100-
115 (see chemical structure in Figure 13) has previously been reported to target various 
phosphatidylinositol 3-kinase (PI3K) isoforms with half-maximal inhibitory concentration 
values ranging from nanomolar to micromolar range.
196,197
 Therefore, TR was been 
submitted to a kinase profiling study comprising more than 100 protein kinases that are a part 
of major signaling pathways governing various aspects of stem cell biology such as 
differentiation, self-renewal and reprogramming. The results of the screening campaign 
showed that TR is a fairly selective inhibitor of casein kinases 1 (CSNK1)
198,199
 alpha 1 
(thereafter A1), delta (thereafter D) and epsilon (thereafter E), in addition to PI3K 
isoforms.
148,149
 The contribution of the PI3K family to the reprogramming mechanism was 
devalidated using structurally diverse inhibitors such as TG100-115, LY294002 and 
AS605240 (see chemical structures in Figure 13). Only upon treatment with the pan-
CSNK1A1/D/E inhibitor D4476
200
 (see chemical structure in Figure 13), the initial cell 
population reactivated Oct4-GFP expression. 
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Figure 13. Chemical structures of the ENaC inhibitor amiloride, PI3K inhibitors TG100-115, LY294002 and 
AS605240 together with the pan-CSNK1A1/D/E inhibitor D4476. 
By means of fluorescence-activated cell sorting (FACS), the biological action of the 
derivatives shown above was quantified. D4476 was found to be slightly more active than the 
initial found hit TR, suggesting that CSNK1 inhibition might, at least partially contribute to 
the reprogramming mechanism (see Figure 14). 
 
Figure 14. Reprogramming activity of ENaC inhibitor amiloride, PI3K inhibitors LY294002, AS605240 and 
TG100-115 together with the pan-CSNK1A1/D/E inhibitor D4476. CTRL = late-stage mEpiCSs treated with 
DMSO. Oct4-GFP intensity of reprogrammed cells was quantified by mean of fluorescence-activated cell 
sorting (FACS). Data are representative of three independent experiments. 
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Therefore, the pteridine-based compound collection was assayed against CSNK1D and 
CSNK1E isoenzymes by means of a luminescent-based readout using the KinaseGlo
®
 reagent 
(Promega)
201
 (see Figure 15 for the chemical reaction underlying the signal generation). 
 
Figure 15. Chemical reactions within the KinaseGlo
®
 assay. The activity of ATP-consuming enzymes 
(reactions) is detected by means of a decrease in the ATP concentration. Upon the ATPase (e.g. kinase) reaction, 
the remaining ATP is employed as substrate by the luciferase enzyme to catalyze the mono-oxygenation of 
luciferin to oxyluciferin producing one photon of light per turnover. 
The principle of the KinaseGlo
® 
reagent assay relies on the ability to evaluate the kinase 
activity by measuring the remaining ATP after the completion of the enzymatic reaction. 
Thus, the residual ATP is consumed in the presence of a thermostable luciferase (Ultra-
Glo™) which uses Beetle Luciferin as substrate and molecular oxygen. As a consequence of 
this enzymatic reaction, a stable “glow-type” luminescent signal is generated, which is 
inversely related to kinase activity. One of the main advantages of the KinaseGlo
®
 reagent is 
the possibility of measuring every type of kinase and substrate (peptide, protein, lipid, sugar) 
combination and its independency of any radiolabeled reagents. According to the 
manufacturer, the Ultra-Glo™ Luciferase is much less prone to small molecule interference 
than other ATP detection kits, thus reducing the false positive rate.
202,203
 Many reports in the 
literature successfully used this platform for high throughput screening campaigns for other 
kinases
204,205,206
 and even for CSNK1.
207,208,209
  
His6-tagged constructs of the human CSNK1D (amino acid sequence 1-294, thereafter 
designated CSNK1D) and CSNK1E (amino acid sequence 1-294, thereafter termed 
CSNK1E) lacking the C-terminus were designed in both cases. The sole purpose of 
generating constructs lacking the C-terminae domains was attributed to the fact that residues 
within this region have been previously reported to be phosphorylated by CSNK1 leading to 
subsequent autoinhibition of the kinase activity.
210,211,212  
The assay conditions for the 
CSNK1D construct were optimized with respect to various parameters such as the 
concentration of the enzyme, substrate and ATP using various incubations and reaction times 
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(initial assay optimization was carried out by Dr. Yasushi Takemoto, RIKEN-Max Planck 
Joint Research Center for Systems Chemical Biology, Wako, Japan; see Figure 16). 
  
Figure 16. Optimization of the assay conditions with respect to the CSNK1D and substrate peptide 
concentration, respectively. (A) Determination of the optimal CSNK1D enzyme concentration at 50 M 
substrate peptide concentration. Different concentrations of purified CSNK1D were incubated with and without 
substrate peptide. (B) Determination of the optimal substrate peptide concentration at a fixed CSNK1D enzyme 
concentration of 10 ng / L. Different concentrations of substrate peptide were incubated with and without 
purified CSNK1D.  The kinase activity was assessed by means of the KinaseGlo
®
 reagent. The results represent 
mean values ± SD of three independent measurements performed in duplicate. [R.L.U. = Relative Light Units] 
First, the optimal enzyme concentration was determined using 50 M of the substrate 
peptide. As shown in Figure 16A, the best results were achieved by using 10 ng / L of the 
CSNK1D kinase under the employed experimental conditions. In this case, the Z’ factor213 
had an excellent value of 0.87.  
After determining the suitable CSNK1D enzyme concentration for the assays, similar 
experiments were performed whereby the optimal concentration for the substrate peptide was 
evaluated. Accordingly, maintaining the CSNK1D enzyme concentration at 10 ng / L, a 
broad range of substrate peptide concentrations was tested from 0 to 50 M (see Figure 
16B). The best results were obtained by using 50 M of the substrate judging by the Z’ factor 
which under these conditions was calculated to be 0.93. Gratifyingly, the conditions 
optimized for CSNK1D were successfully translated to the almost identical CSNK1E 
isoenzyme with very good Z’ factor values of 0.9 and 0.7 for 10 ng / L enzyme (see Figure 
17A) and 50 M substrate peptide (see Figure 17B) concentrations, respectively. 
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Figure 17. Optimization of the assay conditions with respect to the CSNK1E and substrate peptide 
concentration, respectively. (A) Determination of the optimal CSNK1E enzyme concentration at 50 M 
substrate peptide concentration. Different concentrations of purified CSNK1E were incubated with and without 
substrate peptide. (B) Determination of the optimal substrate peptide concentration at a fixed CSNK1E enzyme 
concentration of 10 ng / L. Different concentrations of substrate peptide were incubated with and without 
purified CSNK1E.  The kinase activity was assessed by means of the KinaseGlo
®
 reagent. The results represent 
mean values ± SD of three independent measurements performed in duplicate. [R.L.U. = Relative Light Units] 
Furthermore the effect of DMSO on the CSNK1D enzymatic activity was determined. As a 
result, the final DMSO concentration was set at 1 % to counteract the high tendency for 
precipitation of the pteridine library members (data not shown).  
With the optimized conditions in hands, the inhibitory activity for the previously published 
pteridine derivatives, TR and Epiblastin A, was evaluated for CSNK1D/E isoenzymes. The 
half-maximal inhibitory concentrations (IC50) were found to be 36 M and 0.5 M, 
respectively against CSNK1D (see Figure 18A). These values are in good agreement with 
the previously published reports.
148,149
 A good correlation was found in the case for CSNK1E 
inhibition by Epiblastin A as well, exhibiting an IC50 value of approximately 5 M compared 
to 27 M for TR (see Figure 18B). Furthermore, testing the structurally unrelated pan-
CSNK1 inhibitor D4476
200
 in the assay also gave a good correlation to the IC50 values 
previously reported by commercial profiling at Reaction Biology. Moreover, taking in 
consideration the broad range of IC50 values determined, the described assay can identify 
CSNK1D/E inhibitors with potencies (e.g., IC50 values) ranging from nanomolar to high 
micromolar range.   
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Figure 18. Dose-response curves of TR, Epiblastin A and D4476 for inhibition of CSNK1D (A) and CSNK1E 
(B). The curves represent the mean values ± SD of three independent measurements performed in duplicate. 
Determined IC50 value ± SD were generated by fitting the data with three parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. 
Before proceeding with profiling the members of the library against CSNK1D/E isoenzymes, 
the mode of inhibition exhibited by the pteridine class of compounds was explored. This can 
be proven using the Lineweaver-Burk plot and the shift of the IC50 value upon modifying the 
ATP concentration in the assay. The Lineweaver-Burk plot is obtained by testing various 
concentrations of the inhibitor under investigation at different ATP concentrations. As a 
result, Epiblastin A was found to act as a competitive inhibitor of both CSNK1D (Figure 
19A) and CSNK1E (Figure 19B) isoforms with respect to ATP. 
 
Figure 19. Determination of the CSNK1D/E kinase inhibition mode for Epiblastin A. Lineaweaver-Burk plot 
shows competitive inhibition of CSNK1D (A) and CSNK1E (B) by Epiblastin A with respect to various ATP 
concentrations. Data represent mean values ± SD of three independent measurements performed in duplicate. 
Black arrows indicate the increasing concentrations of Epiblastin A. [R.L.U. = Relative Light Units] 
The ATP competitive nature of Epiblastin A inhibition of these isoenzymes was further 
proven by analyzing the IC50 value at 50 M and 100 M ATP (see Figure 20A for 
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CSNK1D and Figure 20B for CSNK1E). In this case, the IC50 value for CSNK1D/E shifts to 
higher value upon increasing ATP concentrations in the assay suggesting that Epiblastin A 
directly competes with ATP for the nucleotide binding pocket of CSNK1D/E. This type of 
inhibition is not surprising when considering that the 2,4-diaminopyrimidine unit mimics the 
structure of the naturally occurring purine moiety present in the ATP structure. 
 
Figure 20. Half-maximal inhibitory determinations of Epiblastin A for inhibiting CSNK1D (A) and CSNK1E 
(B) at various ATP concentrations. Data represent mean values ± SD of three independent measurements 
performed in duplicate.  
As a next step, the inhibition constant (Ki) of Epiblastin A for CSNK1D/E isoenzymes was 
determined by employing the Dixon plot at 10, 20 and 30 M ATP concentration, 
respectively. The result of this analysis yielded for Epiblastin A an inhibition constant of 0.9 
M for CSNK1D (see Figure 21A) and 3.7 M for CSNK1E (see Figure 21B). 
 
Figure 21. Dixon plot of Epiblastin A for inhibiting CSNK1D (A) and CSNK1E (B) yields inhibition constants 
(Ki) by using different concentrations of this derivative at various ATP concentrations. Data represent mean 
values ± SD of three independent measurements performed in duplicate. Black arrows indicate the increasing 
concentrations of ATP. [R.L.U. = Relative Light Units] 
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In summary, a luminescence-based assay using KinaseGlo
®
 reagent characterized by very 
good Z’ factor values was developed to monitor the enzymatic activity of CSNK1D and 
CSNK1E isoenzymes. Moreover, additional analyses disclosed a competitive type of 
inhibition of CSNK1D/E isoforms by Epiblastin A with respect to ATP. In the subsequent 
sections, the newly developed homogeneous assay was utilized to profile the pteridine library 
for identifying novel potent and / or selective CSNK1D/E inhibitors. 
 
4.4. Screening of TR-based derivatives yields potent and / or selective 
CSNK1D/E inhibitors 
Small changes on the phenyl ring attached to the pteridine core in position C6 are crucial for 
modulating the activity of various enzymes.
194,195,185
  In consideration of these findings, the 
pteridine-based small molecule library was explored for potent and / or selective CSNK1D/E 
inhibitors. Before proceeding with assaying the enzymatic activity in the presence of the 
compounds, the interference of the pteridine derivatives with the luciferase reaction was 
crosschecked in absence of the kinase and the substrate to rule out false positives. Therefore, a 
single-point measurement study at the highest compound concentration employed in the assay, 
namely 50 M, was employed. Fortunately, only a single compound (see entry 39, Figure 22) 
inhibited the luciferase enzymatic activity to various extents and was subsequently discarded 
from the study. 
 
Figure 22. Single-point measurement analyses of pteridine derivatives 2-40 profiled at 50 M for inhibition of 
the luciferin-luciferase background reaction. The results represent the mean values ± SD of three independent 
measurements performed in duplicate.  
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After having ruled out the interference by pteridine derivatives on luciferase reaction itself, 
the remaining derivatives were analyzed for inhibiting CSNK1D and CSNK1E isoenzymes at 
50 M compound concentration (see Figure 23A for CSNK1D and Figure 23B for 
CSNK1E). 
 
 
Figure 23. Single-point measurement analyses of pteridine derivatives 2-40 profiled at 50 M concentration for 
inhibiting CSNK1D (A) and CSNK1E (B). The results represent the mean values ± SD of three independent 
measurements performed in duplicate. Black dashed line suggests the residual kinase activity threshold used for 
the compound selection. Derivatives below this line were further employed in concentration-dependent studies. 
To generate an extended structure-activity relationship study, the compounds that showed at 
least 20 % residual kinase activity upon 50 M compound treatment, i.e more than 80 % 
inhibition of the enzymatic reaction, were selected. All derivatives that fulfilled this criterion 
were further analyzed in dose-dependent experiments employing 10-point IC50 curves. The 
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results of the screening campaign for CSNK1D/E are shown in Table 5. From these results, 
the following conclusions can be drawn (see entries 2-40, Table 5).  
 
Nr. R1 R2 R3 
IC50 [µM] 
CSNK1D 
IC50 [µM] 
CSNK1E 
2 -Ph -NH2 -NH2 36.4 ± 6.4 26.8 ± 4.2 
3 p-F-Ph -NH2 -NH2 68% 67% 
4 p-OAllyl-Ph -NH2 -NH2 99% 86% 
5 p-OCH3-Ph -NH2 -NH2 63% 47% 
6 p-CH3-Ph -NH2 -NH2 52% 48% 
7 p-NH2-Ph -NH2 -NH2 15% 35% 
8 p-NO2-Ph -NH2 -NH2 88% 71% 
9 p-iPr-Ph -NH2 -NH2 95% 90% 
10 p-Ph-Ph -NH2 -NH2 101% 78% 
11 p-Obz-Ph -NH2 -NH2 97% 97% 
12 m-Cl-Ph -NH2 -NH2 0.5 ± 0.1 4.7 ± 0.8 
13 m-F-Ph -NH2 -NH2 61.8 ± 12.5 14.4 ± 4.7 
14 m-Me-Ph -NH2 -NH2 20.2 ± 4.7 30%** 
15 m-Br-Ph -NH2 -NH2 2.5 ± 0.5 42%* 
16 m-CF3-Ph -NH2 -NH2 95% 91% 
17 m-OCH3-Ph -NH2 -NH2 12.3 ± 1.9 26.3 ± 4.9 
18 m-NH2-Ph -NH2 -NH2 32.4 ± 7.0 12.4 ± 3.0 
19 o-OCH3-Ph -NH2 -NH2 70% 26% 
20 o-F-Ph -NH2 -NH2 25%** 28.3 ± 3.8 
21 o,o‘-diCl-Ph -NH2 -NH2 24%** 38.9 ± 5.8 
22 o,p-diCl-Ph -NH2 -NH2 44%** 4.3 ± 0.9 
23 m,p-diCl-Ph -NH2 -NH2 97% 75% 
24 o,o‘-diF-Ph -NH2 -NH2 35.7 ± 5.2 51.5 ± 11.8 
25 m,o‘-diF-Ph -NH2 -NH2 25%** 38.4 ± 6.1 
26 Naphtalen-1-yl -NH2 -NH2 36.5 ± 6.4 1.0 ± 0.2 
27 Pyridin-2-yl -NH2 -NH2 42%* 6.6 ± 1.9 
28 
Benzo[b] 
thiophen-3-yl 
-NH2 -NH2 2.8 ± 0.4 0.6 ± 0.1 
29 Thiophen-2-yl -NH2 -NH2 24.4 ± 6.4 8.1 ± 2.5 
30 Pyridin-3-yl -NH2 -NH2 16.1 ± 4.3 15.5 ± 4.0 
32 -Ph -Ph -NH2 87% 79% 
33 -Ph -H -NH2 80.6 ± 11.7 6.0 ± 1.5 
34 m-OH-Ph m-OH-Ph -NH2 9.6 ± 1.6 6.6 ± 1.5 
37 -Ph -NH2 -CH3 86% 92% 
38 m-F-Ph -NH2 -CH3 78% 91% 
40 m-F-Ph -NH2 -SCH3 99% 105% 
Table 5. Activity of pteridine derivatives 2-40 for inhibition of CSNK1D and CSNK1E. Data represent mean 
values ± SD of three independent measurements performed in duplicate. Residual activities were determined 
upon incubation with 50 M pteridine derivative; * = residual activity at 12.5 M, higher concentration lead to 
precipitation; **  = the IC50 curve has not reach saturation and thus no proper IC50 value could be determined. 
Determined IC50 value ± SD were generated by fitting the data with three parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. 
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Compared to the unsubstituted derivative, TR (entry 2, IC50 = 36.4 ± 6.4 M for CSNK1D 
and IC50 = 26.3 ± 4.9 M for CSNK1E, respectively), any other derivatization of the para-
position of the phenyl ring is detrimental for the inhibition of both CSNK1D/E isoenzymes.  
Even a fluorine atom as shown by derivative 3 (entry 3) yielded an inactive compound 
exhibiting 68 % and 67 % residual kinase activity for CSNK1D and CSNK1E, respectively 
when treated with 50 M derivative concentration. Any other substitutions lead to an almost 
complete loss of the enzymatic activity suggesting that this position is not amenable for 
substitution (entries 4-11). However, derivatization of the meta-position proved to be more 
accessible (entries 12-18). For example, the most active inhibitor against CSNK1D identified 
so far is Epiblastin A (entry 12, IC50 = 0.5 ± 0.1 M) which features a chlorine atom in the 
meta-position. Interestingly, the replacement by a bromine atom as shown for derivative 15 
(entry 15) did not dramatically reduced the activity against the same isoform (IC50 = 2.5 ± 0.5 
M), while the fluorine atom in Epiblastin B (entry 13) yielded a relatively inactive 
derivative (IC50 = 61.8 ± 12.5 M). Of side note, the iodo-derivative was also synthesized but 
could not be used in the study due to severe solubility problems. The halogenated series 
clearly shows that the meta-chloro derivatization fulfills best the steric and electronic 
requirements for achieving a high inhibition degree against CSNK1D (see section 4.6. 
Crystallization studies). Additionally, the methoxy moiety was also tested, as well as methyl- 
and amino-substitutions in the same position in derivatives 17, 14 and 18, respectively 
(entries 17, 14 and 18). The compounds exhibited IC50 values of 12, 20 and 32 M, 
respectively. These decorations are electron-donating groups in nature and might imply a 
possible influence of the electron density of the phenyl ring on the inhibition process.  
The situation is different when analyzing the impact of the meta-substitution on the closely 
related CSNK1E isoform. The introduction of a chlorine atom as shown for Epiblastin A 
(entry 12) generated an IC50 value of 4.7 M, which is approximately ten times less active 
than in the case of CSNK1D. In the same time, meta-fluoro substituted compound 13 (entry 
13) exhibited an IC50 for CSNK1E of 14 M, while the bromine substitution as in derivative 
15 (entry 15) could not completely inhibit CSNK1E activity and reduced the residual kinase 
activity to 58 % at a concentration of 12.5 M. Higher concentrations for this derivative lead 
to precipitation. Worthwhile are the meta-amino and meta-methoxy derivatives 18 and 17 
(entry 18 and entry 17) that showed IC50 values for CSNK1E of 12 M and 25 M, 
respectively. Moreover, 50 M of the methyl-substituted compound 14 (entry 14) could not 
entirely inhibit the CSNK1E enzymatic activity, i.e. at this concentration the residual kinase 
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activity was 30 %. For both the CSNK1D/E isoenzymes, the trifluoromethyl containing 
derivative 16 (entry 16) was found to be completely inactive. A limited number of 
compounds bearing ortho-substitution on the C6 phenyl ring did not yield potent derivatives 
against neither CSNK1D nor CSNK1E. 
In conclusion, decorating the meta-position of the phenyl ring with either a chlorine- or 
bromine-atom as shown for Epiblastin A and derivative 15 (entries 12 and 15) represents a 
promising strategy to obtain potent CSNK1D inhibitors. For example, Epiblastin A shows a 
good selectivity profile for CSNK1D, outmatching other commercial available CSNK1D 
inhibitors such as PF-670462.
214
 Furthermore, the compounds reported here are excellent 
starting points for medicinal chemistry campaigns directed towards improving the activity 
and / or selectivity profile towards CSNK1D. The current findings highlight the importance 
of the substitution pattern on the phenyl ring at position C6 to achieve high potency and / or 
selectivity, which is also in line with previous reports for other classes of enzymes. 
Disubstitution on the phenyl ring furnished interesting features of the pteridine derivatives 
(entries 21-25, Table 5). For example, the chlorine atom distribution dramatically impacts the 
inhibitory activity especially in the case of CSNK1E. Thus, simultaneous introduction of a 
chlorine atom in ortho- and para-positions as shown in the case of derivative 22 (entry 22) 
yielded the most active inhibitor of this series with an estimated IC50 value of 4.3 M for 
CSNK1E. As a comparison, CSNK1D isoenzyme exhibited 44 % residual enzymatic activity 
upon treatment with this inhibitor at a concentration of 50 M. Other chlorine substitutions 
on the phenyl ring yielded inactive derivatives for both CSNK1D/E. Similar results were 
obtained with a limited number of compounds bearing fluorine derivatizations in various 
positions on the phenyl ring at C6. In conclusion, decorating the aromatic moiety with two 
chlorine atoms in specific positions could represent the basis of generating selective CSNK1E 
inhibitors. 
Startling results were obtained when the phenyl ring was replaced by various heterocycles 
(entries 26-30, Table 5). For example, 2-thiophenyl substitution as shown in the case of 
derivative 29 (entry 29) yielded an inhibitor with increased potency compared to TR (entry 2) 
especially for CSNK1E (IC50 = 24.4 ± 6.4 M for CSNK1D and IC50 = 8.1 ± 2.5 M for 
CSNK1E). 3-Pyridinyl substitution as shown for derivative 30 (entry 30) yielded a more 
active agent than TR (entry 2) with respect to both CSNK1 isoforms (IC50 = 16.1 ± 4.3 M 
for CSNK1D and 15.5 ± 4.0 M for CSNK1E, respectively). Moreover, 2-pyridinyl 
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compound 27 (entry 27) showed some degree of selectivity towards CSNK1E (IC50 = 6.6 ± 
1.9 M for CSNK1E compared to 42 % residual kinase activity for CSNK1D at a 
concentration of 50 M). Thus, it might be possible that the nitrogen atom on the pyridine 
unit forms an intramolecular hydrogen-bond with the amino group in position C7 and enables 
trapping of the phenyl ring in a specific conformation that is selectively blocking the 
CSNK1E enzymatic activity. The replacement of the original phenyl ring at C6 with a 1-
naphtalenyl moiety yielded Epiblastin C (entry 26), one of the most selective CSNK1E 
inhibitors to date (IC50 = 36.5 ± 6.4 M for CSNK1D and IC50 = 1.0 ± 0.2 M for CSNK1E). 
Similar selectivity profile was reported for PF-4800567
214
 with IC50 values of 32 and 711 nM 
for CSNK1E and CSNK1D, respectively. These findings imply that further optimization of 
Epiblastin C core structure could substantially improve both the potency and selectivity 
towards CSNK1E. Derivative 28 (entry 28), containing the benzo[b]thiophen-3-yl group at 
the C6 yielded the most potent CSNK1E inhibitor across this series, with an estimated half-
maximal inhibitory concentration value in the low micromolar range, i.e. IC50 = 0.6 ± 0.1 M 
(IC50 = 2.8 ± 0.4 M for CSNK1D). These values indicate a completely opposite inhibitory 
profile compared to Epiblastin A. 
Finally, attempts were made to gain further insights from modifying other positions on the 
pteridine ring (entries 32-34, Table 5). Removing the amino group in position C7 as shown 
for derivative 33 (entry 33) yielded yet another selective CSNK1E inhibitor with an estimated 
IC50 value of 6 M (IC50 = 80.6 ± 11.7 M for CSNK1D). Any other substitution of the 
amino group at the position C7 yielded inactive derivative (see entry 32). One interesting 
example is compound 34 (entry 34) known in the literature as TG100-115,
197
  bearing the 
3,3’-dihydroxyphenyl substitutions in positions C6 and C7, respectively. As previously 
mentioned, this compound is reported as a potent class I PI3K inhibitor
180
 and is currently in 
clinical trials for myocardial infarct.
215
 Besides the PI3K family, TG100-115 also targets 
CSNK1D and CSNK1E isoenzymes with IC50 values of 10 M and 7 M, respectively. In 
conclusion, the amino group located at position C7 is critical for inhibiting CSNK1D/E 
isoforms. However, the replacement with a simple hydrogen atom confers a certain degree of 
selectivity towards CSNK1E. 
At this point, the impact of derivatization at position C2 was investigated as well. Towards 
this end, the original amino group was replaced with either a methyl or thiomethyl group 
(entries 37-40, Table 5). These substitutions yielded inactive compounds of both CSNK1D/E 
isoforms, highlighting the crucial role of the amino group in position C2 for the inhibition 
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process. Even the addition of a fluorine or chlorine atom that proved beneficial for increasing 
the inhibitory activity towards CSNK1D could not block the enzymatic activity of 
CSNK1D/E isoenzymes. Motivated by these findings, a small number of derivatives was 
synthesized that contain an alkoxy substituent in position C4 on the pteridine ring but kept 
the meta-chloro derivatization at position C6. The rationale behind generating these 
compounds was to investigate if these derivatives are more active CSNK1D inhibitors 
compared to Epiblastin A. Synthesis of 4-alkoxy-2,7-diamino-6(3-chlorophenyl) pteridines 
was straightforward from readily accessible starting materials 41-49 as shown in Scheme 4. 
 
a. (3-chlorophenyl)acetonitrile (1.2 eq), Cs2CO3 (1.2 eq), THF, 65
o
C, 3h 
Scheme 4. Synthesis of 4-alkoxy-2,7-diamino-6(3-chlorophenyl)pteridines 50-59. 
Inhibition studies performed with CSNK1D were performed by Dr. Yasushi Takemoto 
(RIKEN-Max Planck Joint Research Center for Systems Chemical Biology, Wako, Japan) 
and are shown in Table 6.  
 
Nr. R
4
 
CSNK1D activity 
upon 1 µM 
Epiblastin A 
CSNK1D activity 
upon 10 µM 
Epiblastin A 
2 -NH2 17% 1% 
50 ethyloxy 101% 91% 
51 n-propyloxy 102% 100% 
52 isopropyloxy 105% 85% 
53 allyloxy 106% 93% 
54 n-butyloxy 103% 93% 
55 sec-butyloxy 102% 98% 
56 cyclopentyloxy 102% 99% 
57 cyclopentylmethyloxy 102% 101% 
58 cyclohexylmethyloxy 101% 97% 
59 benzyloxy 105% 101% 
Table 6. CSNK1D residual enzymatic activity upon treatment with Epiblastin A-based derivatives 50-59 at 1 
M and 10 M, respectively. Data represent the mean values of three independent measurements performed in duplicate. 
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Compared to Epiblastin A, the newly synthesized derivatives bearing alkoxy groups at the 
position C4 failed to inhibit CSNK1D enzymatic activity upon 1 M and 10 M compound 
treatments, respectively (compare entry 2 with entries 50-59). These results suggest that the 
amino group in position C4 is imperative for exhibiting the inhibitory activity against 
CSNK1D at least. 
In conclusion, the structure-activity relationships with respect to the inhibition of CSNK1D/E 
isoenzymes highlight the features also emphasized in Figure 24: (1) substitutions at C6 
generate potent and / or selective CSNK1D/E inhibitors; (2) the amino group at position C7 is 
mandatory for maintaining the inhibitory activity against CSNK1D/E; replacement with a 
simple hydrogen atom renders selectivity towards CSNK1E; (3) amino groups at C2 and C4 
are crucial for inhibiting CSNK1D/E; it can be surmised that these amino groups engage H-
bond donors inside the ATP binding pocket of both kinases. Therefore, a defined array of H-
bond donors and acceptors might be essential for exhibiting proper inhibitory activity. 
 
Figure 24. Conclusions of the structure-activity relationship study derived upon treatment of CSNK1D/E with 
pteridine derivatives 2-40 and 50-59, respectively. 
 
 
4.5. Evaluation of the selected pteridine analogues against CSNK1A1 
Encouraged by the good inhibition profiles obtained for CSNK1D/E, several derivatives were 
tested for inhibition of CSNK1A1, a closely related CSNK1D/E isoform. Because of 
difficulties encountered with the expression of this particular CSNK1 isoenzyme, the selected 
compounds were profiled externally at Reaction Biology. Concentration-dependent 
measurements indicated that the selected compounds are fairly inactive for inhibition of 
CSNK1A1 isoform (see Table 7). As shown in Table 7, the manipulation of the substitution 
pattern of the pteridine ring in various positions allowed the generation of potent and / or 
selective CSNK1A1/D/E inhibitors. Thus, meta-substitution with a chlorine atom as shown 
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for Epiblastin A (entry 12) yielded a selective CSNK1D inhibitor with respect to both 
CSNK1E and CSNK1A1.  
 
Entry R1 R2 R3 
IC50 
CSNK1A1 [µM] 
IC50 
CSNK1D [µM] 
IC50 
CSNK1E [µM] 
2 -Ph -NH2 -NH2 36.81 ± 5.57 36.44 ± 6.49 26.82 ± 4.20 
12 m-Cl-Ph -NH2 -NH2 8.91 ± 2.38 0.50 ± 0.09 4.72 ± 0.79 
15 m-Br-Ph -NH2 -NH2 9.32 ± 1.88 2.46 ± 0.54 42%
***
 
13 m-F-Ph -NH2 -NH2 33.29 ± 4.89 61.79 ± 12.54 14.42 ± 4.70 
22 o,p-diCl-Ph -NH2 -NH2 55.56 ± 8.22 44%
**
 4.30 ± 0.88 
26 Naphtalen-1-yl -NH2 -NH2 35.94 ± 6.63 36.49 ± 6.42 1.00 ± 0.21 
27 Pyridin-2-yl -NH2 -NH2 54%
*
 42%
**
 6.59 ± 1.95 
28 Benzo[b]thiophen-3-yl -NH2 -NH2 5.61 ± 1.13 2.77 ± 0.39 0.56 ± 0.11 
29 Thiophen-2-yl -NH2 -NH2 14.23 ± 2.96 24.44 ± 6.37 8.15 ± 2.47 
33 Ph H -NH2 29.46 ± 5.02 80.61 ± 11.66 5.99 ± 1.54 
34 m-OH-Ph m-OH-Ph -NH2 5.52 ± 1.30 9.65 ± 1.63 6.59 ± 1.51 
Table 7. IC50 values for inhibition of CSNK1A1/D/E by a selected set of pteridine derivatives. Data represent 
mean values ± SD of three independent measurements for CSNK1A and performed in duplicate for CSNK1D/E. 
Determined IC50 value ± SD were generated by fitting the data with three parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. Where no IC50 determination was possible, the 
residual activities are shown as follows: * = residual activity upon treatment with 100 M compound; ** = 
residual activity upon treatment with 50 M compound; *** = residual activity upon treatment with 12.5 M compound. 
 
Figure 25. Dose-dependent profiles of Epiblastin A (A) and derivative 15 (B) for inhibition of CSNK1A1/D/E. 
Chemical structures for these compounds are highlighted in the upper part of each graph. Data represent mean 
values ± SD of three independent measurements performed in duplicate. Determined IC50 value ± SD were 
generated by fitting the data with three parameter nonlinear regression analysis using GraphPad Prism version 
6.00 for Windows. 
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Interestingly, a bromine atom as shown for derivative 15 (entry 15) in the same position 
furnished a dual CSNK1A1/D inhibitor. The inhibition profiles of Epiblastin A and derivative 
15 (entry 15) for CSNK1A1/D/E isoenzymes are shown in Figure 25, together with the 
corresponding chemical structure. 
Conversely, Epiblastin C and derivatives 22, 27 and 33 (entries 26, 22, 27 and 33) rendered 
selective CSNK1E inhibitors (see Figure 26). 
 
 
Figure 26. Dose-dependent profiles of Epiblastin C (A) and derivatives 22 (B),  27 (C), and 33 (D) for 
inhibition of CSNK1A1/D/E. Chemical structures for these compounds are highlighted in the upper part of each 
graph. Data represent mean values ± SD of three independent measurements performed in duplicate. 
Determined IC50 value ± SD were generated by fitting the data with three parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. 
As shown above, Epiblastin A and Epiblastin C are fairly selective CSNK1D/CSNK1E 
inhibitors, respectively that open up new avenues for studying CSNK1-modulated processes 
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in an isoform-specific fashion. Moreover, they represent good starting candidates for further 
optimization. 
 
4.6. Crystallization studies 
Crystallization studies were performed in collaboration with Arthur Porfetye (Max Planck 
Institute of Molecular Physiology, Dortmund, Germany). A crystal structure of the apo-
CSNK1D (amino acid sequence 1-294) was obtained and resolved at a 1.9 Å resolution (with 
an Rfree of 25.3 %) using synchrotron radiation at PXII. The structure of the apo-CSNK1D 
isoenzyme is depicted in Figure 27. 
 
 
Figure 27. Cartoon representation of the apo-CSNKD1 kinase crystal structure, emphasizing the amino acid 
residues involved in ATP and Zn
2+
 binding, respectively. 
The CSNK1D (amino acids 1-294) kinase construct has been previously employed by other 
groups for crystallization campaigns.
216
 Under the used experimental conditions, the enzyme 
crystallized in the P3121 crystal form, containing 1 protein molecule per asymmetric unit. 
This is different from the previously reported CSNK1D crystal structure (PDB ID: 3UYS),
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which was solved in the P1 form containing 4 kinase monomers per asymmetric unit.  
A notable exception in the crystal structure determined in the current study is the presence of 
a Zn
2+
 ion coordinated by the amino acid side chains His50, Cys71 and His278 of the 
symmetry mate and (S,R)-tartrate from the crystallization buffer (see Figure 27). 
Additionally, the nucleotide binding pocket of the CSNK1D unit is unoccupied, in contrast to 
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the previously characterized structure, where this region was sterically blocked by the Arg16 
amino acid side chain of another CSNK1D unit present in the crystal form. 
An overlay of the generated apo-CSNK1D structure with monomer C of the prior report 
(PDB ID: 3UYS) indicates no significant differences, as shown in Figure 28 (0.78 Å over 
281 amino acids).  
 
Figure 28. Structural overlap of the CSNK1D crystal structures obtained in the current (blue) and previously 
reported (green; monomer C from PDB ID: 3UYS) studies. 
Soaking experiments using Epiblastin A (entry 12, Table 2) and derivative 15 (entry 15, 
Table 2) successfully generated crystals that diffracted at 2.56 Å and 2.76 Å resolution, 
respectively (see Figure 29).  
 
Figure 29. Overlaid crystal structures of Epiblastin A (entry 12) and derivative 15 (entry 15) in complex with 
CSNK1D. Carbon and nitrogen atoms are highlighted in orange and blue, respectively. Chlorine atom in 
Epiblastin A is shown in green, while the bromine group in derivative 15 is colored brown. Met80, Met82, 
Glu84, Leu85 and Gly86 point out the amino acid residues that interact with Epiblastin A and derivative 15, 
respectively. Lys35 residue is involved in the phosphotransferase activity of CSNK1D. 
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Both structures show the same crystal forms as previously mentioned for the apo-CSNK1D, 
namely P3121. The crystal structures of both complexes show a high degree of similarity to 
the apo-CSNK1D structure as indicated by the root-mean-square deviation (rmsd) (for 
Epiblastin A: rmsd 0.57 Å over 285 amino acids; for derivative 15: rmsd 0.40 Å over 276 
amino acids). These values suggest that binding of Epiblastin A and derivative 15 does not 
significantly modify the CSNK1D conformation.  
The mode of binding exhibited by Epiblastin A and derivative 15 is perfectly in line with the 
structure-activity relationship study conclusions generated by the enzymatic study directed 
towards CSNK1D/E. For example, three atoms from the 2,4-diaminopyrimidine unit form an 
array of four hydrogen bonds with the hinge region of the CSNK1D nucleotide binding site. 
In particular, the amino group located at C2 position is involved in two hydrogen bonds with 
the carbonyl groups of amino acids Leu and Gly located at positions 85 and 86, respectively. 
The second amino group located at C4 interacts likewise with the carbonyl residue of Glu83. 
Both Epiblastin A and derivative 15 are additionally docked in the hinge region by means of 
a fourth hydrogen bond occurring between the nitrogen atom located at position 3 of the 
pteridine core and the NH backbone of Leu85 that is part of the hinge region. Another 
particular aspect of the Epiblastin A and derivative 15 mode of binding is the meta-halogen 
substitution featured by these compounds. The enzymatic studies previously described (see 
section 4.4. Screening of TR-based derivatives yields potent and / or selective CSNK1D/E 
inhibitors), revealed that the presence of the proper atom or group in this position is 
mandatory to achieve high degree of inhibition of the CSNK1D isoform. Indeed, the crystal 
structure determinations indicate that the chlorine and bromine atom, respectively are deeply 
buried in the hydrophobic cavity shaped by the amino acid side chains of Met80 and Met82. 
Considering the enzymatic studies presented above, the chlorine atom in the meta-position of 
the phenyl ring at position C6 yielded the most active inhibitor of CSNK1D, followed by the 
bromine containing derivative. A fluorine atom in the same position generated an almost 
inactive derivative. These results suggest that the chlorine atom most likely fulfills best the 
steric and electronic requirements for a tight interaction within the hydrophobic pocket. As 
shown in Figure 29, the presence of the slightly larger bromine atom causes a small 
conformational change of the pteridine unit in comparison with Epiblastin A. Moreover, a 
slight shift was observed at the level of the 2,4-diaminopyrimidine unit as well. These aspects 
could, at least partially, explain the lower potency exhibited by derivative 15 in comparison 
with Epiblastin A. 
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Overall, Epiblastin A and derivative 15 (entry 15) tightly fit into the nucleotide binding 
pocket as shown in Figure 30. This clearly shows that the upper part of the pteridine core 
encompassing N at position 3, C2, C4 and C6 is directly engaged in non-covalent interactions 
with the ATP binding pocket of CSNK1D. Therefore, the replacement of these groups will 
abolish the inhibitory activity in good agreement with the conclusions generated by the 
enzymatic studies.  
 
Figure 30. Tight interaction of Epiblastin A and derivative 15 (entry 15), respectively within the ATP binding 
site of CSNK1D. Dashed lines indicate the hydrogen-bond network between Epiblastin A and the hinge region. 
Having determined the crystal structure in complex with Epiblastin A and derivative 15, a 
comparison study with the previously published structures was performed. As a result, the 
pan-CSNK1D inhibitor PF-670662 (IC50 = 13 nM for CSNK1D and IC50 = 80 nM for 
CSNK1E) and the CSNK1E specific inhibitor PF-4800567 (IC50 = 711 nM for CSNK1D and 
IC50 = 32 nM for CSNK1E) were selected. Chemical structures for these inhibitors as well as 
the compounds reported in the current study are shown side by side in Figure 31.    
 
Figure 31. Chemical structures of Epiblastin A, derivative 15, PF-670662 and PF-4800567. Green color marks 
the aminopyrimidine unit embedded within the structures of these derivatives. Blue color highlights the halogen 
substituted phenyl ring of the CSNK1 inhibitors previously mentioned. 
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At first glance, the CSNK1 inhibitors presented in Figure 31 share two common features, 
namely, the aminopyrimidine unit and the halogen substitution on the phenyl ring. A chlorine 
atom is located in the meta-position of the benzene unit of Epiblastin A and PF-670462, 
whereas derivative 15 features a bromine atom. However, PF-4800567 exhibits a fluorine-
substitution in the para-position of the phenyl ring. As a result of these common features, it is 
not surprising that the CSNK1 inhibitors previously described share similar binding modes 
inside the ATP binding pocket, as highlighted in Figure 32.  
 
Figure 32. Superimposed crystal structures of Epiblastin A (orange) – PF-4800567 (green) (A) and derivative 
15 (orange) – PF-670462 (pink) (B). Carbon and nitrogen atoms are highlighted in orange and blue, 
respectively. Chlorine atom in Epiblastin A is shown in green, while the bromine group in derivative 15 is 
coloured brown. The highlighted blue electronic density suggests the anomalous scattering specifically 
generated by the bromine atom when the wavelength of the X-ray is adjusted to the absorption edge of this 
atom, namely 0.91883 Å. 
As shown by Figure 32A, Epiblastin A and PF-4800567 share similar binding modes within 
the hinge region. However, the meta-chlorine phenyl substituted unit is differently oriented 
within the hydrophobic pocket. In particular, the chlorine atom points out to opposite 
directions indicating that the PF-4800567 inhibitor does not engage the hydrophobic pocket 
created by the Met80 and Met82, as reported above for Epiblastin A and derivative 15. 
Conversely, derivative 15 and PF-670462 crystal structures share a higher degree of 
similarity. As expected, the aminopyrimidine units of both inhibitors are H-bonded with the 
amino acids within the hinge region. Moreover, the meta-bromo and para-fluoro substitution 
in the structure of derivative 15 and PF-670462, respectively are oriented towards the 
hydrophobic pocket shaped by Met80 and Met82 amino acid residues. The anomalous signal 
highlighted in Figure 32B is specifically detected due to the presence of the bromine atom in 
the structure of derivative 15. As a result of the strong X-ray absorbance of heavy atoms, 
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anomalous scattering can exclusively be observed when the wavelength of the X-ray matches 
the absorption edge of the bromine atom, namely 0.91883 Å.  This electronic density is 
located in close proximity to the hydrophobic pocket and suggests a high degree of 
interaction between derivative 15 with this cavity.     
The crystal structure of CSNK1D with PF-670662
217
 revealed that the imidazole nitrogen is 
H-bonded to a water molecule found in close proximity (data not shown). A close inspection 
of this particular water unit shows that it further interacts with Lys38 and Asp149 amino acid 
residues that characterize the backbone of the DFG motif. The presence of a water molecule 
(though with low occupancy) was observed in the vicinity of Epiblastin A and derivative 15 
(entry 15) as well. Unfortunately, it is located too far away for a non-covalent interaction 
with the amino group at position C7 to occur. On the other hand, this water molecule exhibits 
the same conserved H-bond network with the amino acid residues of Lys38 and Asp149 
previously reported for PF-670662, suggesting that the appropriate modification of the C7 
position might be able to engage this water molecule to increase potency and / or selectivity 
against CSNK1D. 
The crystal structures presented herein provide useful insights into the basic requirements for 
developing potent and / or selective CSNK1D inhibitors. In this regard, further 
derivatizations at positions C2, C7 and nitrogen atoms at positions 1 and 8 represent the next 
logical step in exploiting the full potential of the pteridine scaffold. 
 
4.7. Detection of target engagement for Epiblastin A 
After profiling the pteridine library in vitro against CSNK1A1/D/E isoenzymes, the focus 
was placed on Epiblastin A.  In order to determine whether this compound engages
218
 these 
isoforms in cell lysate, a kinase enrichment experiment (Thermo Scientific) was 
performed.
219
 The protocol makes use of the ActivX
TM 
ATP probe
220,221,222,223 
to specifically 
address ATP binding proteins, generally referred as the purinome.
224,225 
This subproteome, 
represents approximately 13 % of the entire set of cellular proteins
226
 and comprises protein 
kinases, ATPases, helicases, purinergic receptors, motor proteins, various transferases and 
other proteins.
227
 Most of these proteins feature one or two lysine residues located in the close 
vicinity of the ATP binding pocket.
228,229,230
 The ActivX
TM
 ATP probe exploits this feature 
and contains a labile ester bond located at the -phosphate position which terminates in a 
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desthiobiotin moiety connected via a short linker (see chemical structure in Figure 33). 
Similar probes, bearing an alkyne moiety instead of desthiobiotin have also been reported in 
the literature.
231,232,233
   
 
Figure 33. Chemical structures of the ActivX
TM 
ATP probe (A) and ATP-derivative bearing two alkyne units at 
the -phosphate position (B). 
Crystal structure determinations of ATP binding proteins elucidated that one or even two 
lysine residues are located in close proximity to the activated ester. Due to increased effective 
concentration, which greatly accelerates the reaction rate of labeling, these lysine residues are 
much more prone to react than, for example, other identical residues located on the protein 
surface. By combining short incubation times with relatively low concentrations of the 
ActivX
TM
 ATP probe, the background reactions with other lysine residues can be greatly 
diminished.
234
 After incubation and enrichment using streptavidin coated beads, the labeling 
efficiency can be evaluated by means of immunoblotting against the target of interest. The 
ActivX
TM
 ATP probe was previously reported to deliver robust outcomes using different 
experimental setups, furnishing important insights into inhibitor selectivity
235
 and binding 
constants of small molecules for kinases in cell lysates.
221
 These results highlight the 
versatility and robustness of these chemical probes in revealing novel understandings into 
how members of the purinome are regulated. The main feature of the ActivX
TM
 ATP probe is 
the ability to assess the specificity and inhibitory activity of ATP-competitive agents in 
nucleotide (ATP)-depleted cellular lysates in a similar fashion to competitive activity-based 
profiling.
236
 Therefore, the binding event of a certain compound to an ATP binding protein 
can be evaluated by means of immunoblotting or proteomic analysis.  
Before initiating the target engagement experiments, a suitable cell line had to be identified 
that contains CSNK1A1/D/E isoforms at detectable levels. Therefore, various cancerous cell 
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lines from different tissue origins such as HeLa, HCT116, OVCAR8, MCF7 and ACHN and 
the cell line HEK293T were analyzed by means of immunoblotting using specific antibodies. 
As shown in Figure 34, the HCT116 colorectal carcinoma cell line showed a good protein 
expression profile of CSNK1A1/D/E isoenzymes.  
 
Figure 34. Detection of CSNK1A1/D/E proteins levels in HeLa, HCT116, OVCAR8, MCF7, ACHN and 
HEK293T cell lines. Proteins were separated by means of SDS-PAGE followed by transfer to a PVDF 
membrane. CSNK1A1, CSNK1D and CSNK1E were detected using primary anti-CSNK1A1, anti-CSNK1D 
and anti-CSNK1E antibodies and a secondary antibody coupled to horseradish peroxidase. Tubulin was 
employed as loading control for CSNK1A1 using anti-tubulin antibody. GAPDH was acted as loading control 
for CSNK1D/E using anti-GAPDH antibody. For both controls, the secondary antibody was coupled to                      
horseradish peroxidase. 
In addition to the detectable CSNK1A1/D/E protein levels, Epiblastin A altered the 
proliferation of the HCT116 cell line upon 48 hours incubation as demonstrated by the WST-
1 cell viability assay (GI50 = 2.46 ± 0.25 M; GI50 is defined as the half-maximal growth 
inhibitory concentration; see Figure 35). This preliminary result indicated the possible 
crucial involvement of the CSNK1 kinase in HCT116 cell growth (see section 4.11.1. 
Epiblastin A inhibits the proliferation of wt HCT116 colorectal carcinoma cells).  
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Figure 35. WST-1 cell proliferation assay of wt HCT116 cells upon Epiblastin A treatment for 48 h. 
Experimental details: 4000 cells were initially plated overnight followed next day by addition of Epiblastin A at 
various concentrations. Afterwards, WST-1 reagent is added and the absorption at 450 nm is recorded. Cells 
treated with DMSO were considered 100 % viable. Data represent the average ± SD of three independent 
experiments performed in quadruplicate. Determined GI50 values ± SD were generated by fitting the data with 
four parameter nonlinear regression analysis using GraphPad Prism version 6.00 for Windows. 
As a result of the high CSNK1A1/D/E expression profile at the protein level and the growth 
inhibition effect upon Epiblastin A treatment, the HCT116 cell line was chosen to test 
whether Epiblastin A engages CSNK1A1/D/E isoenzymes in cell lysate. Having determined 
in vitro the IC50 values for the inhibition of CSNK1A1/D/E isoenzymes, Epiblastin A was 
employed at 1, 10 and 100 M, respectively while using 10 M concentration of the 
ActivX
TM
 ATP reagent. Therefore, not only the target engagement of a specific inhibitor in 
cellular lysate could be evaluated in a concentration dependent fashion, but also the dose 
range at which this compound is effective in cell lysate. The cellular lysates were treated with 
DMSO (acting as internal control at a final concentration of 1 %) and increasing 
concentrations of Epiblastin A. Following a short incubation time at room temperature 
ranging from 10 to 60 min, the ActivX
TM
 ATP probe was added for a defined period of time 
of either 10 or 60 min. The labeled proteins were then enriched using streptavidin beads, 
boiled and separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Using specific antibodies for the proposed targets, the labeling extent of the DMSO-
treated sample can be directly compared with the compound-treated samples. If the inhibitor 
would compete with the ActivX
TM 
ATP
 
probe for the nucleotide binding site, the intensity of 
the band revealed by immunoblotting should diminish with increasing concentrations of the 
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inhibitor. Indeed, for Epiblastin A a concentration-dependent protection of CSNK1A1/D/E 
labeling was observed (see Figure 36).  
 
Figure 36. Epiblastin A interferes with the labeling of CSNK1A1/D/E in HCT116 cell lysate. Experimental 
details: ATP-depleted HCT116 lysates were treated with Epiblastin A (1, 10 and 100 µM) for 10 / 60 min 
followed by treatment with ActivX
TM
 ATP
 
probe for 10 / 60 min. Labeled proteins were collected using 
strepatvidin coated beads and separated using SDS-PAGE. Proteins were transferred to a PVDF membrane prior 
to detection of CSNK1A1, CSNK1D and CSNK1E using anti-CSNK1A1, anti-CSNK1D and anti-CSNK1E 
primary antibodies and a secondary antibody coupled to horseradish peroxidase. 
On one hand, 1 M and 10 M of Epiblastin A seemingly did not affect the labeling of 
CSNK1A1/E in line with the determined IC50 values. Thus, it is not surprising that in the 
context of cell lysate more than 10 M of the inhibitor is required to detect a noticeable 
blocking effect. On the other hand, Epiblastin A partially blocked the labeling of CSNK1D at 
10 M compound concentration, in good agreement with the potency in vitro. In all cases, 
adding 100 M of the compound completely protected all three isoforms from labeling. 
Overall, these results confirm the engagement of CSNK1A1/D/E family members by 
Epiblastin A in ATP-depleted cellular lysates and further validate this compound as a novel 
and selective CSNK1D inhibitor. It is noteworthy to emphasize the fact that these results 
were generated using ATP-depleted lysates, whereby the nucleotides and other cofactors 
were partially removed by means of gel filtration.  
In conclusion, by means of a competitive activity-based profiling procedure employing the 
ActivX
TM
 ATP probe and immunoblotting using specific antibodies, the engagement of 
CSNK1A1/D/E isoenzymes by Epiblastin A in ATP-depleted HCT116 colorectal carcinoma 
cellular lysates was successfully validated. This method is simple and easy to perform and 
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could be readily applied to confirm the interaction of Epiblastin A with other ATP binding 
proteins, as discussed in the next section. 
 
4.8. Revealing novel interaction partners of Epiblastin A by means of 
chemical proteomics 
One of the main drawbacks of kinase profiling studies is the limited availability of the 
naturally occurring enzymes in commercial panels. These kinases are mostly expressed as 
truncated constructs and purified using various tags, which consequently might alter their 
native structure and ultimately the enzymatic activity. Encouraged by the results described 
above that confirmed target engagement of CSNK1A1/D/E members by Epiblastin A using 
immunoblotting (see previous section), a proteomics-based strategy was applied to unveil 
novel interaction partners of this compound in HCT116 cell lysates. As compared to the in 
vitro study which mostly analyzes the enzyme activity for a single substrate under defined 
conditions, the cellular lysate encompasses a more complex environment, whereby multiple 
proteins simultaneously compete for the binding partners. On one hand, finding additional 
protein targets for Epiblastin A would be of valuable importance since they might be 
involved in reprogramming of late-stage mEpiSCs and might explain the enhanced potency 
of this derivative compared to the structurally similar hit TR. On the other hand, these 
potential targets might elucidate the reduced cell proliferation rate of the HCT116 cells 
observed upon treatment with Epiblastin A. 
However, the strategy based on the ActivX
TM
 ATP probe addresses only a fraction of the 
proteome, namely the purinome. As a consequence, other target classes are entirely omitted 
from the analysis. Conversely, focusing on a rather small fraction of the proteome would be 
advantageous, since highly expressed background contaminants could be largely removed 
from this procedure. In this way, even low expressed proteins, such as kinases, could be 
readily isolated and subsequently identified. Due to the crucial role of kinases in various 
aspects of stem cell biology and cancer research, the purinome-focused strategy might suit 
the current research interests. Therefore, after labeling with the ActivX
TM
 ATP based probe, 
enrichment using streptavidin coated beads and boiling with Laemmli buffer, the proteins 
were separated by means of SDS-PAGE and digested with trypsin using an in-gel digestion 
procedure. The digested peptides were then analyzed using nano-LC / MS followed by label-
free quantification (LFQ). 
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This protocol was applied under four slightly different conditions (see below). Since 100 M 
Epiblastin A produced a noticeable effect in the immunoblotting experiments, this 
concentration was considered sufficient to detect changes in the peptide intensities generated 
during the MS procedure compared to samples treated with DMSO. Thus, the concentrations 
of Epiblastin A and the ActivX
TM
 ATP probe were fixed at 100 M and 10 M, respectively, 
coupled with varying incubation times of these two components.  
 Protein 
code 
Protein name 
10 min / 
10 min 
10 min /  
60 min 
60 min / 
10 min 
60 min / 
60 min 
STK10 Serine / threonine-protein kinase 10 XX X XX XX 
CSNK1A1 Casein kinase I isoform alpha X XX X X 
PIP4K2A 
Phosphatidylinositol 5-phosphate 4-kinase 
type-2 alpha 
XX X XX X 
PIP4K2C 
Phosphatidylinositol 5-phosphate 4-kinase 
type-2 gamma  
X X X 
PRKDC 
DNA-dependent protein kinase catalytic 
subunit 
XX 
   
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 XX 
   
PRKACB 
cAMP-dependent protein kinase catalytic 
subunit beta  
XX 
  
ATP6V0D1 V-type proton ATPase subunit d 1 
 
XX 
  
MAPK8 Mitogen-activated protein kinase 8 
 
X 
  
MVD Diphosphomevalonate decarboxylase 
 
X 
  
MAP2K4 
Dual specificity mitogen-activated protein 
kinase kinase 4   
X 
 
GNE 
Bifunctional UDP-N-acetylglucosamine 2-
epimerase/ N-acetylmannosamine kinase 
X 
   
EHD4 EH domain-containing protein 4 X 
   
TTL Tubulin-tyrosine ligase 
   
X 
Table 8. Proteins identified to interact with 100 M Epiblastin A using 10 M of the ActivXTM ATP probe at 
specific time points in HCT116 cell lysate. The proteins marked with X were found significant by the median 
test statistical analysis, while the targets labeled with XX were very significant under the same statistical 
parameters; x min / x min suggests the incubation time of the HCT116 cell lysate with Epiblastin A and 
ActivX
TM
 ATP probe, respectively. 
The experimental conditions imply the incubation with Epiblastin A for 10 and 60 minutes 
respectively at 100 M followed by the treatment with ActivXTM ATP probe at 10 M for 10 
and 60 minutes respectively. As a consequence, four experiments (designated in Table 8 as 
10 / 10, 10 / 60, 60 / 10 and 60 / 60, respectively) were performed that would offer not only a 
better coverage of the possible targets but also provide snapshots of the Epiblastin A 
interactomes (protein targets that interact with Epiblastin A) in cellular lysate in a time-
dependent fashion. This in turn could uncover which targets are modulated in the first 10 
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minutes of incubation and possible differences in the target profile after 60 minutes of 
Epiblastin A treatment in cellular lysates. Table 8 shows the proteins that were identified to 
bind to Epiblastin A under the given experimental conditions. A complete list of the 
identified ATP-binding and non-ATP binding proteins can be found in Table 11 (see section 
8. Appendix).  
Subjection of the protein list shown in Table 8 to the CRAPome (Contaminant Repository 
for Affinity Purification)
237
 database that contains lists of common background contaminants 
identified in affinity-purification mass-spectrometry (AP-MS) experiments. With the 
exception of two proteins, namely DYNC1H1 (Cytoplasmic dynein 1 heavy chain 1) and 
PRKDC (DNA-dependent protein kinase catalytic subunit, also known as DNA-PK) that 
exhibited relatively high expectancy, the rest of the identified proteins was not predicted as 
background contaminants (data not shown). Taking in consideration the nature of the 
experiment, which implies stringent washing steps with 4 M urea, and the fact that 
DYNC1H1 and PRKDC only appeared once in these experiments with high statistical 
coverage, suggests that they might indeed be genuine protein targets of Epiblastin A. 
Moreover, to find out if the list contains proteins that might be co-enriched due to the 
formation of macromolecular protein complexes, the same list was also submitted to the 
String database,
238
 which encompasses known and predicted protein-protein interactions. No 
direct association could be found between the targets in single experiments, suggesting the 
validity of the protein list. Two exceptions were identified as PRKDC-MAPK8 (Mitogen-
activated protein kinase 8) and MAPK8-MAP2K4 (Dual specificity mitogen-activated 
protein kinase kinase 4), but these proteins were identified in different experiments. Since 
PRKDC and MAPK8 were previously associated with the modulation of DNA damage and 
stress signaling, respectively, one can only speculate about their inhibition upon Epiblastin A 
treatment as a possible mechanism of action associated with this compound.  
At a first glance Table 8 highlights an important feature of the obtained results. There appear 
to be two types of targets addressed by Epiblastin A. On one hand, STK10 (Serine / 
threonine-protein kinase 10), CSNK1A1 (Casein kinase I isoform alpha), PIP4K2A 
(Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha) and PIP4K2C (Phosphatidylinositol 
5-phosphate 4-kinase type-2 gamma) are significantly present in each one of the experiments 
performed, which might suggest a high degree of interaction regardless of the incubation 
times with Epiblastin A and the ActivX
TM
 ATP probe. A second set of targets was identified 
only once indicating transient association with Epiblastin A, solely at specific time points. 
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Since all the experimental conditions are identical excepting the incubation times, it can be 
argued that the protein list in Table 8 depicts a time-dependent snapshot of the Epiblastin A 
interactome in HCT116 cell lysate. Furthermore, since the cellular lysates represent just an 
averaged protein concentration across a cell population, this scenario might dramatically 
differ from the context of a living cell, where the system is highly dynamic and protein levels 
are modulated in a spatio-temporal fashion. 
Of the main targets CSNK1A1, STK10, PIP4K2A and PIP4K2C, only the CSNK1A1 could 
be identified in each of the four experiments, confirming the target engagement results 
described above using the immunoblotting procedure. However, the chemical proteomics 
experiments could not detect either of the CSNK1D or CSNK1E isoenzymes. This does not 
imply that the interaction between the two isoforms and Epiblastin A does not occurr in the 
cellular context, but rather stresses the lower abundance of these proteins that might not be 
detectable by the mass spectrometer under the experimental conditions. Thus, judging by the 
chemical proteomics results, CSNK1A1 is the main target addressed by Epiblastin A in 
HCT116 cell lysates among the CSNK1 kinase family. 
STK10 was identified as a prominent target during the study, considering the sequence 
coverage and signal intensities. STK10, a polo-like kinase kinase,
239
 represents the human 
homologue of the murine Lymphocyte oriented kinase (LOK) and is part of the Ste20 serine / 
threonine kinase family. To confirm STK10 as a bona fide target of Epiblastin A, the 
inhibitory activity of Epiblastin A on STK10 was investigated (see Figure 37).  
 
Figure 37. IC50 determination of Epiblastin A for inhibition of STK10 (h) determined by mean of radiometric-
based assay at Km-ATP value. Data represent mean values ± SD of three independent measurements. 
Determined IC50 value ± SD were generated by fitting the data with three parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. 
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Concentration-dependent measurement performed at Eurofins (former Milipore) indicated an 
IC50 value of 18 M, confirming STK10 as a novel target addressed by Epiblastin A in vitro 
Additionally, the interaction of Epiblastin A with STK10 in HCT116 lysates was 
demonstrated by means of competition with the ActivX
TM
 ATP followed by immunoblotting 
using the procedure described above for the CSNK1A1/D/E isoenzymes (see Figure 38).   
 
Figure 38. Epiblastin A disturbs the labeling of STK10 in HCT116 cell lysates.  Experimental details: 
nucleotide-depleted lysates of HCT116 cells were incubated with Epiblastin A (1, 10 and 100 M) for 10 / 60 
min followed by treatment with the ActivX
TM
 ATP probe for 10 / 60 min. Labeled proteins were enriched using 
streptavidin beads that were separated by means of SDS-PAGE. Proteins were transferred to a PVDF membrane 
prior to detection of STK10 using anti-STK10 antibody and a secondary antibody coupled to horseradish peroxidase. 
Not surprisingly, Epiblastin A exhibited a similar inhibition behavior for the labeling of 
STK10, namely more than 10 M of this compound is necessary to observe a noticeable 
protection from labeling with the ActivX
TM
 ATP probe. This further validates that the 
developed chemical proteomics method can reveal novel target proteins of Epiblastin A.  
 
4.9. Data analysis of chemical proteomics experiments   
The four chemical proteomics experiments identified between 1187 and 1812, proteins with 
an average of 1440 proteins per experiment (see Table 9).  
 
10 / 10 10 / 60 60 / 10 60 / 60 
Total number of proteins 1187 1383 1378 1812 
ATP binding proteins 327 349 338 408 
Kinase activity 154 168 162 198 
ATP binding and kinase activity 125 134 131 160 
GTP binding 61 75 78 93 
Table 9. Number and type of proteins identified during the chemical proteomics experiments. Proteins 
identified to fulfill a specific biological role were selected by means of the molecular function gene ontology 
(GOMF) classification. x / x suggests the incubation time of the HCT116 cell lysate with Epiblastin A and the 
ActivX
TM
 ATP probe, respectively. 
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From the total amount of proteins, an average of 355 was designated as ATP-binding proteins 
by the molecular function gene ontology (GOMF) analysis. Thus, more than 25 % of the total 
amount of proteins identified is reported to bind ATP. As a comparison, only 77 GTP-binding 
proteins could be detected representing less than 5 % of the all identified proteins suggesting 
a high degree of enrichment of ATP-binding proteins. In addition, approximately 40 % of the 
identified targets that interact with ATP are reported to possess kinase activity as mentioned 
by the GOMF terms which corresponds to roughly137 kinases per experiment. Taking in 
consideration that the human genome encompasses more than 500 kinases, the chemical 
proteomics experiments based on ActivX
TM 
ATP
 
probe was able to enrich approximately 27 
% of the whole kinome from 1 mg of HCT116 protein lysate. As previously reported in the 
literature,
221
 increasing the amount of cell lysate to 5 mg together with more sensitive MS 
detection can increase the overall coverage of kinases, thus allowing for an improved 
profiling capability of a small molecule across the entire kinome, for example.  
In conclusion, the ActivX
TM 
ATP probe represents a robust chemical reagent that allows 
approximately 25 % enrichment of the purinome across the identified proteins. 
Approximately 40 % of the entire ATP binding proteins isolated during the chemical 
proteomics procedures proved to possess kinase activity. Thus, the chemical proteomics 
procedure based on ActivX
TM
 ATP
 
probe offers a suitable method to profile ATP-competitive 
inhibitors across the purinome and to detect target engagement of these derivatives in ATP-
depleted cellular lysates. 
  
4.10. Kinase profiling reveals targets of Epiblastin A potentially 
involved in reprogramming 
As shown above, the stem cell reprogramming activity of TR and Epiblastin A is due to their 
ability to inhibit CSNK1A1/D/E with high specificity.
148,149
 In particular, Epiblastin A is a 
highly specific CSNK1A1/D/E inhibitor in a panel comprised of more than 100 kinases 
including members of the major signaling pathways reported to affect stem cell fate.
148,149
 
Moreover, both compounds also targeted the PI3K family members, albeit to different 
extents. In order to determine whether the compounds might inhibit other kinases that were 
not identified in the first screening campaign or during the chemical proteomic experiments, 
Epiblastin A’s inhibitory activity was investigated in single-point measurements at 10 M 
and Km-ATP value for 123 additional kinases. The rationale in selecting these targets was to 
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cover as many kinase families as possible. Moreover, if several members within the same 
subfamily were available in the panel, only the most representative examples were selected 
that exhibit different sequences within the ATP-binding pocket region. The assay was 
performed at Eurofins (former Millipore) using a 
33
P-radiometric-based assay. This study 
revealed more than 50 % inhibition of brain-selective kinase 1 (BRSK1), eukaryotic 
elongation factor 2 kinase (EEF2K), epidermal growth factor receptor kinase (EGFR), MAP 
kinase-interacting serine / threonine-protein kinase 2 (MKNK2) and receptor-interacting 
serine / threonine-protein kinase 2 (RIPK2) (see Table 10).  
Kinase 
Residual 
activity (%) 
SD Kinase 
Residual 
activity (%) 
SD 
ACK1(h) 80 0 Mer(h) 84 1 
Arg(h) 115 7 Met(h) 94 5 
AMPKα1(h) 109 5 MINK(h) 95 10 
AMPKα2(h) 123 10 MLCK(h) 78 7 
ASK1(h) 90 1 Mnk2(h)* 56 2 
Axl(h) 93 3 MRCKα(h) 86 5 
Bmx(h) 92 3 MSK1(h) 89 1 
BRK(h) 103 9 MSK2(h) 102 7 
BrSK1(h)* 64 3 MSSK1(h) 105 6 
BTK(h) 123 17 MST4(h) 90 3 
CaMKI(h) 98 11 MuSK(h) 91 3 
CaMKIIβ(h) 101 5 NEK9(h) 98 6 
CaMKIIδ(h) 99 3 PAK1(h) 88 8 
CaMKIV(h) 106 1 PAR-1Bα(h) 104 1 
CHK1(h) 99 6 PASK(h) 105 8 
CHK2(h) 112 8 PEK(h) 96 3 
cKit(h) 102 8 PhKγ2(h) 99 2 
CSK(h) 105 2 Pim-1(h) 95 4 
DAPK1(h) 83 4 Pim-2(h) 95 2 
DAPK2(h) 116 11 Pim-3(h) 82 7 
DCAMKL2(h) 110 3 PKD2(h) 83 3 
DDR2(h) 103 16 PKG1α(h) 87 9 
DMPK(h) 103 9 PKG1β(h) 96 6 
DRAK1(h) 86 4 Plk1(h) 95 2 
DYRK2(h) 87 2 Plk3(h) 92 2 
eEF-2K(h)* 56 8 PRAK(h) 88 10 
EGFR(h)* 33 1 PRK2(h) 78 2 
EphA1(h) 100 1 PrKX(h) 85 3 
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Kinase 
Residual 
activity (%) 
SD Kinase 
Residual 
activity (%) 
SD 
EphA2(h) 87 1 Pyk2(h) 112 7 
EphA3(h) 117 11 Ret(h) 74 2 
EphA4(h) 100 2 RIPK2(h)* 49 1 
EphA5(h) 95 2 Ron(h) 88 5 
EphA7(h) 96 5 Rse(h) 93 12 
EphA8(h) 103 7 Rsk2(h) 97 8 
EphB1(h) 89 10 Rsk3(h) 94 2 
ErbB4(h) 101 1 SGK2(h) 110 8 
FAK(h) 88 15 SGK3(h) 86 2 
Fes(h) 95 3 SIK(h) 77 5 
Flt1(h) 100 6 Snk(h) 91 1 
Flt3(h) 102 6 SNRK(h) 81 6 
Flt4(h) 84 1 Src(1-530)(h) 87 1 
Fms(h) 106 0 LOK(h)* 55 10 
Fyn(h) 103 12 LRRK2(h) 77 7 
GCK(h) 100 1 MAPKAP-K3(h) 94 13 
GCN2(h) 95 4 MARK1(h) 94 13 
GRK1(h) 85 5 SRPK1(h) 101 2 
GRK6(h) 94 3 STK25(h) 96 0 
Hck(h) 81 5 Tec(h) activated 90 0 
HIPK1(h) 103 4 TGFBR1(h) 116 4 
IGF-1R(h) 95 5 Tie2 (h) 78 1 
IGF-1R(h), activated 95 3 TLK1(h) 108 2 
IKKε(h) 97 5 TrkA(h) 99 15 
IR(h) 83 8 Txk(h) 90 5 
IR(h), activated 101 6 TYK2(h) 82 11 
IRE1(h) 93 9 ULK2(h) 85 3 
IRR(h) 98 4 ULK3(h) 98 6 
Itk(h) 96 0 Wee1(h) 85 9 
JAK1(h) 100 3 WNK2(h) 91 3 
Lck(h) 81 9 WNK3(h) 86 5 
Lck(h) activated 115 12 ZAP-70(h) 93 6 
LKB1(h) 92 1 ZIPK(h) 111 10 
Table 10. Influence of 10 M Epiblastin A on the activity of 123 selected kinases. Kinase activities were 
determined at Eurofins (former Milipore) by means of a radiometric-based assay using Km-ATP for each 
enzyme. Data are mean values of two independent measurements. Kinases marked with * showed 50 % enzyme 
inhibition upon treatment with 10 M Epiblastin A and were further selected for concentration dependent 
studies (see Figure 39).  
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Analysis of these kinases in concentration-depended manner for inhibition by Epiblastin A 
under the same experimental conditions are described below (see Figure 39). 
 
Figure 39. IC50 determinations for Epiblastin A against BRSK1 (A), EEF-2K (B), EGFR (C), MKNK2 (D) and 
RIPK2 (E), respectively evaluated at Km-ATP of each kinase. Data are mean values of three independent 
measurements performed at Eurofins by mean of radiometric-based assay. (F) Determined IC50 values ± SD 
were generated by fitting the data with three parameter nonlinear regression analysis using GraphPad Prism 
version 6.00 for Windows. 
With the exception of EGFR (IC50 = 8.3 ± 1.5 M), Epiblastin A exhibited higher half-
maximal inhibitory concentration values for all other protein kinases compared to the CSNK1 
family (see Figure 39). This finding might suggest that BRSK1, EEF2K, MKNK2 and 
RIPK2 inhibition might not be significantly involved in the reprogramming mechanism, 
although target engagement experiments in mouse epiblast stem cell lysates are required to 
completely validate these aspects.  
 
4.11. Investigation of Epiblastin A in cancer cell lines 
4.11.1. Epiblastin A inhibits the proliferation of wt HCT116 colorectal 
carcinoma cells 
As a result of various studies connecting CSNK1 and cancer research,
199
 the effect of 
Epiblastin A on the proliferation (in this subchapter the terms proliferation and growth are 
interchangeable) of wt HCT116  (wt refers to HCT116 parental cell line that contains both 
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TP53 alleles, i.e. TP53
+/+
) colorectal carcinoma cells was investigated in-depth. In this 
particular cell line, CSNK1A1/D/E could be detected at the protein level as previously shown 
(see Figure 36, section 4.7. Detection of target engagement for Epiblastin A). Moreover, 
preliminary studies have shown that Epiblastin A inhibited the proliferation of wt HCT116 
cells upon 48 h treatment (GI50 = 2.46 ± 0.25 M, GI50 is defined as the half-maximum 
inhibitory cell growth concentration) as indicated by the WST-1 cell proliferation assay (see 
Figure 35, section 4.7. Detection of target engagement for Epiblastin A).  
 
Figure 40.  WST-1 cell proliferation assay of wt HCT116 cells upon Epiblastin A treatment for 24 h and 48 h 
incubation, respectively. Experimental details: 4000 cells were initially plated overnight followed next day by 
addition of Epiblastin A at various concentrations. After overnight incubation, WST-1 reagent is added and the 
absorption at 450 nm is recorded. Cells treated with DMSO were considered 100 % viable. Data represent the 
average ± SD of three independent experiments performed in quadruplicate. Determined IC50 values ± SD were 
generated by fitting the data with four parameter nonlinear regression analysis using GraphPad Prism                
version 6.00 for Windows. 
On the other hand, incubation of wt HCT116 cells with Epiblastin A for 24 h yielded a 
significantly higher half-maximum inhibitory growth inhibition value (GI50 = 18.28 ± 8.63 
M), suggesting that prolonged treatment with this derivative is required to markedly affect 
the proliferation of wt HCT116  cells (see Figure 40). 
WST-1 reagent evaluates the number of metabolically active cells, i.e. viable cells in cell 
culture by measuring the enzymatic activity of mitochondrial dehydrogenases. Although the 
assay is relatively robust, it cannot exactly explain the cause of the reduced WST-1 signal 
arising upon treatment with a cytotoxic agent. For example, a decrease in the intensity can be 
caused by either a direct inhibition of the mitochondrial dehydrogenases, an inhibition of 
other cellular components that directly regulate the mitochondrial dehydrogenases levels or 
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due to a reduced number of cells in culture. In order to verify the latter hypothesis, this 
number can easily be approximated using Tryphan blue. This diazo dye specifically stains 
dead cells. Viable cells however do not allow the dye to pass the cellular membrane and thus 
are not labeled. As a result, this dye exclusion method allows the possibility to directly asses 
the number of dead cells in cell culture upon treatment with small molecules (see Figure 41).    
 
Figure 41. Cell viability evaluated by means of Tryphan blue upon treating wt HCT116 cells with 5 µM and 20 
M Epiblastin A for 24 h and 48 h, respectively. Experimental details: 4000 cells were initially plated overnight 
followed next day by addition of Epiblastin A at 5 M and 20 M for 24 h and 48 h, respectively. After 
incubation, cells are tryspinized and treated with Tryphan blue. The cells are counted with Countess automated 
cell counter (Life Technologies). Cells treated with DMSO control were considered 100 % viable. The results 
represent the average ± SD of three independent experiments performed in duplicate. 
The results of the Tryphan blue experiment pointed out the following observations: (1) 5 M 
Epiblastin A does not significantly reduce the number of viable wt HCT116 cells upon 24 h 
treatment, whereas 20 M reduce the total number to almost half; (2) 5 M Epiblastin A 
significantly reduces the number of viable wt HCT116 cells only upon 48 h treatment, 
whereas higher concentrations, namely 20 M almost completely blocked cell growth. These 
conclusions are in very good agreement with the GI50 values obtained from WST-1 assay and 
indicate a direct correlation between the mitochondrial dehydrogenase enzymatic activity 
measured by this assay and number of viable cells evaluated by means of Tryphan blue.  
Next, the effect of Epiblastin A treatment on the cellular ATP content was directly measured 
in wt HCT116 culture. For this, CellTiter-Glo
®
,
240
 a commercial available cell viability assay 
that uses luminescence as readout, was employed. Compared to WST-1, the CellTiter-Glo
®
 
reagent quantifies the number of viable cells by means of the cellular ATP content. Upon 
adding the reagent in the cell culture, cell lysis occurs and the released ATP, in the presence 
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of luciferin and molecular oxygen, is converted to AMP and oxyluciferin. As a result of this 
reaction, a “glow-type” luminescent signal is generated. Thus, the intensity of the 
luminescent signal is directly proportional to the cellular ATP content in culture. Dose-
dependent treatment of wt HCT116 cells with Epiblastin A for 24 h and 48 h, respectively, 
yielded the curves as shown in Figure 42.  
 
Figure 42. Cell viability evaluated by means of CellTiter-Glo
®
 reagent upon treating wt HCT116 cells with 
Epiblastin A for 24 h and 48 h, respectively. Experimental details: 4000 cells were initially plated overnight 
followed next day by addition of Epiblastin A at various concentrations for 24 h and 48 h, respectively. Then, 
CellTiter-Glo
®
 reagent was added and luminescence was recorded. Cells treated with DMSO were considered 
100 % viable. Data represent the average ± SD of three independent experiments performed in duplicate. 
Determined IC50 values ± SD were generated by fitting the data with four parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. 
The CellTiter-Glo
®
 experiment suggested that ATP content across the entire cell population 
is not significantly affected upon Epiblastin A treatment for 24 h (GI50 = 46.61 ± 7.74 M). 
Only concentrations higher than 50 M caused a dramatic reduction of the metabolically 
active cells. On the other hand, 48 h of Epiblastin A treatment significantly diminished the 
ATP levels in cell culture (GI50 = 1.03 ± 0.06 M) to a similar extent as shown for WST-1 
and Tryphan blue experiments previously discussed. Thus, treating wt HCT116 cells with 
Epiblastin A causes a decreased activity of the mitochondrial dehydrogenases and an overall 
diminished ATP content across the cell population. These outcomes might be due to a 
reduced cell number compared to the DMSO treated sample.  
CellTox
TM 
Green cytotoxicity assay was further employed to investigate the mode of action 
of Epiblastin A. This assay contains an asymmetric cyanine dye that detects changes in the 
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membrane integrity of cells directly in culture. If treatment with a small molecule results in 
cell death, the cellular membrane disintegrates and thus the dye can easily enter the cell and 
bind to DNA. As a consequence of the binding process, the fluorescent properties of the dye 
are turned on. Therefore, the fluorescent signal produced is proportional to the number of 
dead cells across the entire population. Conversely, the dye is completely excluded from 
viable cells that possess an intact cell membrane which does not allow the dye to pass 
through. As a consequence, the cyanine dye cannot bind to the DNA anymore and therefore 
no fluorescent signal can be detected. Epiblastin A was incubated with wt HCT116 cells for 
24 h and 48 h, respectively and the results of the CellTox
TM
 Green assay are presented in 
Figure 43. The CellTox
TM
 Green experiments nicely parallels the results obtained with WST-
1 and CellTiter-Glo
®
 viability assays as previously discussed.  
 
Figure 43. Cell toxicity evaluated by means of CellTox
TM
 Green reagent upon treating wt HCT116 cells with 
Epiblastin A for 24 h and 48 h, respectively. CellTox
TM
 Green reagent was added and fluorescence emission 
was recorded at 520 nm after exciting the sample with 485 nm light. Cells treated with DMSO were considered 
100 % viable. Data represent the average ± SD of three independent experiments performed in duplicate. 
Determined IC50 values ± SD were generated by fitting the data with four parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. 
Apparently, cell death completely occurs after 24 h only at high Epiblastin A concentrations 
such as 75 M. In the same time, 50 M of Epiblastin A induced cell death to approximately 
half of the wt HCT116 cell population (GI50 = 45.43 ± 1.75 M). Even after 48 h of 
incubation, significant membrane disintegration characteristic to cells undergoing cell death 
can only be observed for Epiblastin A at concentrations higher than 25 M (GI50 = 23.70 ± 
1.00 M). Finally, to test if the growth inhibition mechanism is mediated by CSNK1 kinase 
family, the pan-CSNK1 inhibitor D4476
200
 was tested in the WST-1 assay (see Figure 44).  
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Figure 44. WST-1 cell proliferation assay of wt HCT116 cells upon Epiblastin A and D4476 treatment for 24 h. 
Experimental details: 4000 cells were initially plated overnight followed next day by addition of Epiblastin A or 
D4476 at various concentrations. After overnight incubation, WST-1 reagent is added and the absorption at 450 
nm is recorded. Cells treated with DMSO were considered 100 % viable. Data represent the average ± SD of 
three independent experiments performed in quadruplicate. Determined IC50 values ± SD were generated by 
fitting the data with four parameter nonlinear regression analysis using GraphPad Prism version                                 
6.00 for Windows. 
The dose-response curve yielded a GI50 value of 37 M (GI50 = 37.34 ± 2.81 M) for this 
derivative. Under the same experimental conditions, Epiblastin A yielded a half-inhibitory 
cell growth concentration of 17 M (GI50 = 16.89 ± 7.00 M). This result preliminarily 
indicates that the mechanism of cell growth inhibition mediated by Epiblastin A might not be 
due to the inhibition of the enzymatic activity of CSNK1 kinase family. Further experiments 
are required to fully investigate this aspect.  
In conclusion, Epiblastin A inhibits the cell proliferation of the colorectal carcinoma wt 
HCT116 cell line. As indicated by the WST-1 assay, Epiblastin A treatment only slightly 
reduces the activity of the mitochondrial dehydrogenases upon 24 h treatment. Similarly, the 
ATP content does not seem to be affected at low Epiblastin A concentrations as suggested by 
the CellTiter-Glo
®
 assay. Only at concentrations higher than 50 M significant reduction in 
the cellular ATP content across the wt HCT116 cell population can be observed. 
Additionally, significant membrane disruptions characteristic to cells undergoing cellular 
death occurred only with high concentrations of Epiblastin A such as 50 M as showed by 
the CellTox
TM
 Green assay. However, treating wt HCT116 cells with 25 M Epiblastin A for 
48 hours induced significant lost in mitochondrial dehydrogenase activity and ATP content 
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that subsequently lead to membrane disintegration characteristic to dead cells. Further assays 
are needed to confirm if Epiblastin’s A mode of action involves programmed cell death, 
namely apoptosis. 
 
4.11.2. Growth inhibition of HCT116 cells by Epiblastin A is influenced by 
various parameters   
Having determined that Epiblastin A inhibits the proliferation of wt HCT116 colorectal 
carcinoma cell line, the influence of various parameters was investigated. Factors such as cell 
number and TP53 gene status were analyzed as shown in the following paragraphs.  
To investigate the effect of the cell number on the growth inhibition mechanism promoted by 
Epiblastin A, various wt HCT116 cell numbers ranging from 4,000 to 20,000 cells were 
seeded overnight. Then, Epiblastin A was added for 24 h followed by addition of the WST-1 
reagent (see Figure 45).  Apparently, changing the number of the initially plated cells 
positively influences the cell growth inhibition mechanism observed upon Epiblastin A 
treatment.  
 
Figure 45. WST-1 cell proliferation assay of wt HCT116 cells upon Epiblastin A treatment for 24 h. 
Experimental details: 4,000, 12,000 and 20,000 cells respectively were initially plated overnight followed next 
day by addition of Epiblastin A at various concentrations. After overnight incubation, WST-1 reagent is added 
and the absorption at 450 nm is recorded. Cells treated with DMSO were considered 100 % viable. Data 
represent the average ± SD of three independent experiments performed in quadruplicate. Determined IC50 
values ± SD were generated by fitting the data with four parameter nonlinear regression analysis using 
GraphPad Prism version 6.00 for Windows. 
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Unexpectedly, the increase from 4,000 to 12,000 cells significantly reduced the GI50 value 
(from GI50 = 12.91 ± 4.29 M for 4,000 cells to GI50 = 1.55 ± 0.18 M for 12,000 cells). 
Plating 20,000 cells did not dramatically modify this value suggesting a saturation effect 
(GI50 = 1.55 ± 0.18 M for 12,000 cells to GI50 = 3.12 ± 0.49 M for 20,000 cells).     
In conclusion, the different cell density of wt HCT116 cells initially plated does interfere 
with the mode of action of Epiblastin A. Further investigations in this direction shall focus on 
the involvement of cell-cell contacts in enhancing the cell proliferation blocking effect upon 
Epiblastin A treatment.      
Next, the impact of the TP53 gene levels onto the wt HCT116 cell proliferation upon 
treatment with Epiblastin A was investigated (see Figure 46). The GI50 value was found to 
increase from the wt (TP53
+/+
, GI50 = 11.81 ± 4.15 M) to the mutant variants that either lack 
one allele (HCT116 TP53
+/-
) or both TP53 alleles (HCT116 TP53
-/-
), whereby no GI50 value 
could be determined under the same experimental conditions.  
 
Figure 46. WST-1 cell proliferation assay of TP53 mutant HCT116 cell lines upon Epiblastin A treatment for 
24 h. Experimental details: 4000 cells of TP53
+/+ 
HCT116, TP53
+/-  
HCT116 and TP53
-/-  
HCT116 were initially 
plated overnight followed next day by addition of Epiblastin A at various concentrations. Afterwards, WST-1 
reagent is added and the absorption at 450 nm is recorded. Cells treated with DMSO were considered 100 % 
viable. Data represent the average ± SD of three independent experiments performed in quadruplicate. 
Determined IC50 values ± SD were generated by fitting the data with four parameter nonlinear regression 
analysis using GraphPad Prism version 6.00 for Windows. 
This behavior clearly indicates that TP53
-/-
 HCT116 cells are more resistant to the growth 
inhibition mechanism enacted by Epiblastin A and suggests that the mode of action exerted 
by Epiblastin A is at least in part mediated via the TP53 axis. This is not surprising 
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considering the literature reports linking CSNK1 kinase family to TP53 and other TP53 
pathway components.
199
  
In conclusion, manipulating the initial number of wt HCT116 cells plated indicated that 
increasing the degree of cell-cell contact in culture synergizes with the growth inhibition 
mechanism promoted by Epiblastin A. Moreover, the lack of TP53 gene blocked this 
mechanism, suggesting that this gene is an integral part of Epiblastin’s A mode of action. 
    
4.11.3. Epiblastin A affects the growth of various cancerous and non-
cancerous cell lines 
To investigate the specificity of the growth inhibition mechanism upon Epiblastin A 
treatment, cytotoxicity studies were expanded on other cancerous (see Figure 47) and non-
cancerous cell lines using WST-1 assay (see Figure 48).  
 
Figure 47. WST-1 cell proliferation assay of ACHN, BT549, HeLa, HS588T, HT1080, SKBR3 and U2OS cells 
upon Epiblastin A treatment for 24 h. Experimental details: cells were plated overnight followed next day by 
addition of Epiblastin A at various concentrations. After overnight incubation, WST-1 reagent is added and the 
absorption at 450 nm is recorded. Cells treated with DMSO were considered 100 % viable. Data represent the 
average ± SD of three independent experiments performed in quadruplicate. Determined IC50 values ± SD were 
generated by fitting the data with four parameter nonlinear regression analysis using GraphPad Prism version 
6.00 for Windows. 
As shown in Figure 47, Epiblastin A does not seemingly affect the proliferation of cancer 
cell lines such as HeLa, HS578T, HT1080, SKBR3 and U2OS. However, some degree of 
cytotoxicity was recorded in the case of BT549 ductal carcinoma cell line where an almost 
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linear reduction of the mitochondrial dehydrogenases was observed upon increasing 
concentrations of Epiblastin A. An interesting behavior was observed in the case of ACHN 
renal adenocarcinoma cell line, where the presence of a resistant population was observed 
that was not affected even at high Epiblastin A concentration such as 75 M.  
However, the cell proliferation of non-cancerous cell lines (see Figure 48) such as human 
embryonic kidney 293 (HEK293) and the highly similar HEK293T were affected to a greater 
extent than the cancerous cell lines (GI50 = 37.63 ± 5.48 M for HEK293 and GI50 = 8.54 ± 
0.59 M for HEK293T). This observation suggests an unspecific growth inhibition 
mechanism exerted by Epiblastin A. In addition, the proliferation of MCF10A, an epithelial 
cell line derived from breast, was moderately inhibited (GI50 = 24.55 ± 0.94 M).    
 
Figure 48. WST-1 cell proliferation assay of HEK293, HEK293T and MCF10A cells upon Epiblastin A 
treatment for 24 h. Experimental details: cells were plated overnight followed next day by addition of Epiblastin 
A at various concentrations. After overnight incubation, WST-1 reagent is added and the absorption at 450 nm is 
recorded. Cells treated with DMSO were considered 100 % viable. Data represent the average ± SD of three 
independent experiments performed in quadruplicate. Determined IC50 values ± SD were generated by fitting 
the data with four parameter nonlinear regression analysis using GraphPad Prism version 6.00 for Windows. 
In conclusion, Epiblastin A’s mode of action is not specific to cancer cell lines. Inhibition of 
the cell proliferation was significantly detected for non-cancerous cell lines compared to 
cancerous cell lines, suggesting an unspecific growth inhibition effect.  
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5. Discussion 
Stem cell research can have a major impact on regenerative medicine in areas such as cell 
replacement therapies,
102,103 
disease modeling
106
 and tissue engineering.
104,105 
 One important 
prerequisite to exploiting the full clinical potential of stem cells is accessibility of a large 
amount of high quality embryonic stem cells. These cells are normally isolated from the inner 
cell mass of a developed embryo and maintained in vitro under defined culture conditions. 
Because of the ethical issues related to embryo manipulation for experimental purposes, 
researchers have developed novel protocols to access embryonic stem (like) cells. Following 
on the initial contributions from John B. Gurdon showing that cellular fate can be reset by 
means of nuclear reprogramming,
35
 Yamanaka et al.
39
 succeeded to generate induced 
pluripotent stem cells (iPSCs) from fully differentiated cells by overexpressing a cocktail of 
four transcription factors, Oct4, Sox2, Klf4 and Myc. These cells are hardly distinguishable 
from the original ESCs in terms of morphology, culture conditions, expression of 
pluripotency-associated markers, differentiation potential, chimera contribution and other 
parameters.
39,40
 However, deep molecular investigations revealed several drawbacks of iPSCs 
such as immunogenicity issues, re-expression of transgenes and tumorigenic potential due to 
the presence of Myc in the reprogramming cocktail. These disadvantages hamper the use of 
iPSC technology in clinical context. To overcome these shortcomings, non-integrative 
methods need to be developed that completely avoid the introduction of transgenes into the 
host’s genome. However non-integrative methods developed to date, are not optimal for 
clinical use due to relatively low yields of producing pluripotent stem cells.  
One of the most appealing non-integrative methods relies on the use of small molecules. Such 
compounds were successfully employed in various stem cell research areas such as 
reprogramming of the cellular fate, differentiation towards various lineages and self-renewal 
of pluripotent stem cells. For example, small organic molecules are now an integrative part of 
various self-renewal protocols that robustly and reproducibly allow passaging of (pluripotent) 
stem cells in vitro. Additionally, many small molecules boost the generation of pluripotent 
stem cells in various contexts by either synergizing with the overexpressed transcription 
factors or even acting as surrogates for these transgenes. This allowed the continuous 
reduction of the number of transgene insertion in fully differentiated cells to reach an 
embryonic stem-like state. Recently, chemical reprogramming of fully differentiated mouse 
cells to mESCs was achieved by small molecules only, albeit with low yields.
94
 This 
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emphasized that the proper manipulation of the dosage and order of addition can successfully 
generate embryonic stem-like cells entirely avoiding any genetic intervention into the host’s 
genome.  
Due to the major role played by kinases in various aspects of stem cell biology, it is not 
surprising that kinase inhibitors proved to be active ingredients in various reprogramming 
contexts. However, most of the kinase inhibitors used to date were developed to fulfill the 
goals of other research areas such as oncology and repurposed for use is stem cell research. 
Thus, there is an obvious lack of small molecules that are particularly optimized in a stem 
cell based context. Moreover, there is an unmet need of novel chemical entities that would 
better address the major bottlenecks before clinical onset, in particular stem cell 
heterogeneity and low production yields.  
As a model for the study of reprogramming, stem cells derived from the post-implantation 
(epiblast) developmental stage were chosen, i.e.  epiblast stem cells (EpiSCs).
15,16
 These cells 
are characterized by primed pluripotency
119
 and are molecularly and functionally different 
than naïve ESCs. One major difference between mEpiSCs and mESCs is that the latter do 
contribute to chimera formation compared to mEpiSCs. Literature reports have shown that 
the mEpiSC population is heterogeneous
132
 as assessed by the expression of Oct4, a crucial 
pluripotency associated marker. As a result, two distinct subpopulations were identified. On 
one hand, an Oct4-GFP-positive cell population was identified that represents less than 1 % 
from the total amount of cells and was termed early-stage mEpiSCs. On the other hand, 99 % 
of the remaining cells are Oct4-GFP-negative, do not express Oct4 at detectable levels and 
were designated late-stage mEpiSCs. The two populations are distinct as indicated by the 
chimera formation capacity. The GFP-positive population contributes to chimera although 
with very low yields, whereas the GFP-negative population does not, suggesting that the two 
populations represent slightly different developmental stages.  
Primed mEpiSCs can be converted to naïve mESCs, either by genetic intervention, chemical 
means or even a simple switch in the culture conditions.
136,137,138,139,140,141,142
 However, in all 
cases an unsorted, i.e. heterogeneous mEpiSC population, was used. Thus, it might be 
possible that only the Oct4-GFP-positive cells were converted under the respective 
experimental conditions. To completely rule out this possibility, it has been previously shown 
that the commercialized drug Triamterene (TR) bearing a pteridine scaffold is able to 
reprogram late-stage mEpiSCs to mES-like cells.
148,149
 In-depth characterization revealed that 
110 
 
TR first converts the initial population to a pre-ESC-like state that exhibits most of the naïve 
pluripotency hallmarks but lacks the ability to contribute to chimera formation. Chimera 
competent cells could only be generated if the pre-ES population was cultured in the presence 
of a known MEK1 inhibitor, PD0325901 (PD).  
The current work reports on the optimization of the previously identified tool compound 
Triamterene (TR) through synthesis of a compound collection of closely related analogs. 
Their biological activity was evaluated in combination with PD, in a stem cell-based 
reprogramming assay. The principle of the assay relies on the reactivation of Oct4 
expression, the most important pluripotency-associated marker. This event was monitored 
through a fluorescent Oct4-GFP construct and quantified by means of flow cytometry.  
The biological investigation of the TR-related analogues provided a detailed picture of the 
structural requirements needed for the reprogramming of late-stage mEpiSCs. Even small 
alterations of the parent TR derivative have a strong impact on the phenotype. First, for an 
optimal reprogramming activity, the phenyl ring at position C6 featuring a defined 
substitution pattern needs to be maintained. Second, the derivatization of the meta- and ortho-
positions with specific groups is allowed whereas any manipulation of the para-position led 
to reduced or even abolished biological activity.  Moreover, the amino-groups in positions C2 
and C7 proved to be essential as well, since their replacement with various substituents was 
detrimental to the reprogramming activity.  
Analysis of the pteridine library in the reprogramming assay yielded five derivatives whose 
biological activity was improved compared to the initial hit TR. These compounds were 
collectively designated Epiblastins. The most potent compound was termed Epiblastin A 
whereas the remaining four derivatives are named according to their descreasing activity with 
respect to the initial compound, i.e. Epiblastin B-E. Since the biological activity and mode of 
action were already throughly characterized for Epiblastin A,
149
 the current work focused on 
the in-depth characterization of Epiblastin B-E. For these derivatives, additional experiments 
were employed to prove the reprogramming activity. First, the Epiblastin B-E reprogramming 
activities were analyzed together with Epiblastin A and included an authentic mESC cell line 
for which the endogenous Oct4-GFP expression was quantified. These derivatives 
reproducibly converted late-stage mEpiSCs to Oct4-GFP-positive cells with yields ranging 
from 38 % for Epiblastin E to approximately 70 % for Epiblastin A. Therefore, between 38 % 
and 70 % of the initial starting population reactivated the expression of the Oct4-GFP 
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reporter and were converted to a naïve state. In comparison, the mESC cell line was 
evaluated to 93 %, whereas TR converted only 31 % from the initial population. Moreover, 
by means of immunofluorescence experiments, the expression of Zpf42 (also known as Rex1) 
could be detected in the readily reprogrammed Oct4-GFP-positive cells. This marker is 
associated with the naïve state exclusively and proves that the cellular state obtained by 
treatment of Epiblastin A-E and PD is indeed embryonic stem-like. Taking together, 
Epiblastins A-E represent important tool compounds for chemical reprogramming of partial 
or fully differentiated cells towards naïve pluripotency.   
Although TR was previously reported to target the epithelial sodium channel (ENaC)
150
 and 
dihydrofolate reductase (DHFR),
241,242
 this compound has been barely investigated for 
inhibition of kinase targets. A single study highlights that TR fulfills the ”2-0” kinase-
likeness rule
243
 which allows to distinguish small molecules or fragments that inhibit protein 
kinases from compounds that do not interact with this class of enzymes. If the sum of 
heteroaromatic nitrogen atoms and heteroaromatic NH groups embedded within the 
compound structure is greater than 2, than the compound is likely to inhibit protein kinases. 
The study found that SGK1, p70 S6K and PAK1 kinases were completely inhibited by TR at 
a concentration of 33 M, but no dose-dependent studies have been reported so far. In 
addition to the literature reports, TR and Epiblastin A have been shown to specifically inhibit 
the PI3K and CSNK1 kinase families in a profiling study of more than 100 kinases.
149
 The 
contribution of PI3K to the reprogramming mechanism was devalidated using two 
structurally unrelated inhibitors, LY294002 and AS605240. However, the pan-CSNK1 
inhibitor D4476 was able to generate Oct4-GFP colonies suggesting that blocking the 
CSNK1 activity mediates the cellular transition mechanism. Among the CSNK1 family, the 
genetic ablation of CSNK1A1 and CSNK1E could reproduce the phenotype. In particular, 
knock-down of the CSNK1A1 isoenzyme by means of shRNA showed the highest percentage 
of Oct4-GFP expressing cells among the CSNK1 isoforms tested.  
Since CSNK1 is involved in the reprogramming of late-stage mEpiSCs, a target-based 
approach was applied to characterize the inhibitory activity of the synthesized compound 
library for the CSNK1A1/D/E isoforms. The collection was initially profiled for inhibition of 
CSNK1D/E isoenzymes using an in-house developed assay based on the KinaseGlo
®
 reagent. 
This robust and reproducible assay showed very good Z’ factor values. Using this platform, a 
ATP competitive inhibition by Epiblastin A was determined for both CSNK1D/E isoenzymes 
as concluded from Lineweaver-Burk plots and IC50 determinations at different ATP 
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concentrations. Moreover, selected examples were analyzed at Reaction Biology (Pasadena, 
USA) and analyzed for inhibition of CSNK1A1.  
Profiling of the pteridine collection allowed the delineation of clear structure-activity 
relationship parameters to achieve both potency and / or selectivity across the CSNK1A1/D/E 
isoforms. Protein tree analysis indicates the high structural similarity of CSNK1D and 
CSNK1E, substantiating the difficulty of achieving selectivity across these two isoforms. On 
the contrary, the modulation of the substitution pattern on the phenyl ring at position C6 
allows for the generation of isoform-selective inhibitors. For example, the chlorine and 
bromine derivatization in the meta-position as shown for Epiblastin A and derivative 15 
renders CSNK1D and CSNK1A1/D inhibitors, respectively. The replacement of the phenyl 
ring with naphthalene unit as shown for Epiblastin C switches the selectivity towards 
CSNK1E. As a result, Epiblastin A and Epiblastin C respresent selective CSNK1D/CSNK1E 
inhibitors, outmatching commercially available inhibitors such as PF-670462 and PF-
4800567.
214
 Thus, Epiblastin A and Epiblastin C are novel tools to investigate CSNK1-
mediated processes in an isoform-selective fashion. For example, inhibition of this kinase 
family led to therapeutic gain in diseases such as acute myeloid leukemia (AML),
244,245
 
amyotrophic lateral sclerosis (ALS)
207
 and various types of cancers.
246,247,248,249
 
The structure-activity relationships for the CSNK1A1/D/E isoenzymes corroborate well with 
results of the stem cell reprogramming assay. In both cases, the derivatization of the para-
position of the C6 phenyl ring was detrimental to activity, whereas specific meta- or ortho-
substitutions led to higher activity. There are few exceptions worth mentioning. The 
derivative containing a bromine atom in the meta-position of the phenyl ring at position C6 
inhibits CSNK1A1/D enzymatic activity. Although the IC50 values are lower than for TR, the 
reprogramming activity is almost identical to TR. Conversely, the derivative containing two 
chlorine atoms in ortho- and ortho’-positions was inactive for inhibition of CSNK1A1/D/E 
isoenzymes but two times more potent than TR in the cell-based assay. These observations 
might point out the following assumptions: (1) there are additional targets involved other than 
CSNK1A1/D/E and their modulation might be crucial for generating the phenotype; (2) 
reprogramming can occur independently of CSNK1A1/D/E via another mechanism than 
previously disclosed for Epiblastin A. The existence of multiple pathways for reaching a 
certain cellular state is not surprising when considering the cellular plasticity
250,251
 and 
heterogeneity that characterizes stem cells.
124
 Moreover, several studies reported that the 
modulation of various targets by genetic and / or chemical means at the EpiSC stage can 
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convert these cells to naïve mES-like cells (see section 1.1.10. Reprogramming mEpiSCs to 
mES-like cells – state of the art).        
The target engagement of CSNK1A1/D/E isoforms by Epiblastin A was demonstrated in 
ATP-depleted cell lysate derived from wt HCT116 (wt refers to the parental cell line 
containing both alleles of TP53, i.e. TP53
+/+
) colorectal carcinoma cell line. This cell line 
was chosen because CSNK1A1/D/E could be detected at the protein level and treatment with 
Epiblastin A for 48 h significantly affected the cell proliferation as evaluated by the WST-1 
assay. To address the interaction of Epiblastin A with the CSNK1 kinase family the 
commercially available ActivX
TM 
ATP probe was employed. This has successfully been 
applied before to ATP-binding proteins, collectively known as the purinome. This probe 
features an ATP molecule and contains a labile ester group at the -phosphate position that 
terminates in a desthiobiotin tag connected via a short linker. This probe effectively engages 
the nucleotide binding pocket of various classes of ATP binding proteins most of which 
feature one or even two lysine residues in close proximity of the nucleotide binding pocket. 
Thus, the lysine side chain reacts with the mixed anhydride, the engaged protein is labeled 
and this can be enriched using streptavidin beads. When profiling an ATP competitive 
inhibitor, the derivative can compete with the ActivX
TM
 ATP probe and thus the degree of 
labeling is diminished as compared to the treated sample. The labeling extent can be 
evaluated by either immunoblotting using a specific antibody when the respective protein 
target is known or by means of mass spectrometry. Engagement of CSNK1A1/D/E isoforms 
by Epiblastin A was initially evaluated by means of immunoblotting. This experiment 
revealed that concentrations higher than 10 M were necessary to observe a significant 
protection effect against labeling. The only exception was CSNK1D, where 10 M produced 
a noticeable effect, in line with the IC50 values reported in vitro. Thus, Epiblastin A engages 
CSNK1A1/D/E isoenzymes in cellular lysates and shows selectivity for CSNK1D.   
To reveal ATP-binding protein targets that might additionally be inhibited by Epiblastin A in 
HCT116 cell lysates, a chemical proteomics approach was employed. After incubation with 
Epiblastin A and the ActivX
TM
 ATP probe, the labeled proteins are enriched using 
streptavidin coated beads, washed, the bound proteins were digested and the resulting 
peptides analyzed by means of LC-MS. This procedure was applied in different formats by 
varying the incubation time of Epiblastin A and the ActivX
TM 
ATP
 
probe from 10 to 60 min. 
An average of 1440 proteins per experiment was identified, out of which 25 % have been 
reported to bind ATP by the molecular function gene ontology (GOMF) analysis. 
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Approximately 40 % from the ATP binding proteins enriched were kinases covering 
approximately 27 % of the entire kinome. As a result, the statistically relevant presence of 
CSNK1A1 was confirmed in the protein list generated from all four chemical proteomics 
experiments. Gratifyingly, the same isoform was reported in a previous study to be the main 
target driving the reprogramming of late-stage mEpiSCs. No other CSNK1 isoenzyme could 
be identified in the protein list during the experimental procedures. This does not exclude the 
interaction with Epiblastin A, but rather points out a lower abundance of the other 
isoenzymes in HCT116 cell lysate. 
In addition to CSNK1A1, STK10 (Serine / threonine-protein kinase 10) was identified in all 
experiments as main target possibly engaged by Epiblastin A. By mean of IC50 determination 
in vitro and target engagement in HCT116 cell lysates using immunoblotting, STK10 was 
confirmed as an interaction partner of Epiblastin A. STK10 is the human homologue of 
murine LOK (Lymphocyte oriented kinase)
252
 and is a serine / threonine kinase highly 
expressed in lymphocytes where it fulfills various biological roles.
253,254
 Recently it has been 
reported that STK10 functions as a tumor suppressor, because missense mutations within the 
STK10 sequence led to anti-apoptotic activity in peripheral T-cell lymphoma (PTCL) cellular 
model.
255
 Moreover, STK10 acts as a polo-like kinase kinase regulating the activation status 
of polo-like kinase 1 (PLK1).
239
 In addition, STK10 selectively modulates the proliferation of 
Ewing’s sarcoma cells.256 Knockdown by means of siRNA (small interfering RNA) 
selectively induced apoptosis in model cell lines such as TC-32, TC-71, SK-ES-1 and RD-ES 
compared to normal fibroblasts.  
The chemical proteomics experiments additionally identified with high statistical confidence 
two members of the phosphatidylinositol-5-phosphate (PtdIns5P)-4-kinases (PIP4Ks) kinase 
family, PIP4K2A (Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha) and PIP4K2C 
(Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma). This class of lipid kinases readily 
phosphorylates PtdIns5P to PtdIns(4,5)P2 and mediates oxidative stress signaling. Therefore, 
the members of PIP4K family have been recently proposed as a novel class of anti-cancer 
therapeutic agents.
257,258
 This family comprises three members, namely PIP4K2A, PIP4K2B 
and PIP4K2C and the deregulation of the enzymatic activity directly affects the accumulation 
of reactive oxygen species in mammalian cells. PIP4K2A is by far the most active isoenzyme 
from this series being 100-500 fold more active than the PIP4K2B and more than 1000 fold 
more potent than PIP4K2C.
259,260
 PIP4K2A has been recently proposed as a novel target for 
treatment of  amyotrophic lateral sclerosis.
261
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In addition to the primary list of targets presented above, other ATP-binding proteins could 
be identified. These appeared only once in each experimental condition employed and might 
represent only transient associations with Epiblastin A. For example, SLK (STE20-like serine 
/ threonine-protein kinase) is highly related to STK10 containing an identical sequence within 
the ATP binding site. Literature reports suggest that STK10 together with SLK
239,262
 
modulate the enzymatic activity of polo-like kinase 1 (PLK1) in tissue culture. In addition, by 
sequence homology searches, PRKDC (known as DNA-PK)
263
 has been identified as 
belonging to the phosphatidylinositol 3-kinase family (PI3K).
264,265
 Studies have shown that 
the PI3K catalytic domain of PRKDC kinase phosphorylates a broad range of substrates but 
does not exhibit lipid kinase activity.
265
 Similar to PI3K family, PRKDC is inhibited by high 
concentrations of Wortmannin.
266
 Together with the previous results related to the possible 
inhibition of PIP4K by Epiblastin A and the in vitro studies against PI3K, it can be surmised 
that the pteridine scaffold inherently targets lipid kinase catalytic domains. Further studies 
might offer the possibility to develop specific inhibitors for lipid kinases.   
With the exception of CSNK1A1 that was associated with the DNA-damage response in 
mouse ESCs
267
 only two putative targets identified by the chemical proteomics experiment 
were previously reported in the stem cell literature. MAPK8 (known as JNK1) was 
previously reported as barrier in reprogramming.
268
 Thus, it has been shown that JNK1 and 
the closely related JNK2 isoform directly phosphorylate Thr224 and Thr225 residues of Klf4, 
thus inhibiting its transcription and suppressing the transactivation activity. As a result, 
knockout JNK1
-/-
 or JNK2
-/-
 mouse embryonic fibroblasts (MEFs) yielded a significantly 
higher number of pluripotent stem cell colonies when reprogrammed with Yamanaka factors 
compared to the wt MEFs.  
NRBP1 (Nuclear receptor binding protein 1)
269
 could be a potential candidate for further 
investigations. The loss of this pseudokinase
270,271
 was reported to activate the Wnt pathway 
and led to SALL4 accumulation.
272
 SALL4 is a crucial transcription factor that either directly 
or indirectly modulates the gene network responsible for pluripotency establishment.
11,273,274 
NRBP1 may be a tumor suppressor
269,275,276 
 and its high expression in associated with poor 
prognosis and marked tumor growth.  
In conclusion, the chemical proteomics procedure based on the ActivX
TM
 ATP probe 
revealed potential novel targets addressed by Epiblastin A in cell lysates derived from the 
HCT116 colorectal carcinoma cell line. These proteins might synergize with the CSNK1 
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kinase inhibition and might explain the increased reprogramming efficiency of Epiblastin A 
compared to TR.  
After determining additional binding partners of Epiblastin A in HCT116 cell lysate, this 
molecule was submitted to a profiling study in vitro comprising a panel of 123 kinases in the 
attempt to reveal new targets that might have been missed during the proteomics procedure 
likely due to low abundance. Single-point measurement followed by dose dependent analyses 
revealed a set of five additional kinases, namely BRSK1, EEF2K, EGFR, MKNK2 and 
RIPK2 with IC50 values ranging from 8.3 M for EGFR to 45 M for MKNK2. With the 
exception of EGFR, the other kinases exhibited IC50 values in vitro much higher compared to 
CSNK1A1. Interestingly, EGFR was recently found to play the role of a barrier in the 
transition from an intermediate pre-ESC state derived from mouse to an ES-like state. Tran et 
al.
277
 found that removing the components of the EGF pathway facilitated this late-stage 
reprogramming by upregulating Esrrb, a known transcription factor that is a part of the 
pluripotency network in mouse. Interestingly, we have also previously shown that Epiblastin 
A treatment of late-stage mEpiSCs steadily activates the expression of Esrrb. Future 
experiments are required to address the possible involvement of EGFR inhibition in the 
context of reprogramming late-stage mEpiSCs by Epiblastin A.      
In addition to the reprogramming capacity of Epiblastin A, this compound was investigated in 
the context of cancer cell research as well. Following this direction, it was proven that 
Epiblastin A blocks the proliferation of wt HCT116 colorectal carcinoma cell line as 
evaluated by the WST-1 assay. This assay evaluates the number of viable cells in culture by 
quantifying the enzymatic activity of mitochondrial dehydrogenases. The WST-1 assay 
suggested that prolonged incubation time is required for a significant inhibition of wt 
HCT116 cell growth. Similar conclusions were obtained by counting the number of viable 
cells directly in culture by means of Tryphan blue and CellTiter-Glo
®  
cell viability assay. 
Tryphan blue specifically stains the nucleus of dead cells whereas CellTiter-Glo
® 
quantifies 
the number of viable cells by measuring the cellular ATP content. Finally, a CellTox
TM
 Green 
assay was employed to assess the membrane integrity of the cells upon Epiblastin A 
treatment directly in culture. The result of this analysis showed that upon 24 h treatment, only 
high concentrations of Epiblastin A, i.e. 50 µM produced significant cell membrane 
disruption. As expected, prolonged time significantly reduced the number of viable cells. 
Overall, these results point out that Epiblastin A significantly inhibits the cell proliferation of 
wt HCT116 cells only upon prolonged incubation time, namely 48 h. Moreover, testing the 
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pan-CSNK1 inhibitor D4476 in the WST-1 assay for 24 h incubation, suggested that the 
growth inhibition mechanism exerted by Epiblastin A might not be due to CSNK1 inhibition. 
The growth inhibition was shown to be affected by parameters such as initial number of cells 
plated and the TP53 gene status. Increasing the initial number of wt HCT116 cells plated 
from 4,000 to 12,000 considerably decreased the GI50 value as evaluated by the WST-1 assay. 
Increasing the cell number even further to 20,000 cells did not significantly alter this value 
suggesting a saturation effect. This might indicate that the extent of cell-cell contact might 
mediate the cytotoxic mechanism exerted by Epiblastin A. The lack of TP53 gene seemed to 
have a negative effect on the cell growth inhibition mechanism exerted by this derivative. 
Whereas the presence of both TP53 alleles in the HCT116 TP53
+/+
 cell lines yielded a GI50 
value of 12 µM, no GI50 value could be determined in the case of the mutant cell lines lacking 
one (HCT116 TP53
+/-
) or both TP53 alleles (HCT116 TP53
-/-
). This result suggests the 
inhibition of the HCT116 cell proliferation mediated by Epiblastin A requires TP53 gene 
product. This is not surprising when considering that the CSNK1 kinase family members 
directly phosphorylate amino acid residues within the TP53 sequence and within its 
partners.
199,278,279,280
 
After testing the wt HCT116 cell line, the cytotoxic properties of Epiblastin A were 
investigated on other cancerous and non-cancerous cell lines. No significant growth 
inhibition effect was observed for HeLa, HS578T, HT1080, SKBR3 and U2OS cell lines. 
Some degree of cytotoxicity was observed in the case of BT549 ductal carcinoma cell line 
where an almost linear reduction of the WST-1 signal was observed upon increasing 
concentrations of Epiblastin A. An interesting behavior was obsverved in the case of ACHN 
renal adenocarcinoma cell line, where the presence of a resistant population was observed 
that was not affected even at 75 M Epiblastin A. Surprisingly, non-cancerous cell lines such 
as HEK293, HEK293T and MCF10A were affected to a much greater extent than the 
corresponding cancerous counterparts. These results suggest that the cell growth inhibition 
mechanism mediated by Epiblastin A is rather unspecific across different cell lines.  
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6. Summary  
In the course of this work, an in-depth chemical biology investigation has been performed to 
study the reprogramming of partially differentiated cells termed late-stage mouse epiblast 
stem cells (mEpiSCs) to embryonic stem (ES)-like cells upon treatment with small 
molecules. Triamterene (TR) has been previously reported to convert the starting cell 
population to intermediate embryonic stem (ES)-like cells (designated pre-ESCs) alone or to 
ES-like cells when treated in combination with the MEK1 inhibitor PD0325901 (PD) (see 
chemical structures in Figure 49).  
 
Figure 49. Chemical structures of PD0325901 (PD), Triamterene (TR) and Epiblastin A. R.E. is defined as the 
reprogramming efficiency; for the initial hit TR, R.E. was set to 1. 
To relate chemical structure with biological activity, a compound collection based on the TR 
scaffold was synthesized bearing various substituents at positions C2, C6 and C7 (see above) 
following procedures already established in the literature. For example, mono- and 
disubstituted derivatives on the phenyl ring at position C6 can be synthesized in a single step 
by reacting 5-nitroso-2,4,6-triaminopyrimidine with commercially available phenylacetonitriles. 
Analogously, pteridines functionalized at position C2 can be generated from various 2-
substituted-5-nitroso-4,6-diaminopyrimidines.  
The biological investigation of the compound collection was performed by quantifying the 
selective re-expression of the Oct4-GFP construct, a crucial pluripotency-associated marker, 
in the reprogrammed cells. The structure activity relationship study defined clear structural 
features required for increased reprogramming activity with respect to the initial derivative 
TR. Thus, it could be shown that small changes in the structure of the parent compound have 
dramatic effects on the extent of reprogramming late-stage mEpiSCs. Epiblastin A, a meta-
chloro phenyl-substituted TR analog (see chemical structure in Figure 49) was identified as 
the most active compound that reproducibly achieved reprogramming efficiency of up to 2.3 
fold greater than the parental compound TR. In addition to Epiblastin A, four other pteridine 
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derivatives termed Epiblastin B-E were discovered that exhibited increased conversion rates 
compared to TR (see chemical structures of Epiblastin B-E in Figure 50). 
 
Figure 50. Chemical structures of Epiblastin B-E. R.E. is defined as the reprogramming efficiency; for the 
initial hit TR was set to 1. 
Because casein kinase 1 (CSNK1) family was previously identified to be mediate the cellular 
transition mechanism, pteridine derivatives were investigated for inhibiting the enzymatic 
activity of CSNK1 alpha (A1), CSNK1 delta (D) and epsilon (E). Clear structure-activity 
relationships could be delineated and revealed structural modifications that interfere with the 
CSNK1A1/D/E kinase activity (see Figure 51). For example, simple substitutions at position 
C6 as shown for Epiblastin A and Epiblastin C yielded selective CSNK1D/CSNK1E 
inhibitors, respectively.  
 
Figure 51. Conclusions of the structure-activity relationship study for pteridine derivatives derived from 
enzymatic studies CSNK1D/E activity.  
The Lineweaver-Burk analyses suggested that Epiblastin A is an ATP-competitive inhibitor 
of CSNK1D/E isoenzymes. This conclusion was supported by the shift of the half-maximal 
inhibitory concentration (IC50) to higher values by increasing the ATP concentration in the 
enzymatic reaction catalyzed by CSNK1D/E.  
The crystal structure of CSNK1D in complex with Epiblastin A or derivative 15 which 
contain a chlorine and bromine atom in the meta position of the C6 phenyl ring, respectively, 
furnished important insights on the mode of binding for this class of compounds. These 
derivatives dock in the nucleotide binding pocket by means of four hydrogen bonds with the 
amino acid backbone of the hinge region. Moreover, the chorine / bromine atom in the meta 
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position orient towards the hydrophobic cavity created by the amino acid residues of Met80 
and Met82. The crystal structure of CSNK1D in complex with the two inhibitors provides 
insights into how to design novel pteridine derivatives with improved potency and / or 
selectivity against CSNK1D isoform.  
Target engagement of CSNK1A1/D/E isoenzymes by Epiblastin A in cell lysates was 
investigated using the ActivX
TM
 ATP probe, a reagent that specifically interacts with ATP-
binding proteins, collectively designated as the purinome. This agent is suited for activity-
based profiling studies, where it competes with the ATP competitive inhibitor under 
investigation for the nucleotide binding pocket of the addressed target in complex protein 
mixture. The degree of interaction can easily be assessed by means of immunoblotting if the 
target of interest is known beforehand. Using this strategy significant engagement of 
Epiblastin A with CSNK1A1/D/E isoenzymes was detected in HCT116 cell lysate 
confirming the interaction of this derivative with the CSNK1 family in complex protein 
mixture.   
Moreover, by means of a chemical proteomics strategy using the same reagent, CSNK1A1 
was confirmed the main target of Epiblastin A in HCT116 cell lysate. In addition, serine / 
threonine-protein kinase 10 (STK10), phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 
(PIP4K2A) and phosphatidylinositol 5-phosphate 4-kinase type-2 gamma (PIP4K2C) kinases 
were identified as interaction partners of Epiblastin A. Among these targets, solely the 
interaction of Epiblastin A with STK10 was in-depth investigated in the current study and 
subsequently proven in vitro with purified enzyme and in cell lysate using the ActivX
TM
 ATP 
probe.   
To reveal other kinases potentially addressed by Epiblastin A, an in vitro kinase profiling 
study comprising 123 kinases was performed which additionally revealed brain-selective 
kinase 1 (BRSK1), eukaryotic elongation factor 2 kinase (EEF2K), epidermal growth factor 
receptor (EGFR), MAP kinase-interacting serine / threonine-protein kinase 2 (MKNK2) and 
receptor-interacting serine / threonine-protein kinase 2 (RIPK2) as potential targets of 
Epiblastin A. However, the half-maximal inhibitory concentration values for inhibiting these 
targets were significantly higher than for CSNK1A1 isoenzyme with the exception of EGFR, 
suggesting that only the EGFR inhibition might be relevant in the context of reprogramming 
late-stage mEpiSCs. These studies potentially revealed other targets engaged by Epiblastin A 
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in HCT116 cell lysate that might represent potential reprogramming barriers during the 
cellular transition process.   
Thus, chemical biology approaches can have a tremendous impact in stem cell research areas 
such as cell dedifferentiation mediated by small molecules, i.e. chemical reprogramming. The 
discovery of Epiblastin A-E provides the stem cell community new tools that avoid the 
genetic intervention and reprogram stem cells derived from the later stages of the embryo 
development, i.e. postimplantation stage, to ES-like cells. Moreover, the current study 
identified interaction partners of Epiblastin A whose inhibition might contribute to the 
generation of high quality pluripotent stem cells with high yields, thus bringing stem cell-
based technologies closer to clinical applications.      
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7. Outlook 
The results highlighted in the present study could be extended in various directions. For 
example, developing new methods to access substituted pteridine libraries would have a great 
impact on the various phenotypes associated with these compounds. Generating novel 
Epiblastin A-based derivatives embodying various substituents at positions C2, C4 and C7 
could improve even further the reprogramming activity by iterative cycles of synthesis and 
biological evaluation. Not only potency can in principle be improved but also the cytotoxicity 
reported for these derivatives in the biological context.  
Some of the compounds generated in this report already showed good selectivity profile 
across the CSNK1 kinase family. Another direction to follow would be the improvement of 
the potency and selectivity in an attempt to develop isoform-specific inhibitors. Along these 
lines, Epiblastin A and Epiblastin C are already good candidates to start medicinal chemistry 
campaigns oriented towards these goals. Moreover, the crystal structure of Epiblastin A 
already indicates derivatization points that can be further exploited. The improved inhibitors 
could then be tested in various disease models where CSNK1 kinase activity plays an 
essential role such as acute myeloid leukemia, amyotrophic lateral sclerosis and various types 
of cancers.  
Another interesting aspect of these derivatives that can be exploited is the observation that 
pteridine compounds can reprogram late-stage mEpiSCs alone to an intermediate pre-ESC 
like state. This particular trapped population offers the starting platform to test various stem 
cell differentiation protocols. Thus, it might be possible that this reprogrammed state is 
biased to differentiate to cells belonging to specific lineages with higher propensity than ES-
like cells.  
Thus far we have shown that the combined action of Epiblastin A and PD successfully 
converts late-stage mEpiSCs to ES-like cells with high yields. This represents the first step 
towards the development of a rational strategy to achieve chemical reprogramming with high 
yields starting from a fully differentiated state. The next logical step would be to identify 
small molecules that are able to convert somatic cell populations into a state that resembles 
the late-stage epiblast. Moreover, it would be interesting to test if Epiblastin A-E mode of 
action could promote naïve pluripotency in hESCs, since it is nowadays well accepted that 
these cells resemble mEpiSCs in many cellular and functional aspects.  
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Another important issue to optimize is related to the chemical proteomics protocol. Although 
this so far has proven to be relatively robust in identifying ATP binding proteins from entire 
proteomes, it still requires individual target engagement confirmation experiments using 
immunoblotting for the proposed target addressed by the small molecule under investigation. 
Therefore an increased throughput is required to rapidly delineate between positive and 
negative protein target hits. This could easily be achieved by a simple change of the original 
protocol. For example, after incubation with the compound of interest and the ActivX
TM 
ATP
 
probe, labeled proteins are directly digested instead of subsequent enrichment followed by 
digestion. After this step, the labeled peptides are collected using streptavidin coated beads, 
washed, boiled and identified by means of LC-MS. This particular change of the original 
protocol could foster the identification of the exact position of the lysine amino acid residue 
within the protein sequence that has been labeled by the ActivX
TM
 ATP probe. By mapping 
this lysine residue in the structure of the ATP binding proteins one could simply delineate 
between specific and unspecific labeling effects since only the lysine residue located in the 
vicinity of the binding pocket should in principle be targeted.  
The identification of other interaction partners of Epiblastin A and the related analogues in 
lysates derived from mEpiSCs would offer a better understanding of the reprogramming 
process promoted by these derivatives. So far the experiments have been performed in cell 
lysates obtained from wt HCT116. It would be beneficial to check if the same targets are 
being addressed in lysates derived from mEpiSCs. The protein targets revealed by the 
chemical proteomics study performed in wt HCT116 cell line might represent novel barriers 
in the reprogramming of late-stage mEpiSCs. These proteins might synergize with CSNK1 
kinase inhibition and explain, for example, the increased activity of Epiblastin A compared to 
the initial hit TR.  
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8. Appendix 
Protein Names 10 min / 10 min 10 min / 60 min 60 min / 10 min 60 min / 60 min 
STK10 7,95 2,13 7,66 3,10 
PIP4K2A 1,82 2,07 2,10 1,76 
CSNK1A1 3 / 0 3 / 0 2,20 1,59 
SLK 1,67   1,84 1,44 
PIP4K2C   1,52 1,40 1,50 
DYNC1H1 20,41       
PRKDC 6,11       
MAP2K4     1,61   
ILK     1,54   
GNE 1,49       
GART   1,26 1,29   
PCCB       1,35 
TAOK3     1,24   
ABCF1   1,22     
MVD   3 / 0     
PRKACB   3 / 0     
CHEK2 3 / 0       
NRBP1 3 / 0       
TNK1 3 / 0       
MAPK8   3 / 0     
TP53RK       3 / 0 
Table 11. Total list of ATP-binding proteins identified by the chemical proteomics method employing the 
ActivX
TM
 ATP probe. The numbers represent the ratio between the peptide signal intensity detected in the 
DMSO and Epiblastin A (100 M) treated samples, respectively after incubation with the ActivXTM ATP probe. 
The higher the ratio, the higher the capacity of Epiblastin A to protect the ATP-binding protein against labeling 
with the ActivX
TM
 ATP reagent. 3 / 0 = suggest the case where the protein target could be identified in the 
DMSO control but not a single time in the Epiblastin A treated sample. 
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9. Abbreviations 
ALS     Amyotrophic lateral sclerosis 
AML     Acute myeloid leukemia 
AP    Alkaline phosphatase 
ATP    Adenosine triphosphate 
BSA Bovine serum albumin 
CRISPR / Cas9 Clustered  Regularly Interspaced Short Palindromic Repeats / 
Cas9  
CSNK1   Casein kinase 1 
DMSO   Dimethylsulfoxide 
DNMT   DNA methyltransferase  
dpc    Days post conception  
EGC    Embryonic germ cells 
ENaC    Epithelial sodium channel 
EPL stem cells  Early primitive ectoderm-like stem cells 
FAB stem cells  bFGF, Activin and BIO-derived stem cells 
FACS    Fluorescence activated cell sorting 
FDA    US Food and Drug Administration 
FGF    Fibroblast growth factor 
F.U.    Fluorescence units 
GFP    Green fluorescent protein 
GI50    Half-maximal growth inhibitory concentration 
GOMF   Molecular function gene ontology  
HCSs    Hematopoietic stem cells 
HDAC    Histone deacetylase 
hESCs    Human embryonic stem cells 
hiPSCs   Human induced pluripotent stem cells  
126 
 
IC50    Half-maximal inhibitory concentration  
ICM    Inner cell mass  
iPSCs    Induced pluripotent stem cells 
LC-MS   Liquid chromatography mass spectrometry 
LFQ    Label free quantification 
LIF    Leukemia inhibitory factor 
LOPAC   Library of Pharmacologically Active Compounds 
MEF    Mouse embryonic fibroblast 
mEpiSCs   Mouse epiblast stem cells  
mESCs    Mouse embryonic stem cells 
MS    Mass spectrometry 
NIH    National Institute of Health 
PD    PD0325901 
PGC    Primordial germ cells 
PI3K    Phosphatidylinositol-3-kinase 
R.L.U.    Relative light units 
RNAi    RNA interference 
SDS-PAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
shRNA   Small hairpin RNA 
SSEA-1   Stage-specific embryonic antigen 1 
TR    Triamterene 
Xa    X-chromosome activation 
XEN stem cells  Extra-embryonic endoderm stem cells 
Xi    X-chromosome inactivation 
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11. Compound characterization 
 
6-(4-(allyloxy)phenyl)pteridine-2,4,7-triamine 
Yield = 56 % 
1
H-NMR [400 MHz, DMSO-d6] δ: 7.67 (d, J = 8.7 Hz, 2H), 7.13 – 6.87 (m, 4H), 6.58 (s, 2H), 6.17 
(s, 2H), 6.08 (s, 1H), 5.43 (d, J = 15.7 Hz, 1H), 5.28 (d, J = 11.9 Hz, 1H), 4.63 (d, J = 5.1 Hz, 2H). 
13
C NMR [101 MHz, DMSO-d6] δ: 162.88, 161.99, 158.42, 155.84, 155.48, 137.01, 135.90, 129.73, 
129.71, 128.44, 127.83, 127.60, 114.82, 113.74, 69.22. 
FT-IR (cm
-1
): 3383, 3111, 1610, 1566, 1536, 1425, 1348, 1246, 1177, 840, 817, 778, 754, 728, 684.  
HRMS Calcd for C15H16N7O 310.14108 [M+H
+
]; Found: 310.14145 
 
 
 
6-(3-fluorophenyl)-2-methylpteridine-4,7-diamine (entry 38) 
Yield = 52 %                                                                                                                                                                          
1
H-NMR [500 MHz, DMSO-d6] δ: 7.63 (d, J = 7.8 Hz, 2H), 7.55 (d, J = 6.1 Hz, 1H), 7.41 (s, 2H), 
7.32 (dd, J = 9.8, 7.2 Hz, 1H), 7.05 (s, 2H), 2.37 (s, 3H).                                                               
13
C NMR [101 MHz, DMSO-d6] δ: 167.56, , 161.56, 160.98 (d, J = 244.48 Hz, C-F), 155.82, 153.94, 
139.99 (d, J = 2.5 Hz), 138.71 (d, J = 7.8 Hz), 130.61 (d, J = 8.4 Hz), 124.51 (d, J = 2.7 Hz), 116.05, 
115.79 (d, J = 11.0 Hz), 115.47 (d, J = 7.3 Hz), 26.24.                                                            
FT-IR (cm
-1
): 3465, 3281, 3043, 1633, 1540, 1411, 1332.                                                                 
HRMS Calcd for C13H12FN6 271.11020 [M+H
+
]; Found: 271.11042 
 
 
6-(3-fluorophenyl)-2-(methylthio)pteridine-4,7-diamine (entry 40) 
Yield = 47 %     
                                                                                                                                                                                              
1
H-NMR [400 MHz, DMSO-d6] δ: 7.59 (m, 5H), 7.32 (t, J = 8.2 Hz, 1H), 7.17 (s, 2H), 2.46 (s, 3H). 
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13
C-NMR [101 MHz, DMSO-d6] δ: 170.86, 162.20 (d, J = 244.42 Hz, C-F), 160.74, 155.93, 153.71, 
139.02, 138.63 (d, J = 7.9 Hz), 130.60 (d, J = 8.4 Hz), 124.47 (d, J = 2.7 Hz), 116.01, 115.75 (d, J = 
10.4 Hz), 115.40 (d, J = 15.1 Hz), 13.62.                                                                             
FT-IR (cm
-1
): 3494, 3282, 3044, 1626, 1531, 1336, 435. 
HRMS Calcd for C13H12FN6S 303.08227 [M+H
+
]; Found: 303.08255.   
 
 
6-(3-chlorophenyl)-4-ethoxypteridine-2,7-diamine (entry 50) 
Yield = 44 %                                                     
Rf = 0.12 [Acetone : PE = 4 : 1]                                                                                                                  
1
H-NMR [400 MHz, DMSO-d6] δ: 7.62 – 7.49 (m, 4H), 6.92 (s, 2H), 6.78 (s, 2H), 4.45 (q, J = 7.0 
Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H).                                                                                              
13
C-NMR [101 MHz, DMSO-d6] δ: 165.84, 161.92, 157.63, 155.76, 138.99, 137.30, 133.21, 130.48, 
128.51, 128.24, 127.08, 114.19, 62.05, 14.38.                                                                   
FT-IR (cm
-1
): 3320, 3202, 3055, 2988, 1630, 1532, 1407, 1315, 1255, 1196, 1099, 1016, 816, 763.    
HRMS Calcd for C14H14
35
ClN6O 317.09121 [M+H
+
] and C14H14
37
ClN6O 319.08826 [M+H
+
]; 
found: 317.09174 and 319.08850. 
 
 
6-(3-chlorophenyl)-4-propoxypteridine-2,7-diamine (entry 51) 
Yield = 92 % 
Rf  = 0.14 [Acetone : PE = 4 : 1]                                                 
1
H-NMR [400 MHz, DMSO-d6] δ: 7.64 – 7.51 (m, 4H), 6.94 (s, 2H), 6.80 (s, 2H), 4.36 (t, J = 6.9 Hz, 
2H), 1.79 (dt, J = 14.4, 7.2 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H);                                                
13
C-NMR [101 MHz, DMSO-d6] δ: 166.00, 161.90, 157.61, 155.78, 139.01, 137.30, 133.24, 130.51, 
128.53, 128.24, 127.09, 114.21, 67.65, 21.67, 10.27;                                         
FT-IR (cm
-1
): 3328, 3121, 2970, 1629, 1583, 1565, 1534, 1487, 1429, 1406, 1318, 1255, 1195, 1113, 
1019, 819, 763, 692.                                                
HRMS Calcd for C15H16
35
ClN6O 331.10686 [M+H
+
] and C15H16
37
ClN6O 333.10391 [M+H
+
]; 
Found: 331.10771 and 333.10432.   
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6-(3-chlorophenyl)-4-isopropoxypteridine-2,7-diamine (entry 52) 
Yield = 77 %                                                                                                                                         
Rf = 0.13 [Acetone : PE = 4 : 1]                                                  
1
H-NMR [400 MHz, DMSO-d6] δ: 7.62 – 7.49 (m, 4H), 6.89 (s, 2H), 6.74 (s, 2H), 5.45 (dt, J = 12.7, 
6.3 Hz, 1H), 1.34 (d, J = 6.2 Hz, 6H).                                                                                     
13
C-NMR [101 MHz, DMSO-d6] δ: 165.43, 161.94, 157.73, 155.71, 139.01, 137.28, 133.21, 130.49, 
128.49, 128.28, 127.15, 114.36, 68.87, 21.74.                                               
FT-IR (cm
-1
): 3306, 3153, 2982, 1585, 1562, 1536, 1420, 1313, 1246, 1105, 817, 758, 684, 606.  
HRMS Calcd for C15H16
35
ClN6O 331.10686 [M+H
+
] and C15H16
37
ClN6O 333.10391 [M+H
+
]; 
Found: 331.10788 and 333.10457. 
 
 
4-(allyloxy)-6-(3-chlorophenyl)pteridine-2,7-diamine (entry 53) 
Yield = 76 % 
Rf = 0.11 [Acetone : PE = 4 : 1] 
1
H NMR [400 MHz, DMSO-d6] δ: 7.73 – 7.43 (m, 4H), 6.97 (s, 2H), 6.82 (s, 2H), 6.12 (ddd, J = 
16.1, 10.9, 5.7 Hz, 1H), 5.42 (dd, J = 17.2, 1.7 Hz, 1H), 5.26 (d, J = 1.7 Hz, 1H), 4.94 (d, J = 5.7 Hz, 
2H), 4.08 (q, J = 5.2 Hz, 1H), 3.17 (d, J = 5.2 Hz, 3H). 
13
C-NMR [101 MHz, DMSO-d6] δ: 165.44, 161.79, 157.72, 155.83, 138.95, 137.41, 133.22, 133.09, 
130.48, 128.53, 128.20, 127.05, 118.43, 114.07, 66.55, 48.56. 
FT-IR (cm
-1
): 3312, 3138, 2245, 1578, 1561, 1535, 1485, 1412, 1349, 1316, 1113, 817, 757, 574.                                                                                                                                            
HRMS Calcd for C15H14
35
ClN6O 329.09121 [M+H
+
] and C15H14
37
ClN6O 331.08826 [M+H
+
]; 
Found: 329.09220 and 331.08892. 
(Signals in Italic suggest the presence of the structure 2) 
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4-butoxy-6-(3-chlorophenyl)pteridine-2,7-diamine (entry 54) 
Yield = 92 %                                                                                                                                          
Rf = 0.15 [Acetone : PE = 4 : 1]                                                  
1
H-NMR [400 MHz, DMSO-d6] δ: 7.66 – 7.48 (m, 4H), 6.92 (s, 2H), 6.78 (s, 2H), 4.40 (t, J = 6.8 Hz, 
2H), 1.81 – 1.68 (m, 2H), 1.48 – 1.33 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H).                                     
13
C-NMR [101 MHz, DMSO-d6] δ: 165.98, 161.90, 157.62, 155.77, 139.01, 137.25, 133.22, 130.49, 
128.50, 128.23, 127.07, 114.21, 112.82, 65.93, 30.35, 19.52, 18.67, 13.66.           
FT-IR (cm
-1
): 3303, 3118, 2959, 2872, 1536, 1488, 1468, 1427, 1349, 1322, 1252, 1203, 1112, 1093, 
817, 776, 641, 594.                             
HRMS Calcd for C16H18
35
ClN6O 345.12251 [M+H
+
] and C16H18
37
ClN6O 347.11956 [M+H
+
]; 
Found: 345.12309 and 347.11991. 
 
 
 
4-(sec-butoxy)-6-(3-chlorophenyl)pteridine-2,7-diamine (entry 55) 
Yield = 64 %                                     
Rf = 0.1 [Acetone : PE = 4 : 1]                                                  
1
H-NMR [400 MHz, DMSO-d6] δ: 7.62 – 7.50 (m, 4H), 6.89 (s, 2H), 6.74 (s, 2H), 5.30 (h, J = 6.1 
Hz, 1H), 1.78 – 1.61 (m, 2H), 1.31 (d, J = 6.2 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H);                                                                                                                           
13
C-NMR [101 MHz, DMSO-d6] δ: 165.75, 161.93, 157.72, 155.74, 139.03, 137.26, 133.23, 130.51, 
128.51, 128.28, 127.16, 114.41, 73.38, 28.43, 19.21, 9.73;                                                    
FT-IR (cm
-1
): 3311, 3178, 2972, 2935, 2876, 1621, 1584, 1561, 1536, 1424, 1360, 1302, 1246, 1092, 
817, 685, 646.                                                   
HRMS Calcd for C16H18
35
ClN6O 345.12251 [M+H
+
] and C16H18
37
ClN6O 347.11956 [M+H
+
]; 
Found: 345.12375 and 347.12038.  
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6-(3-chlorophenyl)-4-(cyclopentyloxy)pteridine-2,7-diamine (entry 56) 
Yield = 31 %                                                                                                                    
Rf = 0.10 [Acetone : PE = 4 : 1]                                                  
1
H-NMR [400 MHz, DMSO-d6] δ: 7.62 – 7.49 (m, 4H), 6.90 (s, 2H), 6.76 (s, 2H), 5.51 (tt, J = 7.1, 
3.4 Hz, 1H), 2.07 – 1.95 (m, 2H), 1.79 –1.67 (m, 4H), 1.69 – 1.51 (m, 2H);                              
13
C-NMR [101 MHz, DMSO-d6] δ: 165.70, 161.86, 157.57, 155.72, 139.02, 137.29, 133.24, 130.52, 
128.51, 128.26, 127.15, 114.43, 78.34, 32.22, 23.46;                                          
FT-IR (cm
-1
): 3320, 3180, 2961, 2872, 1566, 1535, 1468, 1445, 1423, 1408, 1325, 1254, 1190, 815, 
772, 756, 690.                                                  
HRMS Calcd for C17H18
35
ClN6O 357.12251 [M+H
+
] and C17H18
37
ClN6O 359.11956 [M+H
+
]; 
Found: 357.12377 and 359.12043.  
 
 
 
6-(3-chlorophenyl)-4-(cyclopentylmethoxy)pteridine-2,7-diamine (entry 57) 
Yield = 44 %                                                      
Rf = 0.10 [Acetone : PE = 4 : 1]                                                                                                                  
1
H-NMR [400 MHz, DMSO-d6] δ: 7.67 – 7.51 (m, 4H), 6.94 (s, 2H), 6.79 (s, 2H), 4.30 (d, J = 7.2 
Hz, 2H), 2.40 (dt, J = 11.7, 7.7 Hz, 1H), 1.81 – 1.70 (m, 2H), 1.67 – 1.49 (m, 4H), 1.39 – 1.27 (m, 
2H);                                                                                                            
13
C-NMR [101 MHz, DMSO-d6] δ: 166.11, 161.89, 157.60, 155.76, 139.03, 137.21, 133.24, 130.51, 
128.50, 128.23, 127.06, 114.22, 70.02, 38.14, 29.06, 24.80;                                                   
FT-IR (cm
-1
): 3325, 3153, 2951, 2868, 2154, 1580, 1535, 1483, 1424, 1353, 1318, 1253, 1193, 1095, 
772, 685, 575.                                                  
HRMS Calcd for C18H20
35
ClN6O 371.13816 [M+H
+
] and C18H20
37
ClN6O 373.13521 [M+H
+
]; 
found: 371.13920 and 373.13590.  
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6-(3-chlorophenyl)-4-(cyclohexylmethoxy)pteridine-2,7-diamine (entry 58)                                                 
Yield = 85 % 
Rf = 0.10 [Acetone : PE = 4 : 1]                                                                                                                  
1
H-NMR [400 MHz, DMSO-d6] δ: 7.70 – 7.43 (m, 4H), 6.91 (s, 2H), 6.77 (s, 2H), 4.21 (d, J = 6.6 
Hz, 2H), 1.88 – 1.61 (m, 6H), 1.31 – 1.00 (m, 5H).                                                                       
13
C-NMR [101 MHz, DMSO-d6] δ: 166.08, 161.88, 157.64, 155.78, 139.04, 137.27, 133.23, 130.53, 
128.51, 128.24, 127.11, 114.23, 71.05, 36.57, 29.19, 25.97, 25.09.                                      
FT-IR (cm
-1
): 3317, 3126, 2924, 2851, 1618, 1581, 1559, 1536, 1485, 1425, 1358, 1319, 685.                                                                                                                                             
HRMS Calcd for C19H22
35
ClN6O 385.15381 [M+H
+
] and C19H22
37
ClN6O 387.15192 [M+H
+
]; 
found: 385.15503 and 387.15192. 
 
 
4-(benzyloxy)-6-(3-chlorophenyl)pteridine-2,7-diamine (entry 59) 
Yield = 65 %                                                                                                                                      
Rf  = 0.13 [Acetone : PE = 4 : 1]                                                 
1
H-NMR [400 MHz, DMSO-d6] δ: 7.60 (t, J = 2.1 Hz, 1H), 7.57 – 7.54 (m, 1H), 7.52 – 7.48 (m, 4H), 
7.36 (m, 3H), 6.96 (s, 2H), 6.86 (s, 2H), 5.50 (s, 2H).                                                         
13
C-NMR [101 MHz, DMSO-d6] δ: 165.62, 161.74, 157.83, 155.85, 138.90, 137.52, 136.46, 133.21, 
130.49, 128.53, 128.37, 128.21, 128.03, 127.10, 114.09, 112.83, 67.31.                              
FT-IR (cm
-1
): 3318, 3137, 2962, 1606, 1577, 1556, 1532, 1474, 1425, 1349, 1316, 1259, 1184, 1094, 
1021, 817, 799, 745, 696, 589.                                                                                             
HRMS Calcd for C19H16
35
ClN6O 379.10686 [M+H
+
] and C19H16
37
ClN6O [M+H
+
] 381.10391; 
Found: 379.10795 and 381.10482. 
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